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Abstract 
Globally, an estimated one-million new tuberculosis (TB) cases occurred in children in 2014. 
For a long time, research of TB in children has been neglected. Most research and 
surveillance of TB is performed in adults, and the resulting lack of evidence in children is a 
major barrier for implementation of rational control strategies for children, including 
diagnosis. More research on TB in children is of importance as children are more susceptible 
to developing severe extrapulmonary TB, children require different approaches to both 
diagnosis and treatment and paediatric TB reflects the ongoing transmission of TB in the 
population. This research gap on the epidemiology of tuberculosis in children, especially in 
high burden countries, should be addressed in order to better understand the dynamics of TB 
transmission in both adults and children. Accurate data are the basis for establishment of 
effective control strategies. This thesis aims to assess the diagnostic role of microscopic 
observation drug susceptibility (MODS) and mycobacterial blood culture for diagnosis of TB 
in children as well as to present the epidemiological characteristics of paediatric TB in 
northern Vietnam with regard to drug resistance and genotypes of Mycobacterium 
tuberculosis (MTB), the causative agent of TB, isolated from them. 
 
MODS is a low cost non-commercial liquid culture assay to detect MTB by microscopy. 
MODS was compared with conventional assays including Ziehl-Neelsen smear (ZN) and 
Löwenstein-Jensen culture (LJ) in a study conducted from 2009 to 2010 at the National 
Hospital for Paediatrics, a general paediatric hospital, in Hanoi, Vietnam. In suspected 
paediatric TB cases, the MODS test was shown to be significantly more sensitive than both 
smear (46.0% vs. 8.8%) and LJ (46.0% vs. 38.9%), and significantly faster than LJ with a 
median time difference of 28 days in favour of MODS (7 days vs. 35 days). The findings 
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suggest that MODS is a rapid low-cost diagnostic tool for TB diagnosis in the paediatric 
population. 
 
The additional yield of mycobacterial blood culture was assessed in comparison to routine 
detection methods for TB diagnosis in children in two hospitals in Vietnam. The findings 
show that mycobacterial blood culture detected an additional six TB cases of which 5 cases 
were negative with other tests and in the remaining case no other tests were done. All six 
cases were susceptible to rifampicin and isoniazid. The overall performance of TB blood 
culture was poor as compared to routine culture with regard to detection rate (2.9%, 16/554 
vs. 16.6%, 92/554) and turnaround time (26 days vs. 14 days). The incremental cost for 
adding one additional TB case is substantial. Therefore, addition of mycobacterial blood 
culture into routine diagnostics has limited utility in resource limited settings.  
 
To assess the molecular epidemiology of paediatric TB in northern Vietnam, a collection of 
125 MTB isolates from children with TB admitted to NHP during 2009 to 2013 was analysed. 
Drug susceptibility testing results from 121 isolates and genotypes from 120 isolates were 
generated. The phenotypic drug susceptibility testing showed that 20.7% was resistant to 
isoniazid (25/121), 3.3% resistant to rifampicin (4/121), 28.1% resistant to streptomycin 
(34/121) and 2.5% resistant to ethambutol (1/121). There were 4 cases with multidrug 
resistant TB. The high frequency of resistance to isoniazid and streptomycin are consistent 
with data from adults in Vietnam, suggesting the ongoing transmission of drug resistant MTB 
in the community. MIRU typing patterns showed that the Beijing genotype was predominant 
in this population (63.3%, 76/120), which is in agreement with various prior studies in adults 
in Vietnam. These findings provide more evidence to support the hypothesis of the epidemic 
spread of the Beijing genotype in Vietnam. In this study, an association between Beijing 
genotype and drug resistance to streptomycin and isoniazid was observed. The number of 
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MDR isolates was too small to draw conclusions regarding association of MDR and Beijing 
genotype. 
 
Collectively, these results demonstrate that liquid culture can improve the yield of TB 
diagnosis in Vietnam and mycobacterial blood culture should not be routinely performed for 
paediatric cases. The molecular epidemiology study also showed that the Beijing genotype is 
the predominant lineage among actively transmitted strains in Vietnam and that it is 
associated with both isoniazid and streptomycin resistance. Paediatric TB remains a 
significant cause of morbidity and mortality in Vietnamese children and sustained political 
and social commitment from all stakeholders, including governments, funders, academics and 
the medical community will be needed to improve diagnosis, treatment and prevention of TB 
in children globally. 
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Introduction 
1.1 History of tuberculosis 
Humans have suffered from tuberculosis (TB) since ancient times and TB has been described 
in ancient texts from China about 2,300 years ago (2). Fragments of the genome of 
Mycobacterium tuberculosis (MTB) - the causative agent of tuberculosis have been detected 
in a 3,300-year-old Egyptian mummy (3). The tuberculosis epidemic reached a peak in 
Europe and North America in the 18th and 19th century, and scientists started to focus more 
on tuberculosis pathogenesis (2). In 1865, the French doctor Jean Antoine Villemin showed 
that tuberculosis could be transmitted from a tuberculous animal to a healthy animal in an 
inoculation experiment. Robert Koch discovered that MTB is the actual infectious agent of 
the disease. He also developed the first staining method to detect MTB, exploiting the acid-
fast property of the bacilli. His announcement of this seminal discovery on 24th March 1882 is 
still celebrated as World TB day (4). In 1907, the tuberculin skin test was developed and the 
Bacillus Calmette–Guérin (BCG) vaccine was created by serial passage of Mycobacterium 
bovis in the laboratory to create an attenuated vaccine strain, which has been widely used 
since 1921. Vietnam, when colonised by the French, was one of the first countries where the 
vaccine was tested by French researchers. Unfortunately, efficacy in reported studies varied 
widely (0-80%) for unknown reasons, which may include variation in ethnicity, prior 
exposure to other mycobacteria in study populations, or variation in the vaccine strains 
themselves (5, 6). Although the protective effect of BCG vaccine is limited, it is widely used 
for perinatal vaccination in endemic countries today because it prevents the most severe forms 
of TB in children, especially tuberculous meningitis and miliary TB (5-8). 
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Along with understanding the disease, the search for a cure became a priority. Before the 
discovery of the first anti-TB drug in the 1940s (9), the only available options for TB 
treatment were sanatoria and surgery. The experience of European sanatoria was described in 
Thomas Mann’s novel “Der Zauberberg” (The Magic Mountain), for which he won the Nobel 
Prize of Literature in 1929 (10). There were many ‘false-dawns’ in the search for an effective 
TB treatment, with the most famous being sanocrysin and gold therapy (11, 12). The 
treatment trials of streptomycin are widely acknowledged to be the first randomised trials of a 
drug. The joy at initial results of streptomycin treatment was quickly tempered by the 
realisation that the relapse rates after mono-therapy were high, due to the emergence of 
streptomycin resistance (13). In the following decades, several new antibiotics were 
discovered: Para-aminosalcylic acid (PAS in 1944), Isonicotinic acid hydrazide (Isoniazid, 
INH in 1952), Pyrazinamide (PZA in 1954), Cycloserine (in 1955), Ethambutol (EMB in 
1962) and Rifampicin (RIF in 1963).  
 
A landmark series of trials by the Medical Research Council (UK) and the International 
Union against TB and Lung Disease (IUATLD, The Union) gradually developed and refined 
the treatment of TB using combination therapy (13). The addition of rifampicin and 
pyrazinamide eventually led to the establishment of a 6-month regimen, termed ‘short-
course’. An ‘intensive phase’ of treatment is used for the first 2 months with four drugs: 
isoniazid, rifampicin, ethambutol and pyrazinamide. This is followed by a ‘continuation 
phase’ of isoniazid and rifampicin in the final four months (14). Variations of this regimen 
were used with some countries adopting an 8-month regimen and thioacetone widely used in 
Africa due to low cost (15). The eight month regimen was shown to be inferior to the 6-month 
regimen in a trial conducted by the The Union, and is no longer recommended by WHO (16, 
17). Thioacetone causes a high rate of severe adverse events in people living with HIV and 
has therefore been discontinued for TB therapy (15). Interest in TB drug discovery evaporated 
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after the 1960’s and no novel anti-TB drugs were discovered in subsequent decades until the 
development of the second and third generation fluoroquinolones in the 1980's (18). 
However, resistance began to emerge and spread worldwide and by the millennium it was 
recognised that novel anti TB drugs were an urgent public-health priority, to prevent a return 
to ‘untreatable’ TB (19).  
 
A major research drive has resulted in the approval by the US food and drug administration 
(FDA) of two new drugs for MDR TB treatment (bedaquiline and delamanid).Importantly, 
the mechanism of action of these drugs differs from that of existing TB drugs (20). Despite 
progress made during the last decades, the pipeline of anti-TB drug development is lagging. 
The need for new combination therapies to treat drug resistant forms and the need for shorter 
treatment regimens for all forms of TB remains urgent.  
 
The last decade has seen major advances but also major disappointments in TB research. The 
Foundation for Innovative New Diagnostics (FIND) has led the systematic evaluation of TB 
diagnostic methods, which, combined with research by other groups, has led to large number 
of evidence-based recommendations from WHO on diagnostic strategies for TB, after long 
stagnation. The use of nucleic acid amplification tests (NAAT) for TB diagnosis has greatly 
increased following the endorsement by WHO in 2010 of the GeneXpert MTB/RIF test (21-
23). This test allows the rapid detection of both MTB and resistance to rifampicin, but has a 
number of important limitations, which stop it being a true point-of-care test (24). Three trials 
of shortened (4-month) regimens including a fluoroquinolone all failed to show efficacy in 
2013, and the first trial of a new TB vaccine also failed in that year (25-28). However, the 
Millennium Development Goals (MDG) for TB control stimulated a renewed focus and 
intensification of control efforts using existing tools. Global TB mortality has fallen by 47% 
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since 1990, with almost all of that gain post-millennium, and most countries are now seeing a 
decline in incidence of 1-2% per year (1). 
 
Paediatric TB has long been neglected as a research area. It was long assumed that control of 
adult TB would naturally eliminate paediatric TB, and the lack of systematic data collection 
on paediatric TB has obscured the problem. The last decade has seen a series of calls for 
intensified research on paediatric TB and a push by WHO for systematic age disaggregated 
data collection (1, 29, 30). Attempts have been made to develop standardised research case-
definitions to improve assessment of new diagnostics (31, 32), paediatric TB is now included 
in systematic reviews of new TB interventions, children have been included in a number of 
recent and planned clinical trials (33) and new much-needed paediatric TB drug formulations 
were developed in 2015 (31, 32, 34).  
 
In 2015 the new END TB strategy of WHO set targets for TB elimination for the first time 
(Table 1.1). To achieve this ambitious goal, we will need new drugs, diagnostics and 
vaccines.  
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 Table 1.1 The End TB strategy at a glance (2016-2035) (35) 
Vision A world free of TB – zero deaths, disease and suffering due to 
TB 
Goals End the TB pandemic 
Indicators Milestones Targets 
2020 2025 SDG 2030a 2035 
Reduction in number of TB 
deaths compared with 2015 
35% 75% 90% 95% 
Reduction in TB incidence 
rate compared with 2015 
20% 
(<85/105) 
50% 
(<55/105) 
80% 
(<20/105) 
90% 
(<10/105) 
TB-affected families facing 
catastrophic costs due to 
TB 
0% 0% 0% 0% 
Principles 
1. Government stewardship and accountability, with monitoring and evaluation. 
2. Strong coalition with civil society organizations and communities. 
3. Protection and promotion of human rights, ethics and equity. 
4. Adaptation of the strategy and targets at country level, with global collaboration. 
Pillars and components 
Integrated, patient-centred care and prevention 
A. Early diagnosis of TB including universal drug-susceptibility testing and systematic 
screening of contacts and high-risk groups. 
B. Treatment of all people with TB including drug-resistant TB and patient support 
C. Collaborative TB/HIV activities and management of co-morbidities. 
D. Preventive treatment of persons at high risk and vaccination against TB 
Bold policies and supportive systems 
A. Political commitment with adequate resources for TB care and prevention. 
B. Engagement of communities, civil society organisations and public and private care 
providers. 
C. Universal health coverage policy and regulatory frameworks for case notification, vital 
registration, quality and rational use of medicines and infection control. 
D. Social protection, poverty alleviation and actions other determinants of TB 
Intensified research and innovation 
A. Discovery, development and rapid uptake of new tools, interventions and strategies. 
B. Research to optimise implementation and impact and promote innovations 
a: Targets linked to the Sustainable Development Goals (SDGs) 
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1.2 Biology of Mycobacterium tuberculosis 
MTB, the causative agent of tuberculosis, belongs to the Mycobacterium tuberculosis 
complex (MTBC) within the family of Mycobacteriaceae (36, 37). The MTBC consists of 
Mycobacterium africanum, Mycobacterium bovis, Mycobacterium canettii, Mycobacterium 
microti, Mycobacterium tuberculosis, and others. 
 
Mycobacteria are aerobic, non-mobile and non-sporulating bacilli with a relatively slow 
replication rate compared to other bacteria (about 24 hours per generation). It possesses a 
unique cell wall structure (38), which is rich in unusual lipids, glycolipids and 
polysaccharides (39). The mycolic acid, the major lipid compound in the cell wall, is strongly 
hydrophobic, allowing the bacteria to survive in the macrophage and resist hydrophilic drugs 
and dehydration (40, 41). The high lipid content of the cell wall renders MTB resistant to 
decolourisation by acid after being stained with aniline dyes like carbol fuchsin, which is the 
basis of the ZN staining. 
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Figure 1.1 The cell envelope of mycobacteria (42).  
Mycolic acids are the major lipids found in the cell envelope of species in the mycobacteria 
species. 
1.3  Epidemiology of global tuberculosis 
Tuberculosis remains a major global health problem. MTB infects approximately one third of 
the world population. MTB is among the leading cause of death from infectious diseases 
globally. In 2014, an estimated 9.6 million people developed disease and 1.5 deaths from TB 
were recorded (43). TB is present in all regions of the world with incidences and death rates 
varying per country (Table 1.2) (Figure 1.2). Approximately 80% of all TB cases occur in 22 
high burden countries with more than half (58 %) in South-East Asia and the Western Pacific 
Region. Globally, the overall TB incidence has been decreasing at an average rate of about 
1.5% per year between 2000 and 2013. However, there is a gap of one third between the 
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number of notified TB cases and the estimated number of TB cases, which needs a major 
effort to close. In 2014, an estimated 3.6 million cases were either not diagnosed, or 
diagnosed but not reported to national TB control programs (43). Tuberculosis is also a major 
problem in risk groups like HIV infected individuals. HIV positive individuals are more 
susceptible to TB infection and have an increased risk to develop active TB following 
infection (approximate 30 times higher than HIV uninfected people) and are more likely to 
fail treatment. In 2014, WHO reported an estimated 12% of 9.6 million TB cases living with 
HIV and an estimated 400,000 deaths from TB among HIV infected people (1, 43). 
 
Another challenge to the global TB control effort is the increasing number of cases resistant 
to the drugs used for treatment. Multidrug resistant tuberculosis (MDR-TB) is caused by 
bacteria that are resistant to at least the two most powerful anti-TB drugs: isoniazid and 
rifampicin. Extensively Drug-Resistant-TB (XDR-TB) is a form of TB caused by MDR-TB 
bacteria additionally resistant to a fluoroquinolone and at least one of three injectable drugs 
(amikacin, kanamycin, or capreomycin). Totally drug resistant TB (resistant to all known TB 
drugs) has been described in the literature but the term is not accepted by WHO due to the 
difficulty of standardising in vitro susceptibility testing for second line drugs (44). Available 
WHO global data of drug resistance show that an estimated 3.5% of new and 20.5% of 
previously treated TB cases had MDR-TB in 2013. Eighty-five percent of these MDR cases 
occurred in 27 countries, with the highest incidences found in a number of former Soviet-
Union states. Globally, an estimated 9% of MDR-TB cases were XDR-TB. Drug resistance is 
a significant cause of treatment failure. Worldwide, the treatment success for MDR-TB cases 
notified and enrolled to treatment was just 48% in 2011, around half of the 86% success for 
new mostly susceptible TB cases in 2013 (43). The majority of MDR-TB is not detected or 
treated with appropriate regimens, despite large improvements in MDR-TB case detection 
following the introduction of GeneXpert MTB/RIF testing.  
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Figure 1.2 Estimated TB incidence rates by countries in 2014 (43)
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Table 1.2 Estimated WHO Regional TB statistics for 2014 
Reproduced from Global TB report 2015 (43) 
Region 
TB deaths 
(HIV -ve only) HIV/TB deaths 
Total incident 
TB cases New cases 
Africa 450,000 310,000 3,200,000 2,700,000 
America 17,000 6,000 350,000 280,000 
Easter 
Mediterranean 
88,000 3200 1,000,000 740,000 
Europe 33,000 3200 440,000 340,000 
South-East Asia 460,000 62,000 5,400,000 4,000,000 
Western Pacific 88,000 4900 2,100,000 1,600,000 
Global Total 1,100,000 390,000 13,000,000 9,600,000 
* The deaths figures exclude the deaths of people who had both TB and HIV infection at the 
time of their death  
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Figure 1.3 Percentage of new TB cases with MDR-TB in 2013 (1, 43)
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1.4 Pathogenesis of tuberculosis (45) 
When people come into contact with an infectious (smear-positive) TB case, they may inhale 
droplets / aerosols containing MTB. These droplets are formed when an active TB patient 
coughs or sneezes. The droplet travels into the lung and may reach the alveoli, where the 
bacteria are recognised and ingested by macrophages (46). Subsequently, the localised 
inflammatory response occurs, recruiting mononuclear and other cells of the immune system 
from the surrounding blood vessels. There are three possible outcomes to MTB within the 
macrophage: (1) MTB infection may progress to primary TB disease, (2) be eliminated or (3) 
become dormant (latent TB, LTBI). LTBI may reactivate after several years or decades to 
cause disease, usually when the infected individual becomes immune compromised due to 
age, malnutrition, illness or immunosuppressive therapy (47). 
 
In most cases (90%), the immune response contains the MTB bacilli in a dormant state, in 
which active replication and tissue damage are prevented and no clinical symptoms or signs 
of active TB disease are observed. The infection is controlled and rarely progresses to disease, 
so called latent infection. In a small number of cases, if the immune system failed to control, 
the bacilli will multiply and cause active TB and may spread into the surrounding area and 
distant organs via the blood stream or lymphatic system. The progress from latent  infection 
to TB disease can occur anytime in person’s life depending on age and immune system status 
(48). As pulmonary disease progresses, granulomas, the hallmark of TB disease, begin to 
form in the lungs as a result of the immune response to the invasion (46, 49). If TB remains 
untreated, cavities will form and lung function is significantly impaired, eventually resulting 
in death in the majority of cases. The factors responsible for successful containment of 
infection or progression to active disease are not completely understood. Significant co-
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morbidities such as HIV and diabetes and the use of immunosuppressive or anti-inflammatory 
drugs are well-documented risk factors for progression to active disease, but in apparently 
healthy individuals the risk factors leading to disease are less well understood. Smoking, 
chronic obstructive pulmonary disease (COPD) and other lung impairment is a risk factor (50, 
51). 
1.5 Paediatric tuberculosis 
1.5.1 Overview of paediatric tuberculosis 
Globally, WHO estimated that 1 million cases of TB occur among children (approximate 10% 
of the total 9.6 million TB cases) with 140,000 deaths  based on an extrapolation from 
estimates of adult TB (43). Approximately 75% of global childhood TB cases occur in the 22 
high TB burden countries (52), where childhood TB incidence contributes up to 20% of total 
TB cases (53). Dodd et al used a mathematical modelling technique, to estimate that 650,977 
children developed TB in 2010 (52). Although childhood TB contributes to the morbidity and 
mortality of children (54-56) and represents a large TB reservoir, it has not been a priority for 
national TB control programmes. One of the reasons for this is that TB in children is difficult 
to diagnose (and therefore both under-diagnosed and unconfirmed in many cases) and is 
considered to be less infectious than adult TB (23, 57). Recently, childhood TB is gaining 
more attention as it contributes considerably to childhood morbidity and mortality and there 
have been several research agendas and calls to action for childhood TB (58-63).  
 
Following exposure to an infectious TB case, children, like adults may successfully eradicate 
the infection or may become infected with MTB and subsequently may contain the bacilli but 
not eradicate them (latent TB) or develop symptomatic active TB. The risk to develop active 
disease varies by age (64) and is highest in very young children and children with 
immunosuppression, such as HIV infection (22) or malnutrition (65-67) (Table 1.3). Disease 
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progression after infection occurs within 12 months in the majority of children (>95%) who 
develop disease. Therefore, most childhood TB reflects ongoing transmission, and the pattern 
of drug resistance observed in children provides an accurate estimate of primary drug resistant 
TB within communities. Children can therefore be considered a sentinel population, with 
childhood TB incidence as an indicator to measure the effectiveness of TB control 
programmes (68).  
 
Like adult TB, TB can occur in any site of the body in children, but mainly occurs in the 
lungs (pulmonary TB) (69). Following inhalation to the lungs, MTB bacilli may disseminate 
to other organs via haematogenous spread, causing extra-pulmonary TB (EPTB) (Figure 1.4). 
Cervical lymphadenitis (also known as scrofula or The King’s Evil) is the most common 
phenotype of extrapulmonary TB for children, followed by tuberculous meningitis. Miliary 
TB and tuberculous meningitis are among the most severe EPTB presentations. Other 
extrapulmonary sites are described less commonly including the eyes, larynx, middle ear, 
mastoid, genitourinary and intestinal tract, pleura, skin etc. Factors contributing to disease 
presentation include: the age at time of primary infection and the time elapsed since infection. 
Very young children and immunosuppressed children are more at risk of severe TB. Children 
may also acquire infection with Mycobacterium bovis through the drinking of unpasteurised 
milk and “BCG-osis” may occur in children with HIV, following BCG vaccination. For this 
reason BCG vaccination is not recommended in known HIV positive children (70). 
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Figure 1.4: Disease manifestations of tuberculosis in a child  
Reproduced from: 
https://microbewiki.kenyon.edu/index.php/Tuberculosis_in_Children_in_Developing_Countri
es 
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Table 1.3 Risk of pulmonary and extra-pulmonary TB in children following infection 
with MTB  
Reproduced from  Ben Marais 2004 (65). 
  
Age at primary 
infection 
Immunocompetent 
children 
Risk of disease following 
primary infection (%) 
< 1 year No disease 50 
 
Pulmonary disease 30-40 
 
TBM or miliary disease 10-20 
1-2 years No disease 70-80 
 
Pulmonary disease 10 
 
TBM or miliary disease 2-5 
2-5 years No disease 95 
 
Pulmonary disease 5 
 
TBM or miliary disease 0.5 
5-10 years No disease 98 
 
Pulmonary disease 2 
 
TBM or miliary disease <0.5 
> 10 years No disease 80-90 
 
Pulmonary disease 10-20 
 TBM or miliary disease <0.5 
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1.5.2 Diagnosis of tuberculosis in children 
The accurate and prompt diagnosis of TB in children is essential, as delayed or incorrect 
diagnosis may lead to disseminated disease, death or severe sequelae in children. The 
diagnosis of TB in endemic countries is based on physical examination, history and contact 
investigation and available diagnostic tools (71). Smear microscopy is usually available with 
chest X-ray at larger centres; MTB culture is rarely available in endemic countries outside 
national reference laboratories. Unfortunately, the diagnosis of TB in children is more 
challenging compared to adults for several reasons. 
 
Firstly, children often have an atypical clinical presentation (including extra-pulmonary 
disease) and the classical triad of adult TB: cough, night sweats and weight loss is often 
absent. Constitutional symptoms may include failure to thrive and reduced playfulness; low-
grade or intermittent fever is less frequently seen. For children with suspicion of pulmonary 
TB, the usual presenting symptoms are a persistent, non-remitting cough or wheeze that is 
unresponsive to the treatment for an alternative cause (e.g. bacterial pneumonia). However, it 
is difficult to distinguish between other common respiratory infections such as pneumonia. In 
children with HIV infection, the clinical evaluation for TB is even more challenging because 
it is difficult to differentiate the TB-related symptoms from those caused by other HIV 
associated conditions and opportunistic infections (72, 73). For example, failure to thrive or 
weight loss is a typical feature of both TB and HIV infection.  
 
Secondly, collection of good quality specimens for diagnosing childhood TB is challenging. 
For PTB suspects, expectorated sputum is not always available in young children because 
they may not produce sputum or swallow their sputum. A gastric aspirate is therefore 
recommended for those who are unable to expectorate sputum, but the gastric aspiration 
procedure requires overnight-fasting, hospital admission and is invasive.  
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With current diagnostics, even with optimal conditions, the TB confirmation rate is extremely 
low, due to the difficulty to collect the appropriate specimen and the low bacterial load 
(paucibacillary) in paediatric specimens. Therefore, childhood TB treatment is often empiric 
without laboratory evidence, resulting in both over and under-diagnosis. Over-diagnosis leads 
to unnecessary treatment for TB, which may cause harm to children from severe adverse drug 
reactions, while under-diagnosis results in disease progression and increased mortality and 
morbidity. Therefore, improving the accuracy of diagnostics is necessary to reduce this risk.  
1.5.3 TB case definition 
For research on paediatric TB diagnostics, one reason for the lack of data has been the lack of 
a standardised research case definition. Like for adult TB, there is no gold standard (100% 
sensitivity and 100% specificity) against which to assess new techniques. For adult 
pulmonary TB, new diagnostic tools are usually assessed against culture, although it is 
recognised that this is an imperfect gold standard at best. In assessments of diagnostics for 
extrapulmonary TB and children, however, culture is known to be negative in over half of 
clinically treated cases. This led to each new published evaluation of TB diagnostics in 
children using, usually minor, variations of similar case definitions. This made it impossible 
to make comparative evaluations between studies and also to conduct meta-analysis of 
published data on each test. It is common to use a diagnostic certainty classification with 
microbiologically confirmed TB as a ‘definite’ diagnosis. Recently, patients with nucleic acid 
amplification positive results have been added to this confirmed category. The remaining 
cases are often classified as ‘probable’, ‘possible’ and ‘not TB’ using different criteria for the 
classification for whom there is inconsistent follow-up data.  
 
In 2012 a consensus case definition for classification of intrathoracic tuberculosis in children 
was first published (32, 74) and this was updated in 2015 following feedback from 
19 
 
stakeholders (75). A standardised case definition for research on tuberculous meningitis also 
incorporates childhood TBM (76), but there remains a need for consensus guidelines to 
standardise the reporting of other forms of extra-pulmonary TB in children.  
1.5.4 Specimen collection 
Alternative less invasive respiratory specimens have been studied to facilitate specimen 
collection and diagnostics in children, including induced sputum and string test. Induced 
sputum (IS) is collected using hypertonic saline to irritate the airways to induce cough and 
obtain material from lung airways (77). Sputum induction is unpleasant for patients, but was 
reported to be safe and useful for MTB confirmation of PTB in both HIV-infected and HIV-
uninfected children (78-80). However, the culture detection rate of IS was found to be less 
than of gastric aspirates (GA; 17.9% versus 32.5%) for diagnosing TB among children (81).  
The string test (ST), which is a method to retrieve enteric pathogens, is a potential tool for 
detection of MTB in patients who are unable to produce sputum (82). The string test uses an 
absorbent nylon string coiled inside a gelatin capsule. One end of the string protrudes from a 
small hole in the capsule. The trailing part of the string is tapped to the patient’s cheek and the 
capsule is swallowed. The capsule then dissolves in the stomach, allowing the string to 
become coated with gastro-intestinal secretions. After the allocated time, the string is 
retrieved by gentle pulling and placed in 0.9% saline solution and processed according to 
standard procedures for TB testing. The string test was reported to have an overall yield for 
culture confirmation in adults similar to IS (83). The culture yield of ST for diagnosis of TB 
in children was also reported to be comparable to IS in the study Nansumba et al of 
evaluating different specimen types for diagnosis of TB in children (84). However, the major 
disadvantage of ST is that it is not always well tolerated by young children (<4 years of age) 
(85).  
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Recently, some attention has been focused on investigating other types of specimens which 
are easily collected such as stool, blood or urine (86, 87). 
 
Detecting MTB by GeneXpert  MTB/RIF on stool samples from children having PTB was 
47.1% sensitive as compared to the sputum MGIT culture standard (87). In a recent small 
study using a modified stool processing protocol, the sensitivity of GeneXpert MTB/RIF on 
stool was 85% of positive cases by GeneXpert MTB/RIF on IS or gastric aspirate (88). For 
using blood sample, in a recent study by Pohl et al (89), detection yield of MTB in the whole 
blood by GeneXpert MTB/RIF was reported to be limited (7.1% of sensitivity using both LJ 
and MGIT culture as the reference standard). The new GeneXpert MTB/RIF Ultra assay is 
reported to have an improved limit of detection, but is unlikely to substantially improve the 
sensitivity on blood sample because the sample is always paucibacillary, even in adults and 
inhibitors present in blood, including haemoglobin, impair the sensitivity of PCR(90) . 
 
Collection of multiple samples has been frequently reported to increase the overall yield of 
detection of paediatric TB cases compared to single specimens (91). The detection rate of 
culture by two consecutive gastric aspirates was 67% versus 38% by single sample in 
diagnosing PTB among children in Cape Town, South Africa (92). Combination of different 
specimen types also was found to be a potential approach to improve the diagnosis TB in 
children (93). For instance, the sensitivity of GeneXpert/MTB RIF increased from 72.4% 
(only using standard samples) to 79.3% (additional samples including nasopharyngeal 
aspirate and stool) in an evaluation of different samples for TB diagnosis in children in 
multiple settings (86).  
1.5.5 TB diagnostic methods 
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During the past decades, systematic multi-country research programs on improving TB 
diagnostic tools were established, primarily led by the Foundation for Innovative New 
Diagnostics (FIND) (Figure 1.5). The Strategic and Technical advisory Group (STAG) of 
WHO also began to conduct systematic review of all published studies on each technique 
which has led to several WHO recommendations on TB diagnosis (Table 1.4). However, the 
most evidence comes from adult studies and there remain questions about their usefulness in 
diagnosis of TB in children.  
  
Figure 1.5 Current tuberculosis diagnostics pipeline listing the development phases and 
the types of technologies in development or evaluation 
Reproduced from Tuberculosis diagnostics in 2015 by Pai et al. (94) 
1.5.5.1 Smear microscopy 
Smear microscopy of mycobacteria for TB diagnosis has been used for more than 100 years. 
The Ziehl-Neelsen (ZN) stain to examine the presence of acid fast bacilli in smear under light 
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microscopy is the most common method performed in almost all microbiology laboratories as 
the primary means of TB diagnostics. The principle of the method is based on resistance of 
mycobacteria to the decolourisation by acid alcohol rinse after bacteria are stained with 
phenol dyes. This feature is attributed to the mycolic acid component present in cell wall of 
mycobacteria. This method is simple and relatively rapid (30 minutes), but requires 100 
microscopic field observations and cannot differentiate MTB from other non-tuberculous 
mycobacteria. The concentration of bacilli should be at least 5000 – 10,000 bacilli per 
millilitre of sputum to be visually detected (95). For diagnosis of adult PTB the sensitivity of 
microscopy was only approximately 20-40% for single sputum and 70% for two sputa (96, 
97). The sensitivity of ZN smear is even lower in paediatric samples. In a recent review, the 
pooled value of sensitivity of ZN staining was found to be less than 10% on sputa (10, 98), 
and very poor on gastric aspirates (99) and other specimen types. The inefficiency of ZN in 
children could be explained by the paucibacillary nature of paediatric TB. In adult patients 
suspected of TB meningitis, concentration of high volumes of cerebrospinal fluid (CSF) does 
improve the yield of ZN considerably (from 28% to 72%) (100) and is successful in diagnosis 
of tuberculous meningitis. However, it is often not feasible to collect such high volumes of 
CSF in children (at least 4 ml).  
 
Fluorescence microscopy (FM), using auramine to facilitate observation of bright acid-fast 
bacilli, can be performed at 400 times (rather than 1000) magnification which decreases 
reading time. The sensitivity of FM on sputum in adults was found to be on an average 10% 
more sensitive than conventional microscopy (95% CI: 5–15%) and almost 98% specific (9, 
96, 101). However, FM only gained 2% of sensitivity compared to light microscopy 
performed on sputum in diagnosing TB in children (14.6% versus 12.5% , p<0.001) (102). 
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In summary, although smear microscopy is commonly performed in the high burden countries 
to diagnose TB, current staining methods are rarely positive in paediatric TB cases (45)  and 
other detection methods should be developed for paediatric TB.  
1.5.5.2 Mycobacterial culture 
Mycobacterial culture is considered the gold standard for confirmed diagnosis of TB, 
although sensitivity and specificity are not 100%. Isolation of MTB is performed on agar-
based medium (solid culture) or liquid medium (liquid culture). The commonly used solid 
media are the egg-based Löwenstein-Jensen (LJ) or agar-based Middlebrook 7H10 media. 
The liquid media which are often used for the recovery of mycobacteria from clinical 
materials are based on Middlebrook 7H9. Liquid culture is more sensitive for MTB detection 
and also has shorter time to positivity; however, it is also more often contaminated, or cross-
contaminated. The choice between these methods usually depends on the availability of 
resources. 
 
In microbiology laboratories in resource-limited countries,  LJ slants are the most commonly 
used solid medium because of lower cost and being easy-to-use (104). The major limitation of 
this method is the slow turnaround time of 4-6 weeks (105), which is too late to influence 
clinical decision-making. In addition, LJ has a lower yield in comparison to liquid culture in 
diagnosing TB (22.8% vs. 29.7%) (104, 106). 
 
There are different commercial automatic liquid based culture systems for TB isolation such 
as MB/BacT [Biomérieux, Marcy l'Étoile, France], BACTEC 9000 [Becton Dickinson, NJ, 
USA] and the mycobacterial growth indicator tube [MGIT; Becton Dickinson]). MGIT 
culture has been endorsed by WHO since 2007 for early diagnosis of TB. The time to 
detection was reported to be 2 weeks shorter compared to LJ culture (107, 108). In a 
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paediatric study by Nhu et al, comparing MODS and GeneXpert  MTB/RIF to the MGIT gold 
standard, the time to detection of MGIT was 8 days (IQR 7–13) for diagnosing TB in children 
(109). Most studies performed on specimens from PTB suspected patients showed that MGIT 
culture is more sensitive than solid culture (104). Although liquid culture has an advantage of 
higher sensitivity and shorter turnaround time in compared to solid culture, the wide 
implementation of automated liquid culture have been limited because of high costs in high 
burden countries with limited resources (104). Therefore, a lower cost alternative has been 
developed, known as microscopic observation  drug susceptibility (MODS).  
 
Microscopic observation drug susceptibility assay 
MODS is a manual liquid culture system developed by a group in Peru for early detection of 
TB and determination of drug susceptibility (110). The principle of MODS is based on 
microscopic observation of MTB growth in cell culture plate wells containing Middlebrook 
7H9 medium with and without antituberculous drugs. The MODS assay uses an inverted 
microscope and standard equipment that most basic microbiological laboratories will have, 
which is suitable for resource limited settings. MODS has the additional benefit that culture 
plates for identification of MTB and susceptibility can be sealed and read while sealed and 
therefore do not require additional biosafety measures. The morphology of MTB growth on 
MODS culture is illustrated in the Figure 1.6, showing characteristic cord formation. This is 
the formation of long, rope-like strings of bacilli in which the bacilli align along the long axis 
in chains. Although cord formation is often used for the presumptive identification of MTB 
over other non-tuberculous mycobacteria, in reality the sensitivity of the method depends not 
only on the experience of the technician but also on the number of bacilli present and 
therefore it is not an accurate technique for MTB identification (111). 
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Regarding identification of MTB, most evaluations of MODS for TB diagnosis have been 
performed in adults with pulmonary TB. In comparison with the MGIT commercial assay, 
MODS shows similar sensitivity and shorter or similar time to detection (10, 112-114). In 
comparison with solid culture (LJ), MODS has a higher sensitivity with shorter time to 
detection (115, 116). Limited number of studies showed performance of MODS for diagnosis 
of TB in children (10), which are discussed in more detail in chapter 3  
 
Figure 1.6 MTB characteristic cording in MODS plate at ×400 magnification with 
inverted microscope (117). 
1.5.5.3 Nucleic acid amplification tests 
The addition of molecular tests can improve the speed and sensitivity to detect active 
tuberculosis (118). The turnaround time obtained by nucleic acid amplification tests (NAATs) 
may be within hours rather than days. However, current available NAATs are not sufficiently 
sensitive for a negative result to exclude tuberculosis, especially in extra-pulmonary TB.  
There are many commercial NAATs for TB in different stages of development (Figure 1.7). 
To be considered for paediatric TB, a commercial NAAT should demonstrate good sensitivity 
and specificity for adult PTB. The sensitivity for paediatric TB will be lower than for adult 
TB due to the paucibacillary nature of paediatric TB. Some of the more advanced NAATs, 
which have potential for TB diagnosis in children, are reviewed here. The only NAAT test to 
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have received WHO endorsement for diagnosis of paediatric TB is the GeneXpert MTB/RIF 
assay.  
 
 
Figure 1.7 Pipeline of molecular diagnostics for tuberculosis, by level of deployment (i.e. 
reference, intermediate, and peripheral microscopy laboratories)  
Reproduced from Tuberculosis diagnostics in 2015 by Pai et al. (94) 
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Loop-Mediated Isothermal Amplification assay 
Loop-Mediated Isothermal Amplification assay is a manual TB detection method based on 
loop-mediated isothermal amplification (LAMP) developed by Eiken Chemicals, Japan. The 
assay is simple, rapid (15-40 min), operation only requires isothermal conditions (requiring 
only a heat block) and results can be read by the naked eye (119, 120). Those characteristics 
should facilitate implementation in laboratories in high burden countries. The initial 
evaluation of LAMP in high burden countries was disappointing, however, with low 
specificity, and LAMP is currently being re-optimised. The recent upgraded LAMP version, 
PURE-LAMP, performed well on smear positive sputum (sensitivity of 89%) but only fair on 
smear negative sputum (sensitivity of 54%) for MTB detection using solid culture as the 
reference method in a study among adults in China (121). Larger multi-country studies will be 
needed to demonstrate sufficient accuracy for endorsement by WHO and scale-up. There is 
no evidence regarding sensitivity of the LAMP test for diagnosing TB in children (122).  
 
GeneXpert MTB/RIF 
GeneXpert MTB/RIF (Cepheid, USA) is a molecular assay, which can simultaneously detect 
MTB and rifampicin resistance, generating a result within 2 hours. This assay was endorsed 
by WHO in 2010 and was recommended for TB diagnosis in children since 2013 (123) (124). 
The accuracy of GeneXpert MTB/RIF for diagnosing TB in children was extensively 
investigated in various studies (98, 109, 125, 126). For diagnosis of PTB in children, the 
overall estimated sensitivity of a single GeneXpert test was 62% (95% CI: 51 - 73 %) for 
expectorated or induced sputum, 66% (95% CI: 51 - 81 %) for gastric fluid, when compared 
with culture as reference method (solid and liquid culture) (127). For diagnosing extra-
pulmonary TB in children, limited evidence of GeneXpert MTB/RIF performance on non-
respiratory specimens showed lower sensitivity compared to culture. GeneXpert MTB/RIF 
performed on CSFs showed sensitivity of 39% against culture for diagnosing paediatric 
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tuberculous meningitis in a study in Cape Town, South Africa (128). Available evidence from 
adult studies also showed the suboptimal sensitivity of GeneXpert MTB/RIF for EPTB 
diagnosis in comparison to liquid culture (pleural TB: 21.4%, 95% CI [8.8–33.9%]; TB 
meningitis: 62.8%, 95% CI [47.7–75.8%])(129)  
 
The major limitation of GeneXpert MTB/RIF is the high cost and test availability, which 
varies widely by country. South Africa has implemented GeneXpert MTB/RIF nationwide 
(130), while most other countries have placed GeneXpert MTB/RIF at a few key locations 
including centralised or reference TB laboratories. Priority is normally given to patients with 
presumed drug resistance or HIV infection, due to limited test availability and a focus on 
detection of MDR-TB. The majority of children with TB initially present at clinics or general 
hospitals, where the GeneXpert MTB/RIF assay is rarely available (123).  
1.5.5.4 Serodiagnostic tests 
Serodiagnostic tests, which detect antigen or antibody, are highly desirable for TB, due to 
potential speed and ease of use. However, accurate serodiagnostic tests have proved elusive 
for TB (131). Detection of MTB lipoarabinomannan (LAM) cell wall antigen in urine for TB 
diagnosis has been developed as a point of care test because it generates rapid results. LAM is 
present in the urine of TB patients. Early studies in adults showed the test has a low 
sensitivity but high specificity, and demonstrated the usefulness in ruling in TB in the group 
of patients with advanced HIV with low CD4 cell counts (132, 133). However, the test 
showed a very poor performance in children, even in children with disseminated (miliary) 
tuberculosis (134-136). In a prospective study of 535 children with suspected PTB, the LAM 
test showed a sensitivity of 48.3% and specificity of 60.8% against culture and did not have 
additional yield in HIV infected children. The LAM urine test also showed the little value in 
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diagnosis of tuberculous meningitis in children with sensitivity of 4.8% and a specificity of 
93.1% against the clinical diagnosis (137).  
1.5.5.5 Biomarkers 
A biomarker can be defined as a molecule found in blood, other body fluids, or tissues which 
can be used as a measurable indicator of normal biological processes. During recent years, 
searching for TB related biomarker has been an active area of research, in particular 
biomarkers which are able to distinguish between active TB, latent TB infection, and no 
disease (138). Availability of an accurate biomarker for TB may be a useful tool to improve 
the diagnosis of TB in children (139), because the current diagnostic tests are limited by the 
paucibacillary nature of paediatric TB as compared to the adult. However, the research into 
biomarkers in children diagnosis has been limited. The validation of biomarkers for use in TB 
diagnostics in children is also challenging due to the lack of standard sets of samples from 
children with and without (active or latent) tuberculosis.  
1.5.5.6 Interferon gamma release assays  
Interferon gamma release assays (IGRA) were developed as an alternative to the tuberculin 
skin test (140). Whole blood or peripheral blood mononuclear cells are stimulated in vitro 
with antigens from MTB and interferon gamma is measured. Early IGRA, which uses ESAT-
6 and CFP-10 antigens for stimulation, are not confounded by prior BCG vaccination because 
these antigens are not found in the BCG vaccine strains. Two commercial IGRAs are 
currently FDA approved for the diagnosis of MTB infection: The QuantiFERON-TB Gold In-
Tube test (Cellestis Limited, Carnegie, Victoria, Australia) and T-Spot test (Oxford 
Immunotec, Abingdon, United Kingdom). However, the use of IGRA for diagnosis of disease 
in children is not recommended, because IGRA cannot distinguish between latent and active 
TB disease, in particular in endemic settings where the latent infection is highly prevalent 
(141, 142).  
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Table 1.4 Laboratory tests for diagnosis of active TB and drug resistance 
 Details of policy guidance at: http://www.who.int/tb/laboratory/en/  
Reproduced from Heemskerk et al 2015 (45) 
Diagnostic tests for active TB 
Test type Principal 
commercial 
tests 
WHO policy  Advantages Limitations 
Smear 
microscopy 
Non-commercial Recommended Inexpensive, 
simple, rapid, 
specific 
Cannot differentiate 
NTMa and MTB 
LED 
microscopy 
  Recommended Inexpensive, 
simple, rapid 
Cannot differentiate 
NTMa and MTB 
Automated real-
time nucleic 
acid 
amplification 
GeneXpert 
MTB/RIF 
Recommended Rapid (2 h to 
result). Detects 
smear-negative 
TB. Also detects 
RIF resistance 
Higher cost than smear 
Loop-mediated 
isothermal 
amplification 
test kit for TB 
LAMP assay Not 
recommended. 
Under further 
development 
Rapid, simple Subjective interpretation 
and poor specificity 
Rapid speciation 
strip technology 
  Recommended For rapid 
differentiation of 
NTMa and MTB 
Expensive 
Serodiagnostic 
tests 
Over 20 
commercial 
variants 
Not 
recommended 
  Poor sensitivity and 
specificity 
Interferon-
Gamma release 
assays 
QuantiFERON-
TB Gold In-
Tube test, T-
Spot test 
Not 
recommended 
for diagnosis of 
active TB 
  Complex to perform and 
indeterminate results 
relatively common 
Drug susceptibility tests 
Test type Principal  WHO policy  Drugs tested Advantages Limitations 
Phenotypic 
DST on solid 
or liquid 
media 
Non-
commercial 
Recommended 
for USE 
All drugsb Gold-standard Extremely 
long time to 
result (6–12 
weeks) 
Commercial 
liquid culture 
and DST 
systems 
Bactec MGIT Recommended 
for USE 
STR, INH, RIF, 
EMB, PZA 
Faster than 
solid culture 
media. Ten 
days if direct 
testing 
Expensive 
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Line probe 
assay first-
line 
MTBDR-Plus; 
INNO LiPA-
RIF TB 
Recommended 
for USE on 
smear-positive 
samples 
RIF, INH Result in 2 
days 
Expensive 
Line probe 
assay second-
line 
MTBDRsl Not yet 
recommended 
due to 
insufficient 
evidence 
Fluoroquinolones, 
aminoglycosides 
and EMB 
Result in 2 
days 
Low 
sensitivity for 
ethambutol 
Automated 
real-time 
nucleic acid 
amplification 
GeneXpert 
MTB/RIF 
Recommended 
for USE 
RIF Result in 2 h Cartridge 
price 
reductions 
only available 
in low middle 
income 
countries 
Microscopic 
observation 
drug 
susceptibility 
(MODS) 
Non-
commercial 
Recommended 
for USE 
RIF, INH Low-tech. 10–
14 days for 
result 
Subjective 
interpretation. 
Laborious 
manual plate 
readingc 
Colometric 
redox 
indicator 
(CRI) 
Non-
commercial 
Not yet 
recommended 
due to 
insufficient 
evidence 
RIF, INH Low-tech. 10–
14 days for 
result 
Subjective 
interpretation 
Nitrate 
reductase 
assays (NRA) 
Non-
commercial 
Not yet 
recommended 
due to 
insufficient 
evidence 
RIF, INH Low-tech 10–
14 days for 
result 
Subjective 
interpretation 
Phage assays FASTplaque, 
lucerferase 
reporter phage 
assay 
Not 
recommended 
RIF, INH N/A Poor 
specificity 
Sequencing Non-
commercial 
No policy Depends on gene 
regions sequenced 
Can provide 
information on 
multiple drugs 
simultaneously 
Requires 
specialist 
interpretation. 
Not generally 
available 
outside 
research 
centres 
a NTM: non-tuberculous mycobacteria; b Reliable for first-line drugs (except pyrazinamide), 
fluoroquinoloes and aminoglycosides. Second-line DST should be interpreted in context of 
treatment history and local prevalence of resistance (if known); c Indicator well must be 
incorporated to differentiate NTM from MTB  
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1.5.6 Treatment of tuberculosis 
1.5.6.1 Purpose of treatment 
The main goals of TB treatment are to cure the patient of TB, to prevent death from TB or its 
late effects and to prevent TB relapse. Successful TB treatment also prevents further 
transmission of TB and drug resistance development. The principles of treatment of TB in 
children are the same as for the treatment of TB in adults (143). TB treatment needs be taken 
at least six months with a combination of TB drugs with different actions. It consists of two 
phases: an intensive phase followed by a continuation phase. In the first phase, the TB drugs 
rapidly eliminate the majority of actively replicating MTB bacteria. The continuation phase 
aims to eradicate any remaining dormant or near-dormant bacteria while preventing the 
emergence of drug-resistant organisms. The treatment regimen of susceptible TB in children 
will be discussed in the next section. 
1.5.6.2 Treatment regimens 
 The first-line anti-TB agents form the core of treatment regimens. They include: isoniazid 
(INH), rifampicin (RIF), ethambutol (EMB), pyrazinamide (PZA) and streptomycin (SM). 
The standard treatment regimen for paediatric TB in the area with high HIV prevalence or 
high isoniazid resistance or both is an intensive phase of isoniazid (H), rifampicin (R), 
ethambutol (E) and pyrazinamide (Z), followed by two months of isoniazid and rifampicin 
(usually written as 2HRZE/4HR). The three-drug antituberculous regimen (2RHZ/4RH), 
which was previously recommended for less severe cases of childhood TB, is no longer 
recommended by WHO for any form of childhood tuberculosis since 2009, due to high 
likelihood of undetected drug resistance (144) 
  
Recommended treatment regimens by WHO are summarised in adolescents and older 
children (once they reach a body weight of 25 kg) can be treated at adult dosages. Prior to 
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2006, paediatric TB doses were extrapolated from adult doses. However, following a series of 
pharmacokinetic studies in children, mainly from South Africa, it was concluded that children 
were severely under-dosed using these guidelines. This is due to a more rapid drug 
metabolism in children and a higher surface area:volume ratio in young children; a well 
recognised phenomena in paediatrics. In 2010, a systematic review of available data showed 
no safety concerns and the WHO dose guidelines were therefore revised to increase the 
paediatric dose of all drugs, except streptomycin. 
Table 1.5 Revised WHO recommendations for first-line drug dosage in children showing 
the 2006 and 2010 recommendations.  
Drug Daily dosage (dose range) in mg/kg 
2010 recommendations (143, 145) 
Daily dosage (dose range) in mg/kg 
2006 recommendations (146, 147) 
INH 10 (7-15)* 5 (4-6) 
RIF 15 (10-20) 10 (8-12) 
PZA 35 (30-40) 25 (20-30) 
EMB** 20(15-25) 15 (15-20)* 
SM 15 (12-18) 15 (12-18) 
* The higher end of the range for isoniazid dose applies to younger children; as the children 
grow older the lower end of the dosing range become more appropriate 
**Previously, EMB was not recommended for children less than 5 years old due to potential 
ocular toxicity but this was withdrawn in the 2010 guidelines following a review of the 
evidence. 
1.6 Tuberculosis resistance 
1.6.1 Classification of tuberculosis resistance 
According to WHO definitions, drug resistant TB (DR-TB) is classified into 4 discrete 
categories: mono resistant, poly resistant, multidrug resistant and extensively drug resistant. 
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In addition, the classification is based on the history of treatment into 2 categories: acquired 
and primary drug resistant TB. Patients are defined as having primary drug resistance if there 
is no history of previous TB treatment when resistance is diagnosed. Patients are defined as 
having acquired drug resistance if they develop drug resistance while on TB treatment or are 
diagnosed with drug resistant MTB that is genetically identical to isolates from the same 
patient collected before treatment or during a previous episode of TB. In 2011, the definition 
of drug resistance in children was proposed in the first consensus statement on drug resistant 
tuberculosis in children (Table 1.6) 
 
Primary drug resistance occurs when a person becomes infected with drug-resistant MTB, 
transmitted from an infected donor, and develops active TB. Acquired drug resistance 
happens when individuals develop resistance during treatment, which is thought to be caused 
by poor treatment quality leading to the selection and stepwise amplification of mutant 
resistant MTB. Specific mutations associated with drug resistance are described in more detail 
in the next sections. Factors that contribute to poor treatment outcomes include: (i) 
inappropriate treatment due to lack of treatment guidelines and training, poor patient 
education and treatment support, poor management of treatment response and adverse drug 
reactions, (ii) inadequate drug quality and supply due to stocks running out, low quality or 
counterfeit drugs and poor storage conditions, (iii) incomplete adherence to treatment by the 
patient. People who belong to vulnerable groups (HIV infection, drug abuse, alcoholism) or 
have poor socioeconomic conditions have poor access to health care service generally have a 
higher risk of drug resistance development (148). 
  
35 
 
 
Table 1.6  Terminology for Drug-Resistant Tuberculosis in Children (149) 
1.6.2 Transmission of drug resistance  
Transmission of drug resistant TB in populations is thought to be attributable to both 
socioeconomical factors and intrinsic microbiologic factors. The socioeconomical factors that 
facilitate TB transmission include poor ventilation, crowding, poor infection control measures 
Terms of drug resistance 
categories Definition 
Monoresistant Resistance to a single TB drug 
Polyresistant Resistance to 2 or more TB drugs other than both rifampicin 
and isoniazid 
MDR-TB Resistant to at least both rifampicin and isoniazid 
Pre-XDR MDR-TB with resistance to either a fluoroquinolone, or at 
least 1 of 3 injectable second-line TB drugs, but not both 
XDR-TB MDR-TB with resistance to both a fluoroquinolone and at 
least 1 of 3 injectable second-line TB drugs 
Primary resistance DR-TB that results from transmission of DR MTB. This 
could be any of the after clinical situations in a child newly 
diagnosed with confirmed or probable DR-TB: 
(a) never treated: a child without previous TB treatment 
who has not yet received any TB treatment; or 
(b) previously treated: a child who was previously treated 
with first-line drugs who was either cured or completed that 
treatment regimen; or 
(c) Currently receiving treatment: a child who is receiving 
first-line drugs for presumed drug susceptible-TB disease 
(DS-TB). 
Acquired resistance A child previously diagnosed with confirmed DS-TB disease 
who developed DR-TB disease (or resistance to additional 
drugs) during TB treatment 
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(especially in closed settings). It has long been hypothesised that MDR-TB is less-
transmissible than drug susceptible TB, due to fitness costs of resistance. However, it has now 
been shown that MTB can develop compensatory mechanisms to mitigate the fitness costs of 
resistance and some MDR TB strains may be as transmissible as drug susceptible strains (150, 
151). Reports have also suggested that certain strains of the Beijing lineage carry a lower 
fitness cost for certain mutations than other lineages. The reasons for this are not completely 
known and may be due to mechanisms such as efflux pumps or other compensatory 
mechanisms such as higher tolerance for oxidative stress that was observed in the INH 
resistant strains carrying katG mutations (152-154). Catalase peroxidase encoded by katG 
also functions to protect against oxidative stress. It was reported that overexpression of ahpC 
encoding for alkyl hydroperoxidase  reductase in katG mutants may compensate for loss of 
katG activity.  In the epidemiological study by Buu et al, MTB of the Beijing genotype 
resistant to streptomycin showed higher rates of transmission than other genotypes (155). 
1.6.3 Introduction of first line anti TB drugs  
The first line drugs include rifampicin, isoniazid, ethambutol and pyrazinamide. Illustration of 
the targets of these anti-TB drugs are shown in Figure 1.8. 
Rifampicin (RIF) was introduced as TB treatment in 1967. RIF prevents RNA transcription 
of MTB by inhibiting the beta subunit of RNA polymerase. Consequently, protein synthesis is 
interrupted, causing bacterial death (156). 
Isoniazid (isonicotinic acid hydrazide, INH) has been the most commonly used 
antituberculous drug since recognition of its clinical activity in 1952. INH is a very powerful 
anti-TB drug with a very complex mechanisms of action against mycobacteria (157). INH is a 
pro-drug which requires to be activated by the MTB catalase-peroxidase enzyme KatG (158). 
The activated INH has several targets in mycobacteria. It interferes with enzymes involved in 
cell wall mycolic acid synthesis (159) and also metabolism of DNA and lipids. 
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Ethambutol (EMB), discovered in 1961, inhibits MTB cell wall synthesis via the inhibition 
of biosysthesis of arabinogalactan, a major polysaccharide in the MTB cell wall. This activity 
interrupts the growth and replication of MTB, therefore EMB is only active against 
replicating bacilli (131). 
Pyrazinamide (PZA) was first tested as an anti-TB drug in the early 1950s. Similar to INH, 
PZA is a pro-drug, which only has antibacterial activity after activated by the enzyme 
pyrazinamidase (PZase) (160). Its active form, pyrazinoic acid (POA), targets the cell 
membrane resulting in dysfunction of ion exchange membrane channels, causing an 
intracellular pH change. This change disrupts enzyme activities and results in cell death. 
Uptake and intrabacillary accumulation of POA is enhanced when the extracellular pH is 
acidic (161). PZA has been hypothesised to act against bacilli residing in acidified 
compartments of the lung that are present during the early inflammatory stages of infection 
(162). 
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Figure 1.8 Illustration of the targets of first line anti-TB drugs. 
 (Source: http://www.niaid.nih.gov) 
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1.6.4 Molecular mechanism of drug resistance to the first line anti TB drugs 
Resistance to anti-TB drugs is caused by spontaneous mutations in the bacterial genome (as 
opposed to plasmids and transferable elements). The rate of mutation varies by drug between 
1 in 106-109 per cell division. Therefore, a small number of drug resistant bacilli to any given 
drug will be present in a large MTB populations (e.g. in granulomas), regardless of drug 
pressure. Therefore, anti-TB drugs have to be given in combination, as the risk of a mutant 
containing two resistance mutations is <10-18. If monotherapy is given, the resistant 
population will be selected, and emerge as dominant. The risk of mutation may also be related 
to the genetic background of the MTB (163). For example, several epidemiological studies 
have shown association between specific mutations and the Beijing lineage of MTB, while in 
vitro work has suggested this may be due to a higher spontaneous mutation rate or ability to 
develop compensatory mechanisms to ameliorate the fitness costs (150, 151, 164, 165). MTB 
does not support plasmids and therefore does not acquire drug resistance through plasmid 
transfer. Resistance may also occur through up-regulation of efflux-pump mechanisms but 
these are poorly understood in MTB at the present time. In the following sections, I 
summarise the molecular mechanisms of drug resistance to individual first line drugs.  
1.6.4.1 Isoniazid 
INH is the most commonly used antituberculous drug and is also used as monotherapy for 
latent TB, therefore, resistance to INH occurs more frequently among clinical isolates than 
other agents (166). INH resistance occurs most often due to mutations in katG (the gene 
encoding the mycobacterial catalase-peroxidase KatG), occurring in 50–80% of INH-resistant 
isolates. INH is a pro-drug which requires KatG to be activated. Mutations, particularly at the 
315 codon, reduce the ability of KatG to activate INH (167). A single point mutation resulting 
in substitution of threonine for serine at residue 315 (S315T) accounts for the majority of 
high-level INH resistance among clinical isolates. Point mutations at other sites in katG and 
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deletion of sections or the whole gene may also confer resistance. INH resistance may also 
arise from mutations in inhA, resulting in reduced affinity of the enzyme for NADH without 
affecting its enoyl reductase activity or in the promoter region of the mabA-inhA operon (most 
commonly -15 C-T) resulting in overexpression of the wild-type enzyme. inhA mutations 
generally confer ‘low-level’ INH resistance (1-2µg/ml) while katG mutations often confer 
much higher level resistance (>3µg/ml). As opposed to other INH resistance conferring 
mutations, the katG 315 mutation also does not come with a fitness cost. Approximately 10-
20% of phenotypically INH resistant isolates carry no mutations in known resistance 
conferring genes. This is one of the reasons for the current limitations of NAATs, such as the 
line probe assays, for detecting INH resistance.  
1.6.4.2 Rifampicin 
Resistance to RIF in MTB results from single point mutations in the 81 base-pair rifampicin-
resistance-determining region of rpoB, which encodes a subunit of the mycobacterial RNA 
polymerase (168). Mutations in codons 531 [Ser] and 526 [His] are the most common. 
Approximately <5% do not contain any mutations in the rpoB gene, suggesting alternative 
resistance mechanisms, potentially including altered rifampicin permeability or mutations in 
other RNA polymerase subunits (169). However, this may be due to inaccurate phenotypic 
testing or misidentification of isolates as rifampicin resistant. Recent work has attempted to 
elucidate the differences in identification of rifampicin resistant isolates between phenotypic 
DST methods, especially solid vs. liquid media. Resistance to rifampicin alone is rare, and 
more than 90% of rifampicin-resistant isolates are also resistant to INH. Rifampicin 
monoresistance is more commonly identified in people living with HIV, but remains rare. 
Therefore, rifampicin resistance is used as a surrogate marker for MDR-TB (170). 
1.6.4.3 Pyrazinamide 
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PZA resistance has been attributed primarily to mutations in pncA encoding pyrazinamidase, 
which activates the pro-drug PZA into its active metabolite (171). Most mutations, including 
point mutations, deletions, and insertions, have been reported in a 561-bp region of the open 
reading frame or in an 82-bp region of its putative promoter. A small percentage of isolates 
with high-level PZA resistance contain no mutations in pncA or its promoter, suggesting 
alternative mechanisms of resistance such as deficient uptake, enhanced efflux, or altered 
pncA regulation.  
1.6.4.4 Ethambutol 
Resistance to EMB in MTB is usually associated with point mutations in the embCAB operon 
(172). As the majority of EMB-resistant clinical isolates contain mutations in embB, EmbB is 
considered to be the main target of EMB (173). Line probe assays targeting embB mutations 
have poor sensitivity (approximately 60%) and 25% of EMB resistant isolates have no 
mutation in the embCAB operon, therefore other mechanisms of resistance clearly remain to 
be identified.  
 
Molecular mechanisms of drug resistance in MTB were thoroughly reviewed by Almeida et 
al. (174). In the CRyPTIC study (Comprehensive Resistance Prediction for Tuberculosis: an 
International Consortium), funded by the Wellcome Trust and led by the University of 
Oxford, 100,000 MTB genomes from around the world will be sequenced, aiming to 
definitively identify all drug-resistance associated mutations and ultimately improve the 
molecular identification of drug resistance in MTB  
 (http://modmedmicro.nsms.ox.ac.uk/cryptic/ ). 
1.6.5 Drug resistance epidemiology in children 
The emergence and spread of drug resistance in MTB has posed a serious threat to global TB 
control. Globally, the WHO reports an estimated prevalence of 3.6% and 20.2% among 
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notified TB cases for primary and acquired multidrug resistant tuberculosis (resistant to both 
rifampicin and isoniazid, MDR-TB), respectively, with significant country and regional 
variations. Children are not a priority in national surveillance programmes and the difficulty 
of isolating MTB from children means drug susceptibility is rarely confirmed. In fact, 
children (defined by WHO as individuals less than 15 years old) are excluded in most designs 
for national TB surveys or, if included, the percentage of children is insignificantly small. For 
instance, in the Global Drug-Resistant Surveillance Project surveys, children account for less 
than 2% of the more than 300,000 patients (175). Therefore, the estimated number of drug 
resistant TB in children can only be inferred from adult data. 
 
With up to 20% of the TB caseload found in children (<15 years of age) in high-burden 
settings (23, 52), the number of children with drug-resistant (DR) TB and MDR-TB is likely 
to be substantial (Table 1.7), as was described e.g. in a recent review by Yuen et al, with risk 
variation by geographical setting, depending on the background prevalence of INH-resistant 
MTB circulating in the population (Figure 1.9). It was estimated that 12.1% of all children 
with TB had isoniazid-resistant tuberculosis, representing about 120,000 incident cases of 
isoniazid-resistant tuberculosis in children in 2010, with the majority of these found in the 
Western Pacific and South-East Asian regions (176, 177). Globally, the number of children 
with MDR-TB is estimated at 3.2 % of all paediatric TB cases, which would give 32,000 
cases of paediatric MDR-TB occurring in 2010 (178) (Table 1.7). MDR-TB in children is 
thought to be usually transmitted from an MDR-TB infected adult, usually a parent or care-
giver, rather than secondary resistance development within the child because of the 
paucibacillary nature of TB in children. The limited published information about children 
with MDR-TB is an obstacle to efforts to advocate for better diagnostics and treatment. 
However, the scattered nature of cases and difficulty of isolating bacteria to confirm the 
diagnosis makes clinical trials for MDR-TB in children extremely challenging.  
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Table 1.7 Estimated numbers of incident cases of TB disease and MDR-TB disease in 
children by region, 2010 (178) 
 
*These regions are aligned with those as defined by the World Health Organization (WHO) 
  
WHO region* Estimated number of child TB cases Estimated number of child MDR-TB cases 
  Estimate 95% Lower 
Confidence 
Bound 
95% Upper 
Confidence 
Bound 
Estimate 95% Lower 
Confidence 
Bound 
95% Upper 
Confidence 
Bound 
African region 279,825 250,187 308,717 4,736 2,829 6,848 
Eastern 
Mediterranean region 
71,162 60,320 83,193 2,417 339 5,087 
European region 43,224 39,572 47,242 5,645 4,206 7,463 
Region of the 
Americas 
27,199 24,935 29,635 606 374 854 
Southeast Asia region 397,040 350,615 447,474 10,000 4,993 15,568 
Western Pacific 
region 
179,515 159,246 202,626 8,349 5,639 11,610 
Total 999,792 937,877 1,055,414 31,948 25,594 38,663 
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Figure 1.9 Estimated percentage of child TB cases that are resistant to isoniazid by 
region (177) 
1.6.6 Drug resistance in Vietnam  
Vietnam is ranked 12th among 22 high burden countries with TB and 14th among 27 countries 
with a high burden of MDR-TB, with  burden being defined as an absolute numbers of cases. 
The estimated incidence and the estimated prevalence of TB in Vietnam is 144 per 100,000 
population per year and 209 cases per 100,000 population, respectively (1). The fourth 
national drug resistance survey was conducted in 2011 (179). There are estimated to be about 
5,100 MDR-TB cases among notified TB cases per year. The proportion of TB cases with 
MDR-TB among new and retreatment cases is estimated to be 4% and 23%, respectively, 
with around 6% among TB cases co-infected with HIV. Figure 1.10 shows the estimated 
number of MDR-TB patients among notified TB cases through Vietnam in 2013.  
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In another study in Hanoi, which investigated the status of drug resistance among newly 
diagnosed patients with sputum smear- and culture-positive TB, isoniazid and streptomycin 
resistance was detected in more than a quarter of TB patients (180). Drug resistance is slightly 
higher in southern Vietnam and is also higher in cities compared to rural areas, a pattern seen 
in many high burden countries (181). 
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Figure 1.10 Estimated number of MDR-TB patients among notified TB cases in 
Vietnam, 2013 (165). 
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Children aged less than 5 years old account for 24.3% of the population (22 million children, 
population statistics 2014) (182). It was estimated that 351,000 children are infected with TB 
annually (National Tuberculosis Programme [NTP] survey 2006) (183), with 13,000 (5%-
10%) children estimated to develop TB, but only a small number were reported by the NTP 
(6%). Besides the difficulties in diagnosis of TB in children as mentioned above, additional 
explainable factors causing the low notification case number among children in other high 
burden countries like Vietnam are ineffective case finding strategies (184), incomplete 
recording, imperfect reporting of current national TB control program (185). Although active 
household contact screening is recommended for improved case finding, it is rarely performed 
in Vietnam and most children are not included in active contact investigations (185, 186). For 
a long time, children have been excluded in national surveys of drug resistance. As a 
consequence, there is limited data of TB drug resistance among children in Vietnam. In line 
with WHO recommendations, the NTP has now begun to systematically collect data on 
paediatric TB and this will provide a baseline to improve both data and management of 
paediatric TB in Vietnam. 
1.7 Molecular epidemiology of TB 
1.7.1 Genetic diversity 
Understanding the genetic epidemiology of a pathogen will help us to understand 
transmission patterns within and between populations (including the spread of drug 
resistance), virulence and evolution of an organism. Early work on MTB genetic variation 
focused on isolates from Europe and North America and therefore the genetic diversity of 
global MTB was underestimated until the last 2 decades, when researchers started to 
systematically analyse global collections(187, 188). However, MTB is relatively clonal 
compared to other bacteria as evolution does not occur via horizontal gene transfer due to its 
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intracellular replication. Variation in MTB therefore principally arises from genomic 
deletions, rearrangements and point mutations. (189). 
 
MTB has been classified into six major lineages. Initially this classification was based on 
large genomic deletions, but this classification has since also been confirmed by whole 
genome sequencing (190, 191). Each lineage is strongly associated with a geographic region 
and therefore the lineages may be known by either numbers or the name denoting the 
geographical area where they are predominantly isolated (188) (Figure 1.11). Lineage 4 is 
mostly found in Europe and America; while lineage 2 is predominant in East-Asia and lineage 
3 in the Indo-Oceanic region. Lineages 5 and 6 are predominantly found in West Africa. A 
seventh lineage has recently been described from Ethiopia (34). Figure 1.11 shows the 
geographic distribution of the six lineages.  
 
Figure 1.11 The global population structure and geographical distribution of MTB  
 (a) Six lineages of global phylogeny for MTB are defined by large sequence polymorphism 
(LPS). The names of the lineage-deﬁning LSPs are shown in rectangles. The geographic 
regions associated with speciﬁc lineages are indicated. (b) The geographic distribution of six 
lineages (190).  
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Typing methods used in epidemiological studies for MTB are described in more detail below. 
Each method has advantages and disadvantages and the most appropriate method will depend 
on the geographical origin of the strains, as the discriminatory power of different typing 
techniques varies widely between the major lineages. The gold standard technique is now 
whole genome sequence analysis, and while this has become cheaper and more accessible in 
recent years, it remains beyond the reach of most national TB control programmes.  
1.7.2 Genotyping method for MTB 
1.7.2.1 IS6110 RFLP 
IS6110 is the insertion sequence which was first recognised by Thierry et al. in the 1990s 
(192). This sequence is a 1,355 base pair long sequence, which is found within the MTB 
complex only. It is present at multiple copies in most members of the MTB complex, ranging 
from 0 to 25 copies. The varying copy number and location in the genome which can be 
visualised using probe hybridisation to digestion fragments is the basis of IS6110 genotyping 
of MTB.  
 
The IS6110 restriction fragment length polymorphism (IS6110-RFLP) is a method starting 
with endonuclease digestion of the genomic DNA with the PvuII restriction enzyme, followed 
by separation of restriction fragments through gel electrophoresis, transfer onto a membrane 
and hybridisation with a labeled probe complementary to the sequence of IS6110 (193). Each 
fragment represents a single copy of IS6110 surrounded by flanking DNA of different 
lengths. 
 
The IS6110-RFLP technique has been standardised. The method is highly discriminatory and 
reproducible. It was one of the most commonly used methods for MTB typing in the 1990s 
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and was long considered the gold standard in the molecular epidemiological investigation of 
TB. However, this technique has some major limitations and has now been largely replaced 
by simpler techniques. Firstly, the technique requires a large volume of high quality DNA for 
restriction enzyme digestion, which necessitates a subculture step. Secondly, it takes several 
days to perform and there is the need for sophisticated and expensive computer software for 
analysis and matching as well as experienced technicians. Finally, the discriminatory power is 
insufficient for those isolates with a low copy number of IS6110 (less than 5 copies) that 
circulate widely in Asia (194). 
1.7.2.2 Spoligotyping 
Spoligotyping (Spacer Oligonucleotide Typing) is based on identifying polymorphisms in the 
spacer units in the direct repeat (DR) region of the genome. The DR region comprises 
multiple identical 36bp regions interspersed with non-repetitive spacer sequences of similar 
sizes (195). Variation in this regions is usually caused by homologous recombination between 
adjacent or distinct DRs or by transformation due to the insertion of IS6110. Forty-three 
spacers among 60 are selected as a basis of standard spoligotyping. The presence or absence 
of these spacers is detected by PCR amplification of short sections of the region by using 
primers targeted to the direct repeat sequence. The resulting PCR fragments, which also 
contain the non-repetitive spacer sequences, are then reversely hybridised to immobilised 
probes for each of the 43 spacer sequences (196). The presence or absence of the spacers in 
each tested isolate is recorded in binary (0/1) code, generating a ‘spoligotype’ for each isolate. 
The spoligotype can be shortened into an octal code format. This method has several 
advantages for typing MTB: it is a simple procedure, robust and with high reproducibility, it 
can be applied directly on smear-positive sputum and a global database for comparison 
between laboratories is available (197). This technique is widely used in both evolutionary 
and epidemiological studies (198). Based on spoligotyping patterns, MTB can be divided into 
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its major families (199). However, spoligotyping is not discriminatory for strains of the East-
Asian/Beijing lineage (lineage 2), and therefore is of limited use in Asia. The Beijing 
genotype lacks spacers 1-34 on spoligotyping. Spoligotyping is useful for discrimination 
between isolates of MTB with only few copies of IS6110 (200), which are usually of lineage 
1 (Indo-Oceanic) and are also common in South-East Asia. In addition, spoligotyping tends to 
homoplasy (independent mutation events causing the same genotype) based on the evidence 
of phylogenetic unrelated isolates share the same spoligotype.  
1.7.2.3 Mycobacterial Interspersed Repetitive Units - Variable Number Tandem 
Repeats (MIRU-VNTR) typing 
Mycobacterial Interspersed Repetitive Units (MIRU) is the term used for variable number 
tandem repeat (VNTR) typing in mycobacteria. MIRU are groups of repetitive units 
distributed throughout the mycobacterial genome, which were first described by Supply et al. 
They are direct tandem repeats and are oriented in one direction relative to the transcription of 
the adjacent genes. Based on the sequence homology of MTB sequences, it was estimated that 
there may be 40-50 such MIRUs per genome (201). Further work by Supply et al. identified a 
total of 41 MIRU loci when analysing the complete genome of the type strain H37Rv (Figure 
1.6) (202). These tandem repeats varied between loci and strains and may be amplified with 
the use of specific PCR primers to each MIRU-flanking region. The number of repeats at each 
locus is calculated based on sizing of these PCR products, generating a numerical sequence: 
the MIRU genotype. Genotyping based on the Variable Number Tandem Repeats on MIRU, 
so called MIRU-VNTR typing, is a well-described method. Exploration of the MIRU loci 
with optimal discriminatory power has resulted in a recommendation of a set of 15 MIRU loci 
for molecular epidemiologic studies and 24 loci for molecular phylogenetic studies (203-207).  
MIRU-VNTR types align with other phylogenetic markers and assigns MTB to its major 
lineages described above (188). The discrepancies sometimes observed between 
52 
 
spoligotyping and MIRU based classification schemes underline that MIRU-based 
classification may group MTB isolates that are phylogenetically close but appear distant if 
only judged based on their spoligotyping patterns (208).  
 
MIRU-VNTR typing is also an extensively characterised tool for transmission studies (209). 
The more MIRU loci are used, the higher the discriminatory power. The old 12 loci format is 
more discriminating for isolates with a low copy number of IS6110 only. When more than 12 
loci are used, or MIRU analysis is combined with spoligotyping, the discriminatory power is 
similar to that of IS6110-RFLP analysis (205). Better resolution and reduced clustering rate 
for MTB belonging to the Beijing lineage has been shown by using an additional four 
hypervariable MIRU-VNTR loci (210). 
 
MIRU-VNTR typing has some advantages: it is a reproducible method, generates digital 
results that are readily exchangeable between laboratories and ensures the availability of 
global databases (211). The method can be simplified even further by the utilization of 
multiplex PCR and automated DNA sequencing technologies (212) although a manual 
protocol is more suitable for low workload laboratories in resource limited setting. 
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 .  
Figure 1.12 Location of MIRU loci in MTB H37Rv genome . Source from Supply et al. 2000 (202)   
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1.7.2.4 Whole genome sequencing 
Whole-genome sequencing (WGS) technologies provide a complete genomic sequence 
including lineage characterisation and drug-resistant mutations (213-216). WGS is used in 
some developed countries to predict drug resistance in MDR-TB, but is not yet routinely 
applied to all TB cases due to high costs. It is likely to become more widely used as the costs 
decrease and simplicity of the technique increases. It is also the gold standard for outbreak 
investigation and tracking transmission (217). However, there are obstacles to implement 
these technologies in lower income countries, including the costs and specialised skills 
required for data interpretation. Several predictive software tools have been developed for 
MTB drug susceptibility prediction from WGS (218), but they are not yet field validated and 
our knowledge of resistance determinants is incomplete. Thus, older methods still have value, 
as they have a faster turnaround time and can handle a higher batch capacity at an affordable 
cost.  
1.8 Outline of the thesis 
Early and accurate diagnosis of TB will not only improve the outcome of treatment but also 
interrupt chains of transmission. During the past decades, improved diagnostic tools have 
shortened the time to detection and increased accuracy, but a true point of care test remains 
elusive (219). The characteristics of the ideal diagnostic test can be summarised by the 
ASSURED acronym (220): A-Affordable by those at risk of infection, S-Sensitive, S-
Specific, U-User-friendly, R-Rapid, E-Equipment-free, D-Deliverable to those in need. 
Diagnostic tests for adult TB are still not sufficiently sensitive to rule out disease, and the 
challenges are amplified in paediatric TB. Children, particularly those under 5 years of age, 
do not produce sputum, the samples that are obtainable have very low bacillary loads, 
presenting symptoms are often non-specific and young children are unable to report 
symptoms.  
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Evaluation of novel diagnostic tests for TB is complicated by the lack of a gold standard for 
comparison due to the low sensitivity of culture in paediatric TB. However, it is vital that, as 
we develop new tests for the diagnosis of adult TB, we continue to evaluate them in children 
so this extremely vulnerable population can benefit from advances in TB research. In this 
thesis, therefore, we examine the application of available culture methods in TB detection in 
children living in endemic context.  
 
The non commercial liquid culture assay, which is based on the microscopic observation of 
MTB growth using inverse microscopy (MODS) has been proven to have a similar 
performance as commercial culture assays regarding time to detection and accuracy in adults 
in various different settings (221). The data on the usefulness of this assay in diagnosing TB 
in children is limited therefore I aimed to evaluate the usefulness of this assay in a general 
paediatric hospital context in Vietnam, which is often the first point of contact with the health 
system for children with the general symptoms consistent with TB, such as fever and failure 
to thrive.  
 
Confirmed diagnosis of tuberculosis in children remains challenging because of the difficultly 
of collected appropriate clinical specimens for testing. Therefore, specimens, which are easily 
collected, such as blood and urine, should be evaluated with assays for diagnosis of TB in 
children. In this thesis, therefore, I assessed the added value of mycobacterial blood culture to 
for diagnosis in children with TB suspicion.  
 
Because of difficulty in specimen collection and limited diagnostic resources in endemic 
settings, confirmation of TB in children using culture is not often performed and even when 
MTB is successfully isolated, the drug susceptibility testing is not often performed due to 
additional expenses and lack of adequate infrastructure. Most endemic countries have limited 
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or no capacity of reliably performing TB culture and DST under appropriate biosafety 
conditions (222). In addition, childhood TB surveys are not a priority for most TB control 
programmes in endemic countries. Consequently, there is a shortage of data on drug 
resistance to anti-TB drugs in children, although this is a sentinel population for active 
transmission within a population. In this thesis, therefore, I also performed a molecular 
epidemiological analysis of drug susceptibility characteristics of TB in children in northern 
Vietnam.  
 
In my thesis I aimed to answer the following questions: 
1) What is the performance of MODS compared to conventional diagnostic methods in 
diagnosing TB in children? 
2) Does adding mycobacterial blood culture increase the overall yield of TB diagnosis in 
children? 
3) What is the prevalence of drug resistance in paediatric TB in Vietnam? 
4) Is there an association between drug resistance and the lineage of MTB among 
children with TB in northern Vietnam? 
 
The outline of the chapters is as follows: 
- In Chapter 2 I describe the methodology used in the results chapters of the thesis. 
- In Chapter 3 I describe a study to evaluate the accuracy of MODS assays compared to 
the conventional diagnostic methods in diagnosis of TB in children in the National 
Hospital of Paediatrics, the largest general paediatrics hospital in northern Vietnam, 
in Hanoi. 
- In Chapter 4 I present the findings of a study to evaluate the additional value of 
mycobacterial blood culture in diagnosing TB in children in the same hospital and the 
paediatric department of the National Lung Hospital in Hanoi. 
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- In Chapter 5 I describe the first line TB drug susceptibility patterns of MTB from 
patients enrolled in the MODS study and explore the association between drug 
resistance and the genetic characteristics. 
- In Chapter 6 I present an overview of the findings from my thesis, and I discuss the 
implications of the results and suggestions for further research to improve laboratory 
diagnosis of tuberculosis in children in resource-limited settings.  
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Materials and Methods 
2.1 Study settings 
2.1.1 National Hospital of Paediatrics, Hanoi 
The National Hospital of Paediatrics (NHP), established in 1981, is the largest hospital for 
general paediatric care in northern Vietnam with 1,100 beds. Annually, approximately 60,000 
patients are admitted to NHP. The NHP microbiology department has a dedicated BSL2 
laboratory for mycobacterial work where MODS was implemented in February 2009. 
Children with confirmed TB diagnosis are often referred to the National Lung Hospital 
(NLH) for free treatment and follow-up as per national guidelines except severe cases 
requiring paediatric intensive care unit (PICU) admission.  
2.1.2 National Lung Hospital, Hanoi 
The National Lung Hospital (NLH) is the nationally designated referral hospital for a range of 
pulmonary conditions, including adult and childhood TB. Children with suspected TB are 
referred to the NLH by several mechanisms: (1) self/family referral through the outpatient or 
emergency department, (2) from district or provincial hospitals throughout northern and 
central Vietnam, (3) and from the National Hospital of Paediatrics in Hanoi. Annually, there 
are approximately 800 children presenting at the paediatric department of NLH for TB 
treatment. The microbiology department of NLH functions as the national reference 
laboratory for TB diagnostics. The laboratory routinely performs tests for MTB detection and 
identification as well as drug susceptibility testing. MTB detection tests include smear 
staining, solid and liquid culture and molecular detection and typing assays. Drug resistance 
of MTB is determined by either phenotypic or molecular methods. 
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2.2 Sample size 
2.2.1 Sample size calculation in MODS study 
On a yearly basis, around 350-400 specimens for TB diagnostics are received by the NHP 
microbiology laboratory. Therefore, it is expected that 750 specimens from approximately 
600 patients will be enrolled in this study. The estimated TB prevalence in our study 
population is estimated to be 20% based on the estimated TB prevalence in endemic countries 
(53), resulting in 120 positive cases in two years. At an estimated sensitivity of MODS to 
detect pulmonary TB of 90% (115), we will be able to assess to the sensitivity with the 
preciseness of  ± 6.4% (Appendix A)  
2.2.2 Sample size calculation in mycobacterial blood culture. 
The population of main interest were culture negative patients by all diagnostic tests of smear 
and gastric fluid (about 90% of the total study population). With the aim of this study to prove 
a “significant extra yield” by blood-culture in this population, the assumption was that the 
extra yield by blood culture would need to be at least 5% in the population of main interest. 
Based on this assumption, we need 795 patients to “prove” that the extra yield is >3% (i.e. to 
reject the null hypothesis that extra yield<=3%), with a power of 80% (based on an exact 
binomial test with one-sided significance level 2.5%) (Appendix B) 
2.3 Study timing and duration 
The enrolment for the MODS study was conducted from February 2009 to December 2010. 
The enrolment of the mycobacterial blood culture study was carried out from June 2011 to 
December 2014. The enrolment of the drug resistance study was conducted from February 
2009 to December 2013. 
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2.4 Scientific and ethical approval 
All protocols, parental  informed  consent form  (ICF)  and  case  report  form  (CRF)  were 
approved by the Institutional Review Board (lRB) at NHP and the University of Oxford 
Tropical Ethical Review Board (OxTREC), as applicable. The  ICF  form is shown in 
Appendix C .  
2.5 Enrolment 
2.5.1 Enrolment sites 
MODS study 
All patients with clinical symptoms suspicious of tuberculosis presenting to NHP were 
enrolled into the study of evaluation of MODS in diagnosis of TB (chapter 3). 
Mycobacterial blood culture study 
All patients with clinical symptoms suspected of tuberculosis presenting to NHP and the 
paediatric department of NLH were enrolled into the study of evaluation of mycobacterial 
blood culture study in diagnosis of TB (chapter 4) 
Anti-TB drug resistance study 
All patients with a new TB diagnosis at NHP and having a positive MODS culture with MTB 
were included in the study of characterising anti-TB drug resistance of MTB isolates (chapter 
5).  
2.5.2 Inclusion criteria 
Patients suspected of having TB included in all studies met all of these following criteria: 
aged under 15 years, not or less than one week on TB treatment and having signs or 
symptoms of suspected TB. The specific requirement for patient enrolment of each study is 
explained in the method section of each chapter.  
2.5.3 Exclusion criteria 
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TB suspected children whose conditions did not allow for collection of study specimens. For 
the study of evaluating mycobacterial blood culture, patients were not enrolled if written 
inform consent from patients or their parents/guardians was not obtained. 
2.5.4 Data collection 
Most data on socioeconomic and demographic features, TB history, TB contact history, HIV 
status and presenting clinical features were collected prospectively on a standard case report 
form (CRF). Exceptions are specifically mentioned in each chapter. 
2.6 Definition and TB classification  
2.6.1 TB case definition in MODS study 
Patients were categorised into one of three groups: confirmed TB, probable TB or TB 
unlikely based on microbiological findings, intention to treat and outcome.  
 
Tuberculosis was defined as "confirmed TB" if the patient had clinical signs and symptoms 
consistent with TB according to the guidance for national tuberculosis programmes on the 
management of tuberculosis in children by WHO (223) and either smear or LJ was positive in 
any sample, including samples which were collected before the enrolment started. These 
samples were not included in the sensitivity comparison but patients with prior samples 
positive in this illness episode by smear were classified in the "confirmed TB" group. A 
positive MODS culture was not considered as part of the definition of 'confirmed TB' because 
this was the test under evaluation. 
 
The patient was defined as having "probable TB" on 'intention to treat' if the patient had 
clinical signs and symptoms consistent with TB but had no microbiological confirmation 
(yet), received no alternative diagnosis and initiated TB treatment and was transferred to a 
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NLH for treatment and follow-up. Patients who satisfied the first two characteristics of 
"probable TB" but self-discharged prior to treatment were also classified in this group if the 
clinician intended to treat for TB. It was impossible to either rule-out or confirm TB in this 
group due to the lack of microbiological confirmation. 
 
Patients were defined as "TB unlikely" if they recovered without TB treatment, had TB 
treatment but deteriorated or received an alternative diagnosis and treatment. It was 
impossible to 'rule-out' TB in these patients completely because clinical deterioration on 
therapy may have been due to undetected drug-resistant TB. HIV screening is not a routine 
test for patients at NHP. HIV counseling and testing was offered if HIV was clinically 
suspected by the treating clinician, according to routine guidelines 
2.6.2 TB case definition in blood mycobacterial study 
Clinical case definition categories for TB in children were determined based on standardised 
case definitions recently published by Graham et al. as described in Figure 2.1  (75). TB signs 
and symptoms are defined as persistent unexplained fever, persistent cough, night sweats, 
weight loss, failure to thrive, reduced playfulness or lethargy, neonatal pneumonia, 
unexplained hepatosplenomegaly or sepsis like illness. 
‘Confirmed TB cases’ were defined as children with microbiologically confirmed TB, 
defined as at least one positive smear or culture or WHO-endorsed nucleic acid amplification 
test (Xpert MTB/RIF) in any sample. 
 
‘Unconfirmed TB cases’ were defined as children meeting at least 2 of the following criteria: 
defined signs or symptoms suggestive of TB; chest radiograph consistent with tuberculosis; 
close tuberculosis exposure or immunologic evidence of MTB infection, i.e positive 
tuberculin testing; positive response to tuberculosis treatment. 
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 ‘Unlikely TB cases’ were defined as children not meeting criteria for ‘confirmed TB cases’ 
and ‘Unconfirmed TB cases’ . 
Figure 2.1 Algorithm for classification of case definitions in mycobacterial blood culture 
study.  
Source from Graham et al 2015 (75) 
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2.7 Sample collection and transfer 
2.7.1 Sample collection 
The number of routine samples collected from patients was determined by the treating 
clinicians. In the MODS study, no additional samples were collected as part of this study. 
Blood samples were collected for the mycobacterial blood culture study. The collection 
procedure followed hospital routine practice. Gastric aspirates were not subjected to 
neutralization with bicarbonate on delivery because culture yield difference among 
neutralized and non-neutralized samples was not significant (224). Inadequate samples 
(insufficient volume, evidence of contamination or incorrect specimen) were rejected and 
resubmission was requested from the wards. All study specimens were collected prior starting 
anti TB therapy. Study clinicians were trained to collect and send specimens before starting 
TB treatment, or, as exception, no later than the first week of treatment. Date of start of 
treatment was, however, not recorded in the CRF. 
2.7.2 Sample transfer 
Blood specimen 
Blood was collected after patient enrolment and sent to the microbiology laboratory. Samples 
from NLH were temporary incubated in a 37 °C incubator and then twice weekly transferred 
at room temperature to the NHP microbiology laboratory for 42 days incubation in automatic 
monitoring Bactec 9050 instrument (Becton Dickinson, USA).  
Other specimens 
Most samples were collected during working hours in weekdays and transferred to the 
microbiology laboratory for processing the same day. If the samples were collected outside of 
office hours, they were kept in refrigerator at the wards and were sent to the microbiology 
laboratory the next working day. Samples were kept cool on ice during transferring to NLH 
for LJ culture.  
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2.8 Laboratory methods 
2.8.1 Sample preparation 
All samples, except CSF, were decontaminated and homogenised with 0.5% N-acetyl-L-
cysteine (NALC) (Sigma Aldrich, Wicklow, Ireland) - 4% NaOH (Sigma Aldrich, Wicklow, 
Ireland) solution. Briefly, the equal volume of NALC-NaOH was added to the sample tube. 
After mixing on the vortex, the sample tube was left standing for 20 minutes for liquefaction 
and decontamination. Then, sterile phosphate buffer solution (pH 6.8) (Sigma Aldrich, 
Wicklow, Ireland) was added up to 15 ml to neutralise the alkaline solution. Next step was to 
concentrate by centrifugation at 3000g for 20 minutes. CSF was not decontaminated before 
centrifugation. After discarding the supernatant, the pellet was resuspended in 0.5 ml PBS 
(Sigma Aldrich, Wicklow, Ireland). The diluted deposit was divided for smear preparation 
and culture isolation.  
2.8.2 Ziehl-Neelsen (ZN) smear 
Sample smear was prepared by dropping 2 drops of processed sample (approximately 0.1ml) 
onto the middle of a slide using a Pasteur pipette. Next, the smear was dried on a slide heater 
or at room temperature for 15 - 30 minutes, followed by heat-fixation using a Bunsen burner 
before staining by ZN method according to WHO standard protocol (225). Briefly, smears 
were flooded with 0.3% Carbon Fuchsin solution (supplied by the National Lung Hospital), 
followed by being heated on the flame of a Bunsen burner until steaming. Then, free stain 
was washed under running water. Next step was to decolourise the first dye with alcohol-acid 
solution (supplied by the National Lung Hospital). Lastly, the smear was stained with 0.3% 
Methylene blue solution (supplied by the National Lung Hospital). Under light microscopy, 
AFB appear as a pink-red slightly curved rod shape against a blue background. 
2.8.3 Mycobacterial culture methods 
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2.8.3.1 Microscopic Observation Drug Susceptibility assay 
Microscopic Observation Drug Susceptibility assay (MODS) uses a liquid medium containing 
MTB growth enhancing chemicals and antibiotic mixture for normal bacterial inhibition. The 
growth of MTB in MODS is observed under an inverted microscope and shows as strings or 
tangled cord. 
 
MODS was performed as described in Park et al. (226) using the modification described by 
Caws et al.. Briefly, MODS media were prepared with 7.9 g Middlebrook 7H9 broth (Difco, 
Sparks, MD, USA), 4.13 ml glycerol (Sigma, USA) and 1.67 g bactocasitone (Difco, Sparks, 
MD, USA) in 880 ml sterile distilled water. The media were autoclaved and stored in 22 ml 
aliquots at 4 °C. Each new batch was tested for sterility by incubating one aliquot at 37 °C for 
1 week. Before use, OADC (Oleic acid Albumin Dextrose Catalase) and PANTA (Polymycin 
Amphotericin B Nalidixic acid Trimethoprim Azlocillin) (Becton Dickinson, New Jersey, 
USA) were added into each tube to final concentrations of 5.5% and 0.22% to make working 
MODS media. Seven hundred and fifty microlitres of working MODS media was aliquoted to 
each well of a 48 well cell culture plate and 250 µl of processed sample was added. One 
positive control (M.bovis BCG) and one negative control well (sterile distilled water) were 
inoculated to each plate. Samples were inoculated into alternate wells to reduce potential for 
cross-contamination. 'Blank' wells contained MODS media only. To prevent cross-
contamination from evaporation, plate seals (optical films, Biorad, California, USA) were 
used. The plate was incubated at 37 °C, and the result was recorded every alternate day after 
five days of inoculation for evidence of growth. Any cord formation including long cords or 
comma-shaped cords was recorded as positive and no cord was recorded as negative. The 
negative results were confirmed at day 30. Contamination was recorded if there was any non-
mycobacterial growth (based on microscopy and colour) and/or turbidity in any negative 
control well. 
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2.8.3.2 Löwenstein-Jensen culture 
Löwenstein-Jensen (LJ) is the most widely used medium for tuberculosis culture. It is an egg-
based medium and contains glycerol/pyruvate which favours the growth of MTB 
complex/non-tuberculous mycobacteria (NTM), respectively and malachite green, which 
suppresses the growth of non-mycobacterial organisms.  
 
The procedure of LJ culture was performed from the standard protocol by WHO (227). Two 
drops (0.l ml) of processed specimen suspension were inoculated on each slope of LJ slant 
(supplied by the National Lung Hospital). The tube was then incubated at 37 °C in a slanted 
position for 24-48 hours and contamination was checked. After that, the tube was placed 
upright in racks for the remaining incubation time. The culture tube was examined weekly for 
bacterial growth. The positive growth of MTB was often detected within 3-5 weeks with the 
observation of rough, crumbly, waxy and non-pigmented colonies. However, if bacterial 
growth was observed within 5 days of incubation, rapidly growing mycobacteria were 
suspected. The culture is recorded as negative if no growth was observed after eight weeks. 
Quantitative results are recorded according to WHO guidelines. If NTM growth was 
suspected, a niacin test (see below) was performed. MTB was confirmed by a positive niacin 
test.  
2.8.3.3 Mycobacterial Growth Indication Test 
Mycobacterial Growth Indication Test (MGIT) from Becton Dickinson (New Jersey, USA) 
uses Middlebrook 7H9 broth for cultivation of mycobacteria. The bacterial growth results in 
the reduction of dissolved oxygen in the culture medium and subsequent release of 
fluorescent signals, which are otherwise quenched by free oxygen. The fluorescent signal is 
recorded automatically in the BACTEC™ MGIT™ 960 Mycobacterial Detection System.  
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The processed samples were subjected to MGIT culture, following the protocol of Becton 
Dickinson. In brief, 0.1ml PANTA, 0.5ml OADC and 0.5ml of each processed sample were 
added into a MGIT culture tube. The mixture was mixed by manual inversion and then 
incubated at 37 °C in the MGIT machine. Any positive MGIT culture was then subjected to 
ZN smear staining to determine presence of AFB. Positive AFB in culture broth confirmed 
MTB growth. 
2.8.3.4 Mycobacterial blood culture 
The recovery of mycobacteria in blood was performed with BACTEC™ Myco/F Lytic 
culture bottles (Becton Dickinson, Sparks, MD, USA) containing non-selective culture 
medium. The procedure followed the manufacturer’s protocol. Briefly, venous blood (1-
5mLs) was directly inoculated into a Bactec MycoF-lytic bottle. Then, the inoculated blood 
bottles were incubated in the Bactec 9050 instrument at 35 °C for 42 days by default. Bottles 
with a positive signal were checked for the presence of AFB by ZN smear staining. MTB 
identification was confirmed by GenoType MTBDRplus assay (Hain Lifescience, Nehren, 
Germany), which also provided the drug resistance to rifampicin and isoniazid. Samples with 
no growth signal by day 42 were considered negative. 
2.8.4 Phenotypic drug susceptibility testing  
Drug susceptibility testing (DST) was performed using the proportional method based on 
WHO guidelines (228). A pure culture of isolate in the active phase of growth (about 4 
weeks) was used and previously characterised MTB were used as controls. In brief, bacterial 
suspensions were prepared by shaking several loops of colonies in a sterile flask containing 
glass beads. Next, the suspension was transferred to screw-capped tubes for adjusting the 
turbidity of the bacterial suspension to match the 1.0 McFarland standard with sterile distilled 
water, and then 10-2 and 10-4 dilutions were prepared. Finally, 200µl volume of suspension at 
the diluted concentrations of 10-2 and 10-4 were transferred to drug-free LJ slants and drug-
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containing slants, respectively. The drug concentration was used as follows: rifampicin (40 
μg/mL), isoniazid (0.2 μg/mL), ethambutol (2.0 μg/mL) and streptomycin (4.0 μg/mL). The 
inoculated slants were continuously incubated at 37 °C. The contamination was checked after 
1 week of incubation and slants were read after 4 and 6 weeks of incubation for definitive 
interpretation. An isolate was considered to be susceptible if there were no colonies or the 
counted number of colonies was less than 1% of growth on the drug-containing medium 
compared with drug-free slant. An isolate was considered to be resistant if the number of 
colonies on the drug-containing medium exceeds that on the drug-free slant with the 1% 
inoculum. The DST was repeated when the colony count in the control tube was less than 200 
or the percentage of resistant organisms appeared to approach 1%, by subjective assessment. 
2.8.5 Niacin test 
The niacin test detects the accumulation of niacin in culture media, which is used for the 
identification of MTB. Almost every strain of MTB excretes a large amount of niacin 
(nicotinic acid) into culture media. Niacin-negative MTB strains are very rare, and very few 
other mycobacterial species yield positive niacin tests.  
 
The test was performed with paper strip BBL Taxo TB Niacin Tests Reagents (Becton 
Dickinson, New Jersey, USA) following the manufacture’s instruction. In brief, 1ml of 
distilled water was added into a positive culture slant and allowed to cover the entire surface 
of the medium for 30 minutes. 0.5ml of the broth was then transferred to a sterile screw 
capped tube and a niacin paper was placed into the tube for 30 minutes. The result was 
interpreted based on colour change. If no colour was observed, a negative result was recorded. 
If the strip turned yellow, a positive result was recorded, confirming the presence of MTB. 
2.8.6 Multiplex allele-specific PCR (MAS-PCR) 
70 
 
Genomic DNA of MTB isolates was extracted by heating method ( see section 2.7.7.1). 
MAS-PCR to detect rifampicin resistance followed the procedure published by Tho et al. 
(229). Three separate PCR reactions were performed to amplify the RIF resistance 
determining region (RRDR) targeting hot spot codons 516, 526 and 531. Briefly, 5 µl DNA 
was added to the PCR mixture containing 0.75 U Taq DNA polymerase, 0.2 mM of each 
dNTP (Roche, Basel, Switzerland) and 125-400 nM of primers and 2 mM MgCl2. The 
amplification programme was as follows: 95 °C for 1 min, followed by 35 cycles of 95 °C for 
10 s 68 °C for 20 s, 72 °C for 20 s and a final step of 72 °C for 5 min. Negative control 
(water) and positive control were included in each PCR run. PCR products were analysed by 
electrophoresis on 1.5% at 120V for 40 min. The results were read with 2 bands for wild type 
isolates and only one band for mutant isolates. 
 
MAS-PCR to detect isoniazid resistance was performed in a PCR reaction following the 
protocol developed by Tho et al. (230). The reaction containing three primer pairs: first one 
targeting Hsp65, which is specific for MTB and served as an internal control, the second one 
was used to detect the mutation C-15T in the inhA promoter region and the third one targets 
the katG region where the most common mutation (S315T) is located. The PCR reaction 
contained 1U Taq DNA polymerase, 0.2 mM each of dNTPs (Roche, Lewes, UK), 150-250 
nM of primers, 2 mM MgCl2 and 5 µl DNA templates. The amplification condition was as 
follows: 95 °C for 2 min, 10 cycles of (95 °C for 20s 68 °C for 60 s, 72 °C for 40 s) then 25 
cycles of (95 °C for 20 s 68 °C for 20 s, 72 °C for 40 s) and a final step of 72 °C for 5 min. 
Negative control (water) and positive control (H37Rv) were included in each PCR reaction. 
PCR products were analysed by electrophoresis on 1.5% at 120V for 40 min. The PCR 
reactions yielded two bands for wild type isolates, a single band for katG 315 mutants and 
three bands for isolates mutated at inhA C-15T. 
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2.8.7 Mycobacterial Interspersed Repetitive Unit - Variable Number of Tandem Repeats 
(MIRU-VNTR) typing  
MIRU-VNTR typing procedure followed the protocol described by Supply et al. (206). The 
simpler system using electrophoresis with agarose gels was used because it was reported to be 
as reproducible as the fluorescence-based DNA analyser based system at intra- and inter-
laboratory levels, if appropriate quality control and quality assurance measurement were used 
(231, 232). The typing procedure consisted of three steps: DNA extraction, PCR amplification 
and electrophoresis. 
2.8.7.1 DNA extraction 
MTB isolates from MODS were subcultured in enrichment medium (7H9, Becton Dickinson, 
Sparks, MD, USA) supplemented with glycerol for one month. After that, one ml of culture 
medium was transferred into 1.5 ml tubes containing 500 l of phosphate buffered saline 
(Sigma Aldrich, Wicklow, Ireland). The tubes were placed in a heating block at 100 °C for 15 
min to heat lyse the cells. The tubes were vortexed at five minute intervals to assist in the heat 
lysis of the cells. Microtubes were centrifuged at 6000g for 2 min. The supernatant was 
transferred into a clean, labeled 1.5 ml tube. DNA template was stored at -20 C.  
2.8.7.2 PCR amplification 
The 24 MIRU-VNTR loci consist of ten original MIRU-VNTR loci; six loci of exact tandem 
repeats (ETRs: ETR-A, -B, -C, -D, -E and –F), five Mtub loci (Mtub4, 21, 30, 38, and 39), 
and three Queen’s University of Belfast (QUBs) loci (QUB-11b, -26, and 4156c). Each of 24 
loci were amplified with specific primer sets described in  
 using the Hotstar Taq DNA polymerase kit (QIAGEN, Hilden, Germany) in separate PCR 
reactions. Reaction volumes of 20 µl containing 2 µl DNA template, 2.0 µl of 10X PCR 
buffer (supplied with kit), 0.2 µl of 20 pM primer set, 0.4 µl (100 µM) of each of the four 
deoxynucleoside triphosphates, dATP, dGTP, dCTP and dTTP, 0.4 - 4µl of 5 × Q-solution 
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(supplied with kit), 0.15 µl of Hotstar Taq (0.75 unit) and 8.8 -10.8 µl of pure H20. A DNA 
extract from MTB H37Rv was included in each set of reactions as a positive control and 
sterile distilled water as a negative control. The amplification protocol consisted of 15 min of 
denaturation at 95 °C, followed by 40 cycles comprising 1 min at 95  ºC , 1 min and 30 s at 59  
ºC and 1 min at 72  ºC and a final extension at 70 ºC  for 10 min.  
2.8.7.3 Electrophoresis 
The amplified products were electrophoresed on 1.5% (w/v) agarose gels (Sigma Aldrich, 
Wicklow, Ireland) with RedSafe™ dye (Sigma, 10mg/ml) with a final concentration of 
0.5µg/ml in 1X Tris Borate-EDTA buffer (Sigma) at 110V for 30-60 minutes depending on 
the investigated loci. A 100 bp DNA ladder (Invitrogen, MA, USA) was included on the gel 
in every run. Product sizes were visualised and photographed using an ultraviolet (UV) 
transilluminator. Product sizes were established by Table 2.2comparing the bands with the 
DNA ladder bands. The number of repeats was estimated based on the Table 2.2 and Table 
2.3 
2.8.7.4 GenoType MTBDRplus assay 
The GenoType MTBDR plus assay (Hain Lifescience, Nehren, Germany) is a strip based 
hybridization assay, or Line Probe Assay (LPA) which has the ability to identify rifampicin 
and isoniazid resistance. The identification of rifampicin resistance is enabled by detection of 
the most significant mutations of the rpoB gene (coding for the β-subunit of the RNA 
polymerase). For testing high-level isoniazid resistance (>2ug), the 315 position of katG 
(coding for the catalase peroxidase) is examined and for testing low-level isoniazid resistance, 
the promoter region of inhA (coding for the NADH enoyl ACP reductase) is analysed.  
 
These tests were performed according to the manufacturer’s protocol. Briefly, for 
amplification, 35 μl of a primer-nucleotide mixture (provided with the kit), amplification 
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buffer containing 2.5 mM MgCl2, 1.25 U Hotstar Taq polymerase (QIAGEN, Hilden, 
Germany), and 5 μl of a preparation of chromosomal DNA in a final volume of 50 μl were 
used. The amplification protocol consisted of 15 min of denaturation at 95 °C, followed by 10 
cycles comprising 30 s at 95 ºC and 120 s at 58 ºC; an additional 20 cycles comprising 25 s at 
95 ºC, 40 s at 53 °C, and 40 s at 70 ºC; and a final extension at 70 ºC for 8 min. Hybridisation 
and detection were performed in an semi automated washing and shaking device (Profiblot; 
Tekan, Maennedorf, Switzerland). The hybridisation procedure was performed at 45 °C for 
0.5 h, followed by washing steps and the colourimetric detection of the hybridised amplicons. 
After a final wash, the strips were air dried and fixed on paper. The strips were pasted on the 
result-report sheet to analyse the results and stored protected from light. 
2.9 MTB lineage classification  
Isolates were assigned to the specific genotype lineages according to their 24 loci MIRU 
patterns by comparing with isolates in reference MIRU databases stored in the MIRU-
VNTRPlus website http://www.miru-vntrplus.org/MIRU/index.faces (211). The MIRU-
VNTRplus website is freely accessible and allows users to assign genotypes and compare 
these with global representative databases of different genetic markers including MIRU, 
spoligotype, large sequence polymorphism and single nucleotide polymorphism data. In this 
thesis, the definition of lineages was done by best-match analysis and tree-based identification 
using the categorical index (204). Isolates unclassified by MIRU-VNTR were assigned using 
the prediction algorithm on the TB lineage website 
http://tbinsight.cs.rpi.edu/run_tb_lineage.html (233). TB lineage uses a large collection of 
databases from most available datasets (US CDC, MIRU-VNTRplus, Brussels and SpolDB4) 
and can predict 7 seven major lineages using two different methods: rule-based systems 
(RULES) and conformal Bayesian network (CBN). In the RULES method, the isolates are 
classified based on the values of MIRU loci. In the CBN method, the major lineages are 
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predicted using a conformal Bayesian network. Some isolates that could not be assigned to a 
specific family by both databases were categorised as “unclassified”.  
2.10 Statistics 
Accuracy of diagnostic tests (sensitivity, specificity, positive and negative predictive values) 
was compared using McNemar’s test for patient analysis and a binary marginal generalised 
linear regression model (GLM) for sample analysis. The GLM is very flexible, allows for the 
inclusion of covariates and accounts for the fact that results of multiple samples from the 
same patient or test results of different tests on the same sample may be dependent. 
 
Time to positive result of test was defined as the time period from sample processing to 
recorded final positive result. Time to positive result for different methods was compared 
using Wilcoxon signed rank test. Time-dependent sensitivity curves were estimated with the 
Kaplan-Meier method and samples without a positive test result were formally regarded as 
censored on day "infinity".  
 
Proportion comparison of demographic and clinical features of patients between TB 
diagnoses was done with Chi-square test or Fisher's exact test for categorical data and the 
Kruskal-Wallis test for continuous data.  
 
Association among factors was analysed using a logistic regression model. Factors with 
biological meaning and showing P<0.2 in univariate analysis were included in the 
multivariate mode. All statistical analysis was performed using SPSS version 22 (IBM Inc, 
Armonk, New York, USA) and a P-value <0.05 was considered as statistically significant. 
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Table 2.1 Primer sequences for the 24 MIRU-VNTR loci 
PCR 
mixture set 
Locus Alias Primer sequences (5' - 3') 
Mix 1 
580 
MIRU 4; ETR D GCGCGAGAGCCCGAACTGC  
    GCGCAGCAGAAACGCCAGC 
2996 MIRU 26 TAGGTCTACCGTCGAAATCTGTGAC 
    CATAGGCGACCAGGCGAATAG  
802 MIRU 40 GGGTTGCTGGATGACAACGTGT  
    GGGTGATCTCGGCGAAATCAGATA 
Mix 2 
960 MIRU 10 GTTCTTGACCAACTGCAGTCGTCC 
    GCCACCTTGGTGATCAGCTACCT 
1644 MIRU 16 TCGGTGATCGGGTCCAGTCCAAGTA 
    CCCGTCGTGCAGCCCTGGTAC 
3192 MIRU 31; ETR E ACTGATTGGCTTCATACGGCTTTA 
    GTGCCGACGTGGTCTTGAT 
Mix 3 
424 Mtub04 CTTGGCCGGCATCAAGCGCATTATT 
    GGCAGCAGAGCCCGGGATTCTTC 
577 ETR C GTGAGTCGCTGCAGAACCTGCAG  
    GGCGTCTTGACCTCCACGAGTG 
2165 ETR A AAATCGGTCCCATCACCTTCTTAT  
    CGAAGCCTGGGGTGCCCGCGATTT 
Mix 4 
2401 Mtub30 CTTGAAGCCCCGGTCTCATCTGT 
    ACTTGAACCCCCACGCCCATTAGTA 
3690 Mtub39 CGGTGGAGGCGATGAACGTCTTC  
    TAGAGCGGCACGGGGGAAAGCTTAG 
4156 QUB-4156 CGTCCGAGCGACATCAC  
    AGGATCGAGCGGTCCAG 
Mix 5 
2163b QUB-11B CCGATGTAGCCCGTGAAGA  
    AGGGTCTGATTGGCTACTCA 
1955 Mtub21 AGACGTCAGATCCCAGTT  
    ACCCGACAACAAGCCCA 
4052 QUB-26 GAGGTATCAACGGGCTTGT  
    GAGCCAAATCAGGTCCGG 
Mix 6 
154 MIRU 2 TGGACTTGCAGCAATGGACCAACT 
    TACTCGGACGCCGGCTCAAAAT  
2531 MIRU 23 CTGTCGATGGCCGCAACAAAACG  
    AGCTCAACGGGTTCGCCCTTTTGTC 
4348 MIRU 39 CGCATCGACAAACTGGAGCCAAAC 
    CGGAAACGTCTACGCCCCACACAT  
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Mix 7 
2059 MIRU 20 TCGGAGAGATGCCCTTCGAGTTAG  
    GGAGACCGCGACCAGGTACTTGTA 
2687 MIRU 24 CGACCAAGATGTGCAGGAATACAT 
    GGGCGAGTTGAGCTCACAGAA  
3007 MIRU 27; QUB-
5 TCGAAAGCCTCTGCGTGCCAGTAA 
    GCGATGTGAGCGTGCCACTCAA  
Mix 8 
2347 Mtub29 GCCAGCCGCCGTGCATAAACCT  
    AGCCACCCGGTGTGCCTTGTATGAC 
2461 ETR B GCGAACACCAGGACAGCATCATG  
    GGCATGCCGGTGATCGAGTGG 
3171 Mtub34 GGTGCGCACCTGCTCCAGATAA 
    GGCTCTCATTGCTGGAGGGTTGTAC 
 
Final concentration of MgCl2 (HotStart buffer already contains 1.5 mM MgCl2) was 1.5 mM 
in mixes 3, 5, and 7; 2 mM in mixes 2 and 8; 2.5 mM in mix 6; and 3 mM in mixes 1 and 4
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Table 2.2  Allele calling table of MIRU-VNTR 
Allele 
MIRU 
02 
Mtub04 ETRC 
MIRU 
04 
MIRU 
40 
MIRU 
10 
MIRU 
16 
Mtub21 
MIRU 
20 
QUB2163b ETRA Mtub29 
0 402 537 171 175 354 482 565 116 437 67 195 335 
1 455 588 208 252 408 537 618 149 514 136 270 392 
2 508 639 266 329 462 590 671 206 591 205 345 449 
3 561 690 324 406 516 643 724 263 668 274 420 506 
4 614 741 382 483 570 696 777 320 745 343 495 563 
5 667 792 440 560 624 749 830 377 822 412 570 620 
6 720 843 498 637 678 802 883 434 899 481 645 677 
7 773 894 556 714 732 855 936 491 976 550 720 734 
8 826 945 614 791 786 908 989 548 1053 619 795 791 
9 879 996 672 868 840 961 1042 605 1130 688 870 848 
10 932 1047 730 945 894 1014 1095 662 1207 757 945 905 
11 985 1098 788 1022 948 1067 1148 719 1284 826 1020 962 
12 1038 1149 846 1099 1002 1120 1201 776 1361 895 1095 1019 
13 1091 1200 904 1176 1056 1173 1254 833 1438 964 1170 1076 
14 1144 1251 962 1253 1110 1226 1307 890 1515 1033 1245 1133 
15 1197 1302 1020 1330 1164 1279 1360 947 1592 1102 1320 1190 
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Table 2.3 Allele calling table of MIRU-VNTR (continuous) 
Allele Mtub30 ETRB 
MIRU 
23 
MIRU 
24 
MIRU 
26 
MIRU 
27 
Mtub34 
MIRU 
31 
Mtub39 QUB26 QUB4156 
MIRU 
39 
0 252 347 150 395 285 498 326 492 272 153 563 540 
1 305 404 200 447 336 551 380 545 330 264 622 593 
2 363 461 253 501 387 604 434 598 388 375 681 646 
3 421 518 306 555 438 657 488 651 446 486 740 699 
4 479 575 359 609 489 710 542 704 504 597 799 752 
5 537 632 412 663 540 763 596 757 562 708 858 805 
6 595 689 465 717 591 816 650 810 620 819 917 858 
7 653 746 518 771 642 869 704 863 678 930 976 911 
8 711 803 571 825 693 922 758 916 736 1041 1035 964 
9 769 860 624 879 744 975 812 969 794 1152 1094 1017 
10 827 917 677 933 795 1028 866 1022 852 1263 1153 1070 
11 885 974 730 987 846 1081 920 1075 910 1374 1212 1123 
12 943 1031 783 1041 897 1134 974 1128 968 1485 1271 1176 
13 1001 1088 836 1095 948 1187 1028 1181 1026 1596 1330 1229 
14 1059 1145 889 1149 999 1240 1082 1234 1084 1707 1389 1282 
15 1117 1202 942 1203 1050 1293 1136 1287 1142 1818 1448 1335 
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Diagnostic accuracy of Microscopic Observation Drug Susceptibility 
(MODS) 
3.1 Introduction 
 In 2014 there were an estimated 1 million cases of paediatric tuberculosis (TB) and 
130,000 associated deaths in the world (43, 234). The overall 13% global mortality rate is 
considerably higher than the 0.5% mortality rate in paediatric tuberculosis recorded in the 
United States and other developed nations (235, 236). While there are undoubtedly a number 
of contributing socio-economic factors, this gap highlights the need for accelerated diagnosis 
and initiation of appropriate chemotherapy in order to improve outcomes of paediatric TB 
cases within developing nations. Under-diagnoses of TB is a critical concern as children are 
failing to receive appropriate treatment (237). 
 
 Currently, diagnosis is complicated by three factors. First, high rates of extra-
pulmonary disease contribute to non-specific clinical presentation of tuberculosis resulting in 
misdiagnosis (238-240). Second, adequate specimens for microbiological diagnosis are 
difficult to obtain because children often do not have a productive cough as presenting 
symptom and do not readily expectorate sputum. Finally, when samples are obtained, 
available tests are often insensitive, slow, or too expensive due to the paucibacillary nature of 
paediatric TB (241, 242). As a result, children who lack typical symptoms are seldom referred 
to TB hospitals where they can receive additional testing and appropriate treatment. 
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In Vietnam and other high TB burden countries, Ziehl-Neelsen (ZN) staining of acid-fast 
bacilli (AFB) is the primary method of diagnosis. While results are typically available within 
hours of sample collection, the test relies on the experience of the microscopist and is best 
suited for detecting higher concentrations of AFB. Direct smear is rarely positive in children 
(243). In addition to poor sensitivity, the test cannot distinguish between mycobacterium 
species and does not include susceptibility testing (239). In Vietnam, referral TB hospitals 
have access to more sensitive culture-based techniques. The most commonly used solid 
culture method is culture on Löwenstein-Jensen (LJ) media, which is more sensitive than ZN 
staining but requires long incubation times of up to 6 weeks (244-246). Commercial liquid 
culture systems, such as BACTEC MGIT 960 (Becton Dickinson, USA) and MB/BacT 
(Biomérieux, France), significantly reduce the time to detection and have higher sensitivities 
than LJ culture (9-22 days), and therefore should be used for the usually paucibacillary 
paediatric samples, but the high costs prevent routine use in resource-constrained settings 
(244, 247). The microscopic observation drug susceptibility (MODS) assay has been 
estimated to cost less than one dollar per test in 2007 and has been endorsed by WHO (117). 
MODS is a closed liquid culture system and has a low risk of contamination (248). The test 
was initially developed in Peru and was adopted nationally for TB diagnosis and rapid 
detection of MDR-TB. MODS culture has been evaluated in Ho Chi Minh City and Lima as a 
sensitive and rapid liquid culture technique for TB detection in paediatric specimens (249-
251). While these MODS paediatric studies produced promising results, they were performed 
in populations in whom TB was highly suspected with a high pre-test probability of TB. 
These evaluations in referral populations may overestimate the clinical utility of the assay in a 
general population where the primary paediatric TB diagnosis is usually made. In addition, 
there have been limited reports of MODS for diagnosis of extra-pulmonary TB. To that end 
our study aimed to assess relative accuracy and time to positivity of MODS for diagnosis of 
both pulmonary and extra-pulmonary TB in children admitted to a large general paediatric 
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hospital in Vietnam. Direct susceptibility testing (inoculation of primary specimen into both 
drug-free and drug-containing wells) was not performed in this evaluation for paediatric 
samples, because of the paucibacillary nature of paediatric specimens and the high risk of 
many uninterpretable or false positive results due to bacterial inoculation into only one of the 
wells. This study therefore evaluated the culture technique of MODS for primary TB 
diagnosis only. 
3.2 Methods 
3.2.1 Study Design 
The study design is summarised in Figure 3.1. The National Hospital of Paediatrics (NHP) 
implemented MODS to detect TB in children as of February 2009. Children with clinical 
suspicion of tuberculosis presenting at NHP, Vietnam were tested with ZN stain, MODS and 
LJ culture. In this study we evaluated MODS prospectively from February 2009 to December 
2010.  
 
Suspected TB cases were considered to have at least two of the following signs: unexplained 
fever for more than 1 week, unexplained cough for more than 1 week, radiographic findings 
suggestive of tuberculosis, failure to thrive or weight loss compared against the standard 
growth chart, malnutrition defined by WHO guidelines (25), enlarged non-tender lymph 
nodes or lymph node abscess, signs of meningitis with history of at least 1 week, HIV 
positive, contact with TB source within the preceding 2 years. Weight loss was defined as 
unexplained reduction in weight compared with the highest weight recorded in last 3 months. 
Failure to thrive or malnourishment was recorded if the weight for age or weight for height z 
score were equal or less than 2 in the normal growth chart. For HIV positive individuals, the 
definition included lack of response to nutritional rehabilitation or antiretroviral therapy. TB 
contact history was investigated by interviewing the patient or patient’s parent. Any exposure 
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to a case of tuberculosis was considered as having TB history contact. The presence of a BCG 
scar on the arm of the patient was also checked by study clinicians. Data on demographic 
features, TB history, TB contact history, HIV status and presenting clinical feature were 
collected on a standard MODS test request form. HIV testing is not performed routinely at 
NHP and the decision to offer an HIV test is determined by the treating clinician. The treating 
clinicians collected samples according to routine protocols, depending on presenting 
symptoms.  
 
Patients were categorised into one of three groups as previously described in chapter 2: 
confirmed TB, probable TB or TB unlikely based on microbiological findings, intention to 
treat and outcome. This study was designed before the recently published standardised case 
definition for research on childhood pulmonary TB (32).  
3.2.2 Sample collection 
For pulmonary TB diagnosis, two gastric fluid aspirates or two sputum samples were 
collected on successive mornings for microbiological testing at NHP. In case of suspected TB 
meningitis (TBM), cerebrospinal fluid (CSF) was obtained with a recommended minimum 
volume of one millilitre. For the other forms of TB suspected, other samples (bronchoalveolar 
lavage, pleural fluid, biopsy, or others as appropriate) were taken as clinically indicated at the 
discretion of the treating clinician. All specimen types referred for TB culture were assessed 
in this study. For each sample, one aliquot was reserved for smear and MODS culture at NHP, 
and another aliquot was transferred to the National Lung Hospital (NLH) for LJ culture. 
Morning specimens were processed for both culture methods on the same day of collection; 
specimens collected in different time in day were stored overnight at 4 °C and cultured on the 
following day. 
3.2.3 Sample processing 
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All samples, except CSF, were homogenised and decontaminated with NaOH-NALC 2% 
following the protocol described in chapter 2. The supernatant was discarded and the pellet 
was re-suspended in 1ml PBS. This suspension was then aliquoted into two 1.5 ml vials, one 
for smear and one for MODS. 
TB smear 
Two drops of pellet from each sample were put onto a slide for homogenous smear 
preparation. The smears were then stained by Ziehl-Neelsen (ZN) method according to World 
Health Organization (WHO) standard protocol (252). 
Löwenstein-Jensen culture 
For culture at the National Lung Hospital, after decontamination, a drop of sediment was 
placed onto Löwenstein-Jensen (LJ) medium prepared according to international standards. 
LJ cultures were examined visually weekly for up to 8 weeks. Final identification of the 
isolates was performed according to standard recommendations. 
MODS 
MODS was performed as described by Caws et al. (117). More details are provided in chapter 
2.  
3.2.4 Contamination analysis 
All MODS positive cultures were typed by 15-loci MIRU typing (206) to detect potential 
cross-contamination. The positive control culture inoculated to each MODS plate was an M. 
bovis BCG strain to enable easy detection of cross-contamination from the positive control. 
Furthermore, we left negative control (non-inoculated) wells in between inoculated wells to 
check for contamination. 
3.2.5 Ethics 
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This study was approved by the Institutional Review Board of NHP. The need for informed 
consent was waived by NHP ethics committee as the study was considered to be an evaluation 
of medical services and did not alter routine patient care at NHP. 
3.2.6 Statistical Methods 
Accuracy measures of smear, LJ and MODS were calculated on clinical diagnosis (clinical 
gold standard including confirmed TB group and probable TB group) as the reference test. In 
addition, we analysed data on a ‘per patient’ and ‘per sample’ basis. In per patient analysis, 
the patient was regarded as positive if at least one sample yielded a positive test result. Exact 
binomial confidence intervals for accuracy measures (sensitivities, specificities, positive and 
negative prediction values) were calculated with the epiR package for R (253). Comparisons 
of accuracies between tests were done using an Exact McNemar’s test. For the time to 
detection analysis, we performed a log rank test on the ‘days to positive culture’ data for 
samples that were both LJ and MODS positive (254).  
 
Demographic and clinical features of patients between all TB groups (confirmed, probable 
and unlikely) were compared using a Chi-squared test for categorical data and Kruskal-Wallis 
test for continuous data. When comparing only 2 groups at a time, Fisher’s exact test was 
used for categorical data, and a Wilcoxon rank sum test for continuous data. 
 
All reported confidence intervals are two-sided 95% confidence intervals and P-values ≤ 0.05 
were regarded as statistically significant. All analyses were done with R program (255) or 
SPSS program version 22 (IBM Inc, Armonk, New York, USA)  
  
85 
 
 
Figure 3.1 Study Design. 
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3.3 Results 
From 1 February 2009 to 31 December 2010, 726 children suspected of having TB were 
evaluated in this study. Twenty-one patients were excluded from the analysis because there 
was insufficient specimen volume collected to be able to perform LJ culture. 1129 samples 
from 705 children remained: sputum (n = 59), gastric aspirate (n = 775), CSF (n = 148), 
pleural fluid (n = 33), bronchoalveolar lavage (n = 45), tracheal fluid (n = 41), other (n = 28). 
The other samples included nasal washes (n = 2), fine needle lymph node aspirates (n = 7), 
pericardial fluid (n = 1), nasopharyngeal aspirates (n = 8), ascites (n = 1) and synovial fluid (n 
=1). 
 
Forty-four patients (6.2%, n = 44/705) had microbiological confirmation by LJ culture 
(‘confirmed TB’). Sixty-nine (9.8%, n = 69/705) patients were classified as ‘TB probable’ 
(see Figure 3.2). Among unlikely TB patients (n=592), 94.8% of patients (n=561) were 
diagnosed as having one of the following infectious disease syndromes: respiratory, non-TB 
(68.3%), central nervous system diseases (19.1%) or prolonged fever of unknown origin 
(7.3%).  
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Figure 3.2 Patient recruitment and assignment to ‘confirmed TB’, ‘probable TB’, or 
‘TB unlikely’ group. 
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3.3.1 Demographic characteristics  
General demographic characteristics of the study population are presented in Table 3.1. In 
brief, the male to female ratio was 1.9:1 and the median age was 2 months (IQR = 1-48 
months). The confirmed and probable TB cases were significantly older than the unlikely TB 
group (P = 0.016, P = 0.001, respectively). These findings could be explained by the 
possiblity that older children produce better quality and more sputum in comparison to the 
young children Only 55.7% had evidence of BCG vaccination. 9.2% (n=65/344 tested) of 
patients were HIV , positive, and the confirmed and probable groups had significantly higher 
proportions of HIV positive children than the unlikely group: 18.2%, 15.9% and 7.7%, 
respectively (P<0.05). History taking showed that 6.5% of the children had a TB contact and 
80.4% of those reported contacts were with a household family member. The confirmed and 
probable groups had a significantly higher proportion of reported TB contacts than the 
unlikely group: 15.9%, 17.4% and 4.6%, respectively (P<0.05). 
3.3.2 Clinical Symptoms  
Clinical records could not be obtained for 115 patients and therefore the data available only 
concerns 590 of the 705 study patients. Clinical symptoms of TB of this referral study 
population (Table 3.2) included cough (73.7%), fever (80.2%), weight loss (22.5%), 
lymphadenopathy (11.9%), malnutrition (28.5%), failure to thrive (27%), and chest X-ray 
consistent with TB (26.4%). The median history of illness (14 days, IQR = 8-20 days) did not 
vary significantly across groups. The confirmed TB group had a significantly higher 
proportion of patients with malnutrition (53.7%), weight loss (43.9%), failure to thrive 
(48.8%), and meningitis (51.2%) compared to the probable TB and unlikely TB groups (). 
The unlikely TB group had a significantly lower proportion of patients with chest X-ray 
suspected of TB than the confirmed TB and probable TB groups (21.8% versus 43.9% and 
51.6%). Prevalence of lymphadenopathy was 22% amongst confirmed TB patients, 17.7% 
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amongst probable TB patients, and 10.3% amongst unlikely TB patients. The difference 
between confirmed and unlikely groups was statistically significant (P = 0.035). 
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Table 3.1 Demographic characteristics of patients 
Category Subcategory Total Population N=705 Confirmed N=44 Probable N=69 Unlikely N=592 Comparison* 
Age Median (IQR) in months 2 (1-48) 23 (2-87) 36 (1-96) 2 (1-42) P < 0.001 [P1=0.995; P2=0.001; P3=0.003] 
 <5 years 545 (77.3) 29 (65.9) 41 (59.4) 475 (80.2) P < 0.001 [P1=0.544; P2<0.001; P3=0.033] 
Sex Male 463 (65.7) 22 (50) 48 (69.6) 391 (66) P = 0.073 
BCG Vaccination Yes 393 (55.7) 26 (59.1) 39 (56.5) 328 (55.4) .. 
 No 44 (6.2) 5 (11.3) 5 (7.2) 34 (5.7) P = 0.310 
 Unknown 268 (38) 13 (29.5) 25 (36.2) 230 (38.9) .. 
HIV Status Positive 65 (9.2) 8 (18.2) 11 (15.9) 46 (7.7) P = 0.009 [P1=0.8; P2=0.037; P3=0.025] 
 Negative 279 (39.6) 17 (38.6) 36 (52.2) 226 (38.2) .. 
 Unknown 361 (51.2) 19 (43.2) 22 (31.9) 320 (54.1) .. 
TB Contact Yes 46 (6.5) 7 (15.9) 12 (17.4) 27 (4.6) P < 0.001 [P1=1; P2<0.001; P3=0.006] 
 Yes & Contact was household family member 37 (80.4) 7 (100) 11 (91.7) 19 (70.1) P = 0.111 
 No 440 (62.4) 28 (63.6) 35 (50.7) 377 (63.7) .. 
 Unknown 219 (31.1) 9 (20.5) 22 (31.9) 188 (31.8) .. 
Summary Measure for categorical data is n (%). * P is used to compare across all three groups (confirmed, probable, and unlikely). For continuous 
variables a Kruskal-Wallis rank sum test was used. When P < 0.05 Fisher’s Exact test was used to compare confirmed with probable (P1), probable with 
unlikely (P2), and confirmed with unlikely (P3). For continuous variables a Wilcoxon rank sum test was used for P1, P2, and P3 calculations. 
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Table 3.2 Clincial feature of 590 paediatric TB suspects 
Characteristic 
Total Population 
N=590 
Confirmed 
N=41 
Probable 
N=62 
Unlikely 
N=487 
Comparison* 
Cough 435 (73.7) 32 (78.0)  48 (77.4)  355 (72.9)  P = 0.6048 
Fever 473 (80.2) 37 (90.2) 52 (83.9)  384 (78.9) P = 0.158 
Malnutrition 168 (28.5)  22 (53.7) 15 (24.2)  131 (26.9)  P = 0.001 [P1 = 0.003; P2 = 0.761; P3 = 0.001] 
Weight loss 133 (22.5)  18 (43.9) 10 (16.1)  105 (21.6)  P = 0.002 [P1 = 0.003; P2 = 0.41; P3 = 0.003] 
Failure to Thrive 159 (27.0)  20 (48.8)  15 (24.2)  124 (25.5)  P = 0.005 [P1 = 0.012; P2 = 0.878; P3 = 0.003] 
Lymphadenopathy 70 (11.9)  9 (22.0)  11 (17.7)  50 (10.3)  P = 0.027 [P1 = 0.619; P2 = 0.086; P3 = 0.035] 
Meningitis 137 (23.2) 21 (51.2) 12 (19.3)  104 (21.4)  P < 0.001 [P1 = 0.001; P2 = 0.869; P3 < 0.001] 
Chest X-ray suspected of TB 156 (26.4)  18 (43.9)  32 (51.6)  106 (21.8)  P < 0.001 [P1 = 0.546; P2 < 0.001; P3 = 0.003] 
History of Illness: median (IQR) in days 14 (8 - 20)  14 (8 - 20)  15 (10 - 25)  14 (8 - 24)  P = 0.639 
Summary Measure for categorical data is n (%) 
* P is used to compare across all three groups (confirmed, probable, and unlikely). For continuous variables a Kruskal-Wallis rank sum test was used. When 
P < 0.05 Fisher’s Exact test was used to compare confirmed with probable (P1), probable with unlikely (P2), and confirmed with unlikely (P3). 
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3.3.3 Diagnostic Accuracy 
The clinical reference standard was defined as patients who satisfied characteristics of either 
the “confirmed TB” group or the “probable TB” group. 113 patients (16%) were diagnosed 
with TB by clinical features and/or microbiological confirmation and 592 patients (84%) were 
classified as ‘TB unlikely’. See Table 3.3 for the diagnostic yield of three methods by disease 
spectrum in each patient group.  
 
The sensitivity of MODS versus smear and LJ culture is summarised in Table 3.4. When 
analised by patient or specimen, MODS was more sensitive than smear (P < 0.001 for both) 
and more sensitive than LJ culture (P = 0.019, P = 0.015). Specificity and positive predictive 
value (PPV) of MODS were 99.2% [95%CI: 98.0, 99.7] and 91.2% [95%CI: 80.7, 97.1] 
respectively. The negative predictive value (NPV) of smear, LJ culture, and MODS was 
85.2% [95%CI: 82.3, 87.7], 90% [95%CI: 87, 91.8], and 90.6% [95%CI: 88.1, 92.7]. Further 
analysis on sensitivity of tests in different age groups is shown in Table 3.5. The MODS 
shows a significantly higher sensitivity than smear in all groups. When compared to LJ, the 
MODS was more sensitive but the difference did not reach statistical significance due to the 
small numbers of patients in each age group.   
 
To investigate whether sample type had a strong impact on the sensitivity of the three 
methods, we investigated the number of each sample type collected from 113 clinically 
diagnosed TB patients and analised the sensitivity of these methods in terms of sputum 
sample, gastric aspirate, and CSF. Our data in Table 3.4 show that MODS was more sensitive 
than smear in all sample types, and more sensitive than LJ culture only for gastric aspirates.  
Table 3.6 shows the diagnostic yield of three methods by sample type. 
 
Of the 79 samples that were MODS positive only, five were collected from five patients in the 
“unlikely TB” group. The LJ subculture and molecular typing on these isolates confirm four 
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cases of MTB and one atypical mycobacterium. Inspection of inoculate position on culture 
plate and genotyping with MIRU-VNTR method ruled out the possibility of cross-
contamination. Three of these five patients did not have enough remaining specimen for re-
culture and the remaining two were discharged to die at home. If the additional four cases 
detected by MODS are considered to be true TB cases, the adjusted sensitivity “by patient 
analysis” of smear, LJ, and MODS are 8.8% [95%CI: 4.3, 15.7], 38.9% [95%CI: 29.9, 48.6] 
and 49.6% [95%CI: 40.0, 59.0], respectively.  
Table 3.3 Diagnostic yield of smear, LJ and MODS by disease status among 705 children 
at NHP during 2009-2010 
Group Diagnosis AFB (n, %) LJ (n, %) MODS (n, %)  
Confirmed TB (n=44) PTB (n=22) 6 (27.3) 22 (100) 21 (95.5) 
  TBM (n=21) 4 (19.0) 21 (100) 20 (95.2) 
  Others (n=1) 0 (0) 1 (100) 1 (100) 
Probable TB (n=69) PTB (n=52) 0 (0) 0 (0) 7 (13.5) 
  TBM (n=11) 0 (0) 0 (0) 3 (27.3) 
  Others (n=6) 0 (0) 0 (0) 0 (0) 
Not TB (n=592) Suspected PTB (n=407) 0 (0) 0 (0) 3 (0.7) 
  Suspected TBM (n=101) 0 (0) 0 (0) 0 (0) 
  Others (n=84) 0 (0) 0 (0) 1 (1.2) 
 
n: number of MTB positive cases. PTB: pulmonary tuberculosis. TMB: tuberculous meningitis 
%: percent of positive cases in the diagnosis group 
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Table 3.4 Sensitivity of MODS, LJ culture, and smear against clinical gold standard 
 Sensitivity n (%) [95% CI] P-Value* 
 MODS LJ Smear vs LJ vs Smear 
By patient (N = 113) 
52 (46) 
 [36.6, 55.6] 
44 (38.9) 
 [29.9, 48.6] 
10 (8.8)  
[4.3, 15.7] 0.019 <0.001 
By all samples (N = 195) 
69 (35.3) 
 [28.7, 42.5] 
59 (30.3) 
[23.9, 37.2] 
11 (5.6)  
[2.8, 9.8] 0.015 <0.001 
By sample type:      
Sputum (N = 23) 
8 (34.8) 
 [16.4, 57.3] 
7 (30.4)  
[13.2, 52.9] 
1 (4.3) 
 [0.1, 21.9] 0.500 0.008 
Gastric Aspirate (N = 103) 
28 (27.2)  
[19, 36.8] 
20 (19.4) 
 [12.3, 28.4] 
3 (2.9) 
 [0.6, 8.3] 0.004 <0.001 
CSF (N = 33) 
22 (66.6) 
[48.1, 82] 
22 (66.6) 
 [48.1, 82] 
3 (9.1) 
 [1.9, 24.3] 0.688 <0.001 
 
The sensitivities of MODS, LJ culture, and smear were calculated against the clinical gold 
standard. Sensitivities were calculated by all samples (some patients provided more than one 
sample), by patient, and by sample type. Exact binomial 95% confidence intervals were 
calculated.  
*Comparison of sensitivities using Exact McNemar’s Test: MODS vs LJ and MODS vs Smear 
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Table 3.5 Comparison of sensitity of  MODS, smear, LJ versus clinical standard in 
different age categories 
By age 
(years). 
Sensitivity n (%) [95% CI] P-Value* 
MODS LJ Smear vs LJ Vs Smear 
0 to < 2 
24 ( 48.0) 
[33.7, 62.6] 
21 (42.0) 
[28.2, 56.8] 
6 (12.0) 
[4.5, 24.3] 0.29 < 0.001 
2 to < 5 
9 (45.0) 
[23.1, 68.8] 
8 (40.0) 
[19.1, 64.0] 0 (0) 0.25 0.001 
5 to < 10 
10 (41.7) 
[22.1, 63.4] 
7 (29.1) 
[12.6, 51.1] 
2 (8.3) 
[1.0, 27.0] 0.13 0.004 
>= 10 
9 ( 47.4) 
[24.5, 71.1] 
8 (42.1) 
[20.3, 66.5] 
2 (10.5) 
[1.3, 33.1] 0.5 0.008 
 
The sensitivities of MODS, LJ culture, and smear were calculated against the clinical gold 
standard. Sensitivities were calculated by all samples (some patients provided more than one 
sample), by patient, and by sample type. Exact binomial 95% confidence intervals were 
calculated.  
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Table 3.6 TB diagnostic yield by specimen type in 1129 samples collected from 705 
paediatric patients admitted to NHP. 
  Number of positive samples (n) 
Specimen type AFB LJ MODS 
Gastric aspirate (n=775) 3 20 31 
Tracheal aspirate (n=41) 0 2 2 
Pleural fluid (n=33) 0 0 1 
BAL (n=45) 3 6 5 
Sputum (n=59) 1 7 8 
CSF (n=148) 3 22 24 
Nasal wash (n=1) 0 0 1 
Lymph node aspirate (n=7) 1 1 1 
Joint pus (n=1) 0 1 1 
Others (19) 0 0 0 
All (n=1129) 11 59 74 
 
AFB: Acid Fast Bacilli Staining; LJ: Löwenstein-Jensen culture; MODS: Microscopic 
Observation Drug Susceptibility assay; BAL: bronchoalveolar lavage 
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3.3.4 Time to Detection 
Time to detection was defined as the number of days from sample processing (day 1) to when 
results were available. Smear results were available on the same day as processing. Median 
time to detection using MODS was faster than LJ culture, 7 days (IQR: 6-11) vs. 35 days 
(IQR: 32-40). Six among seventy-four MODS positive samples (8%) were detected after three 
weeks. In the 55 samples that were positive by both MODS and LJ culture, MODS was faster 
in all 55 samples (100%) and the median time difference was 25 (20-29) days in favour of 
MODS (log rank P < 0.001) (see Figure 3.3). 
 
Figure 3.3 Paired Time to Detection by MODS and LJ Culture. 
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3.3.5 Contamination 
The MODS contamination rate was low (26/1129, 2.3% of wells), and most contamination 
was due to fungi in samples from HIV patients. Cross-contamination was not observed during 
this study period. 
3.4 Discussion 
This study presents a direct comparison between MODS culture, LJ culture, and smear, across 
multiple specimen types, for diagnosis of paediatric pulmonary and extra-pulmonary 
tuberculosis in a large Vietnamese general paediatric hospital. MODS proved to be a 
relatively sensitive and rapid technique for the diagnosis of paediatric TB. MODS was 
significantly more sensitive than both smear (46% vs. 8.8%) and LJ (46% vs. 38.9%), and 
significantly faster than LJ with a median time difference of 25 days in favour of MODS. The 
sensitivity of MODS (46%) was slightly higher than the sensitivity reported in a paediatric 
study (39.7%) performed in HCMC, Vietnam (250). For smear negative patients in our study, 
the sensitivity of LJ and MODS was 33% [95%CI: 24.1, 43] and 41.7% [95%CI: 32.1, 51.9], 
respectively. Most of the improved yield from MODS, as compared to LJ, in our study can be 
attributed to an improved yield from gastric aspirates where MODS sensitivity was 27.2% 
and LJ sensitivity was 19.4% (Exact McNemar Test P = 0.004). 
 
The time to detection was also significantly shorter for MODS than LJ. The recently proposed 
MODS standard operation procedure states that if no growth is observed after day 21, the 
result is recorded as negative (59). However, in this study 6 specimens were positive after day 
21. Therefore, based on the finding in this study, the authors recommend that MODS should 
be incubated for at least one month. 
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In comparison with the HCMC study that was performed at a TB referral hospital, our study 
had a higher MTB recovery rate from CSF samples (33/148 = 22.3% vs. 4/30 = 13.3%), and 
therefore a higher detection rate of paediatric TB meningitis. Nine of the 33 patients with 
positive CSF samples also had respiratory specimens positive for MTB. It is possible that the 
increased recovery rate from CSF samples in NHP can be attributed to a difference in disease 
spectrum and empirical anti-tuberculosis treatment of patients with TBM prior to referral.  
 
Furthermore, the participants in our study were much younger than those in the HCMC study. 
The mean (IQR) age of participants in the HCMC study was 9 years (3-13 years) whereas the 
mean (IQR) age of TB confirmed patients in our study was 24 months (10-87 months) (239). 
Our study results therefore show that MODS has diagnostic utility in very young children 
(241).  
 
This study has several limitations. Firstly, several patients were lost to follow-up at the TB 
hospital and their classification in the “probable TB” group may have been a 
misclassification, which would overestimate the specificity of the MODS assay. Patients may 
have been misclassified as probable TB when in fact they did not have TB due to a number of 
reasons. Once a patient had begun TB treatment this misclassification was difficult to detect. 
Treatment response is often not a reliable indicator of TB disease as patients may have 
undiagnosed drug resistance, deteriorate despite adequate therapy, or conversely, have a non-
TB bacterial infection, which responds to antituberculous drugs or a self-resolving viral 
illness and therefore improve while on TB treatment without having TB. The impossibility of 
definitively categorising cases is a recognised limitation in all studies assessing TB 
diagnostics in children (31). The use of ‘intention to treat’ rather than a strictly defined case 
definition for probable TB was chosen to represent the spectrum of disease in a high-burden 
clinical setting. A strictly defined case definition will likely overestimate the sensitivity of a 
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diagnostic test for TB (due to some true TB cases being misclassified as ‘not TB’), while a 
broad case definition (as used here) will usually overestimate the specificity due to some non-
TB cases being classified as TB. Although the MODS assay can be used to test for drug 
susceptibility, DST was not performed by MODS in this study due to the paucibacillary 
nature of paediatric samples. Further study is needed to confirm if MODS direct DST is 
applicable for paediatric specimens.  
 
The GeneXpert system (Cepheid, Belgium) is being implemented with rapid scale-up in 
developing nations as part of the WHO monitored global rollout plan (256). The GeneXpert 
MTB/RIF assay is more sensitive than smear microscopy, performed in under two hours, safe 
for technicians, and accurate for detecting rifampicin resistance (257). A cost-effectiveness 
analysis of TB diagnosis demonstrated that GeneXpert MTB/RIF use for initial diagnosis of 
suspected TB cases would substantially decrease TB associated mortality and morbidity at a 
reasonable cost, according to conventional cost-effectiveness benchmarks (258). However, 
the accompanying sensitivity analysis shows that higher usage of culture methods would 
result in a less favourable cost-effectiveness ratio for GeneXpert MTB/RIF. GeneXpert 
MTB/RIF should not be considered a replacement for culture methods, especially considering 
the need to test for resistance beyond rifampicin (259). Moreover, in regards to paediatric TB, 
various studies showed the suboptimal sensitivity of GeneXpert MTB/RIF as compared to the 
culture. In recent meta-analysis, the pooled sensitivities of GeneXpert MTB/RIF for 
pulmonary tuberculosis detection in children were 62% (95% CI: 51-73) using sputum 
samples (induced or expectorated) and 66% (51-81) using gastric lavage in compared with 
culture (127). A study of 452 suspected cases performed across two hospitals in Cape Town, 
South Africa found that 25% of children with culture confirmed tuberculosis were negative by 
the GeneXpert MTB/RIF assay (260). Similar findings also were reported in a study of 150 
suspected children in HCMC, in which more than 30% of MGIT culture positive cases failed 
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to be detected by GeneXpert MTB/RIF (98). Although the implementation of the GeneXpert 
MTB/RIF will increase case detection and considerably shorten time to treatment for those 
children who are diagnosed, given the high rate of false negatives and a negotiated cartridge 
price of $10 USD/test, GeneXpert MTB/RIF alone will not be the solution for paediatric TB 
diagnosis in resource constrained settings (261).  
 
 There was one misclassification of NTM as MTB in this study (1/69 positive MODS 
samples) due to cording observed in the MODS well. This issue has been addressed by a 
revision to the MODS standard operating procedure that includes additional wells containing 
p-nitrobenzoic acid (PNB) to distinguish MTB from NTM growth (59). The agreement of 
MTB species identification between MODS and LJ increased from 94.8% to 100% when 
adding PNB (111). 
 
In conclusion, MODS is a rapid low-cost diagnostic tool for TB diagnosis in the paediatric 
population. General paediatric hospitals in TB endemic countries can improve their TB 
diagnosis by implementing MODS in case other liquid culture systems are absent. Access to 
the MODS assay increases TB case-finding and early diagnosis, which can shorten the time to 
appropriate therapy. 
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Mycobacterial blood culture for diagnosis of TB in children 
4.1 Introduction 
Diagnosis of childhood TB is difficult due to the unspecific clinical signs and symptoms and 
difficulty in microbiological confirmation (234). Most guidelines recommend isolation of 
MTB from any sample and a positive culture is considered the gold standard for TB diagnosis 
in children (262-264). Young children typically are unable to expectorate sputum; therefore 
gastric aspiration is used instead. However, this procedure is invasive and may require 
hospital admission. Alternative specimen types, such as induced sputum or string test are 
unpleasant and not well tolerated by young children (84). Therefore, use of a more easily 
accessible specimen, such as blood or urine should be evaluated for its applicability in clinical 
diagnostics in paediatric TB. 
 
The isolation of MTB from blood has been attempted in TB suspects with a high risk of 
mycobacteraemia, such as HIV infected (265, 266), extrapulmonary TB suspects or children 
(267). The yield of blood cultures in detecting MTB varied between 2% and 64% depending 
on the study population (268). A study of HIV infected individuals from South-East Asia 
found a 5% incremental yield of blood culture for TB from adults (265, 269-271). It is known 
that young children also are at higher risk of TB bacteraemia due to an immature immune 
system (234, 272) but there is limited evidence of the utility of blood culture for childhood 
TB diagnostics. Therefore, we undertook a prospective study to investigate the additional 
yield of mycobacterial blood culture for TB diagnosis in children at two tertiary hospitals in 
northern Vietnam. Mycobacterial blood culture was compared with other liquid culture 
methods using the standardised case definition.  
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4.2 Methods 
Patient enrolment 
Any child (< 15 years of age) presenting at NHP or the paediatric ward of NLH with 
suspected TB was eligible to join the study if they met all the following requirements: (1) 
having at least two inclusion criteria (see below); (2) not receiving TB treatment or having TB 
treatment less than one week; (3) and written informed consent from their parents/guardians. 
The inclusion criteria are: unexplained fever (>2 weeks), unexplained cough (>2 weeks), 
chest X-ray suspicious for TB, evidence of malnutrition or failure to thrive/loss of weight, 
lymph adenopathy, suspected meningitis (> 1 week), HIV infection or contact with TB cases. 
Inclusion criteria were broad in order to recruit all children with any suspicion of TB in the 
differential diagnosis. 
 
One 1-5 ml blood sample and other routine diagnostic samples were collected for the study. 
The number and type of routine specimens were judged by the treating clinicians. All 
specimens were collected before starting anti-TB therapy.  
Case definition 
Clinical case definition categories for TB in children were determined retrospectively and 
taken from the standardised case definition published by Graham et al. (75). Three categories 
were defined including: confirmed TB cases, unconfirmed TB cases and unlikely TB. The 
definition of each TB category is described in chapter 2, section 2.5.2.  
Laboratory testing 
All patients had blood collected for mycobacterial culture (chapter 2, section 2.7.3). All 
samples, except CSF, were decontaminated using the NALC-NaOH protocol (chapter 2, 
section 2.7.2). Sample pellets were then divided for smear microscopy and MODS or MGIT 
culture. Smear staining was performed following the WHO standard protocol (252) (chapter 
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2, section 2.7.2). All test results were informed to treating clinicians for diagnosis and 
following up. 
 
Ethics 
Eligible children were invited to participate in the study through their parents who gave 
written informed consent following consultation. The protocol, patient information sheet 
(PIS), informed consent forms (ICF) and case report forms (CRF) were approved by the NHP 
Institutional Review Board (IRB) and the Oxford Tropical Ethics Committee (OxTREC 
number 13-10).  
Statistical analysis 
We compared the demographic and clinical characteristics of patients between diagnosed 
categories of TB (confirmed TB cases, unconfirmed TB cases and unlikely TB cases) using 
Fisher’s exact test for categorical variables and Kruskal-Wallis test for continuous variables. 
The simple proportion comparison was used to assess the incremental yield of mycobacterial 
blood culture. To determine risk factors for MTB bacteraemia, logistic regression was 
included in analysis. All analyses were done using SPSS version 21 (IBM Inc, Armonk, New 
York, USA) . Two sided P-values < 0.05 were regarded as statistically significant.  
4.3 Results 
4.3.1 Study population 
From July 2011 to December 2014, a total of 554 suspected cases of paediatric TB were 
enrolled into the study. A recruitment flowchart is shown in Figure 4.1. Using the 
standardised case definition (chapter 2, section 2.5.2), 92 patients (16.6 %, n = 92/55) were 
classified as ‘confirmed TB’, 345 patients (62.3%, n = 345/554) were ‘unconfirmed TB’ 
cases, 73 patients (12.3% n = 73/554) were ‘unlikely TB’ cases and 44 patients, having no 
routine samples, were classified as a separate group, which was excluded from analysis. 
105 
 
 
 
 
 
 
 
 
 
  
 
Figure 4.1 Flowchart of diagnosis for patients included in the study showing final TB diagnosis and mycobacterial blood culture  
 
Enrolment 
(554 patients) 
MTB blood +: 10 
MTB blood -: 82 
Patients with routine TB 
culture  
(510 patients) 
Unlikely TB 
(73 patients) 
Confirmed TB 
(92 patients)  
Unconfirmed TB 
(345 patients)  
Patients without samples for 
routine TB culture 
(44 patients) 
MTB blood +: 1 
MTB blood -: 44 
MTB blood +: 5 
MTB blood -: 340 
MTB blood +: 0 
MTB blood -: 73 
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The treating clinician determined the number and type of routine samples collected. In total, 
1028 samples were collected from 510 patients including: sputum (n = 81), gastric aspirates 
(n = 831), and others (n = 116). There were 125 patients from whom one sample was taken, 
263 patients had 2 samples taken, 111 patients 3 samples and 11 patients had 4 samples taken. 
General demographic characteristics of the study population are shown in Table 4.1. Overall, 
the median age of children in the study population was 29.9 months (IQR: 10.9-85.2). 
Evidence of BCG vaccination was recorded  in 92.2% of patients (n = 470/510) (scar or parent 
report). Neonatal BCG vaccination is compulsory under the Expanded Vaccination Program 
(EVP) of Vietnam. Over one-fourth (25.3%, n = 129/510) of the study population had a TB 
contact within the previous one year according to parent interviews and of those contacts 12% 
(n = 15/129) were a household member. 
 
The clinical presentation of patients reported in this study population included fever (79.4%), 
persistent cough (82.4%), weight loss (44.2%), failure to thrive (54.9%), lymphadenopathy 
(11.5%) and chest X-ray consistent with TB (61.7%) (Table 4.2). Over 70% (n = 384/510) of 
the children had a TST done; 127/384 (33.1%) of these were positive. The median history of 
illness for all children in the study was 30 days [IQR 6.45-90]. 
  
107 
 
 
Table 4.1 Demographic characteristics of 510 patients in different TB catagories. 
Characteristics Total Patients in different TB categories (N, %) p-value  
    
Confirmed 
TB 
N=92 
Unconfirmed 
TB 
N=345 
Unlikely TB 
N=73   
Male 323 (63.1) 49 (53.3) 224 (64.9) 50 (68.5) 0.12 
Age (months)  
Median [IQR] 29.9 [10.9-85.2] 39 [7.5-150.8] 29.6 [11.5-81.5] 23.5 [12.5-65.4] 0.47 
BCG vaccination      
Yes 470 (92.2) 84 (91.3) 316 (91.6) 70 (95.9) 0.908 
No 38 (7.5) 8 (8.7) 27 (7.8) 3 (4.1)  
Unknown 2 (0.4) 0 2 (0.6) 0  
TB contact      
Any contact 129 (25.3) 30 (32.6) 96 (27.8) 3 (4.1) 0.036 
Family member 15 (2.9) 3 (3.3) 11 (3.2) 1 (1.4) 
 No contact 146 (28.6) 19 (20.7) 116 (33.6) 11 (15.1) 
 Unknown  220 (43.1) 40 (43.5) 122 (35.4) 58 (79.5) 
 HIV infection 
     # of HIV tests done 223 47 157 19 0.716 
# positive HIV tests 13 (5.8) 2 (4.3) 11 (7.0) 0 (0)   
 
* p- value for comparison of all 3 groups. Total of 510 patients were classified into three TB 
categories: confirmed TB (92 patients); unconfirmed TB (345 patients), unlikely TB (73 
patients) 
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Table 4.2 Clinical characteristics of patients by final clinical classification 
Characteristics Total: N (%) Patients in different TB categories: N (%) p-value$  
    
Confirmed TB 
N=92 
Unconfirmed TB 
N=345 
Unlikely TB 
N=73   
Fever (> 38oC) 404 (79.4) 79 (82.6) 276 (80.0) 49 (68.1) 0.017 
Prolong fever > 2wks 229 (56.7) 60 (76.0) 209 (75.7) 30 (61.2) 0.132 
Cough 420 (82.4) 76 (82.6) 285 (82.6) 59 (80.8) 0.934 
Persistent cough > 2wks 362 (86.2) 57 (75.0) 253 (88.8) 52 (88.1) 0.117 
Weight loss 211 (44.2) 50 (58.1) 140 (43.6) 21 (30.0) 0.002 
Failure Thrive 261 (54.9) 49 (57.6) 168 (52.3) 44 (63.8) 0.192 
CXR consistent to TB 309 (61.7) 77 (86.5) 229 (66.8) 3 (4.3) < 0.001 
Lymphadenopathy 54 (11.5) 16 (19.5) 26 (8.2) 12 (17.4) 0.004 
Positive tuberculin skin test* 127 (33.1) 48 (63.2) 79 (33.6) 0 (0) < 0.001 
* )  % positive tuberculin skin test (TST) was calculated from 384 among 510 patients who 
had Mantoux tests done. $  )p-value for comparison of all 3 groups. Total of 510 patients were 
classified into three TB categories: confirmed TB (92 patients); unconfirmed TB (345 
patients), unlikely TB (73 patients). CXR: chest X-ray. 
4.3.2 Overall yield of mycobacterial blood culture 
Of 554 blood culture specimens, a positive signal was recorded in 32 samples from which 
MTB was isolated in 16 (2.9%) (Table 4.3). Of the remaining positive blood cultures, 
Talaromyces marneffei (formerly: Penicillium marneffei) was found in 2 (6%). The median 
time to detection of positive MTB growth in 16 blood culture samples was 25 days (IQR: 
13.5-29).   
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Table 4.3 Results of mycobacterial blood cultures for diagnosis of tuberculosis in 
children 
Test results Test done % 
Negative 522 94.2 
Positive  32 5.8 
Mycobacterium tuberculosis 16 2.9 
Staphylococcus epidermidis* 9 1.6 
Talaromyces marneffei 2 0.4 
Burkholderia cepacia* 2 0.4 
Unclassified  3 0.5 
*Staphylococcus epidermidis and Burkholderia cepacia were considered to be contaminants. 
4.3.3 Comparison of mycobacterial blood culture to other cultures 
Of the 16 patients with MTB bacteraemia, there were 15 patients that also had a routine 
sample collected for comparison (Table 4.4). Only two among these 15 cases were AFB 
smear positive. As compared to routine culture, positive MTB growth in blood was found in 5 
cases whose routine culture was negative (Figure 1). Mycobacterial blood culture increased 
the total number of TB cases having bacteriological confirmation from 92 to 97 cases (5% 
added to the overall confirmation yield). The results of GenoType MTBDRplus assay showed 
that all 6 additional cases were sensitive to RIF and INH. Among 28 disseminated cases 
determined by clinical diagnosis, the overall yield of MTB positive blood culture was lower 
than that of routine liquid culture (6/28 , 21.4% vs. 21/28, 75%) although mycobacterial blood 
culture detected one additional case for whom routine culture was negative. When analysing 
15 mycobacteraemia cases having submitted routine samples, the median time to detection 
was 26 days (IQR: 13.0- 31.0) for mycobacterial blood culture and 14 days (IQR: 8.8 – 16.0) 
for routine culture.  
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Table 4.4 Diagnostic yield of 16 cases having MTB isolation from blood 
Patient ID Routine specimen 
tested 
AFB smear 
results 
Routine 
culture results 
TAT of positive 
routine culture (days) 
20-018 NA NA NA NA 
20-029 Gastric aspirate 1st Neg Neg NA 
20-043 CSF Neg Pos 23 
Gastric aspirate 1st Neg Neg NA 
20-065 Gastric aspirate 2nd Neg Pos 9 
Gastric aspirate 1st Neg Pos 7 
CSF Neg Neg NA 
Gastric aspirate 3rd Neg Neg NA 
20-097 Gastric aspirate 1st Neg Pos 14 
CSF Neg Pos 11 
20-106 Gastric aspirate 1st Pos Pos 9 
22-017 Gastric aspirate 1st Neg Pos 8 
Gastric aspirate 2nd Neg Neg NA 
22-046 Sputum Neg Pos 5 
22-053 Gastric aspirate 1st Neg Neg NA 
Gastric aspirate 2nd Neg Neg NA 
22-066 Gastric aspirate 2nd Neg Pos 16 
Gastric aspirate 1st Neg Pos 10 
22-072 Gastric aspirate 1st Neg Neg NA 
Gastric aspirate 2nd Neg Neg NA 
22-084 Gastric aspirate 2nd Neg Pos 16 
  Gastric aspirate 1st Neg Pos 15 
22-101 Gastric aspirate 1st Neg Neg NA 
22-133 Gastric aspirate 1st Neg Neg NA 
22-242 Gastric aspirate 1st Neg Pos 16 
Gastric aspirate 2nd Neg Pos 15 
CSF Neg Neg NA 
22-327 Gastric aspirate 2nd Pos Pos 17 
Gastric aspirate 1st Neg Pos 13 
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NA: not available; Neg: negative result; Pos: positive result; CSF: cerebrospinal fluid; TAT: 
turnaround time  
4.3.4 Characteristics of patients having MTB bacteraemia 
The demographic and clinical characteristics of patients having MTB isolated from blood are 
summarised in Table 4.5. Among 16 cases having MTB bacteraemia, 10 cases presented with 
disseminated TB (3 having tuberculous meningitis and 7 having miliary TB). Two patients 
with positive mycobacterial blood culture were found to be HIV infected. In the bivariate 
analysis, only HIV infection showed a significant association with mycobacteraemia (p = 
0.046). Outcome is considered as unfavourable if the patients died at the hospital or the 
patients withdrew from treatment to go home because of the severity. Unfavourable outcome 
was more frequently found in TB patients having MTB isolated from blood (26.7% versus 
5.5%, p = 0.01) (Table 4.6). 
 
One among 16 cases with MTB bacteraemia had no routine culture taken and blood was the 
only sample to detect MTB. That patient was HIV infected and presented with persistent 
cough, prolonged fever and a CXR consistent with TB. The patient’s condition progressed 
quickly to severe on admission and no further samples were collected before the patient 
withdrew from treatment to go home. 
 
Among 5 cases having mycobacterial blood culture as the sole source of MTB, there were 2 
cases who received TB treatment with a final clinical diagnosis of miliary TB. The remaining 
3 cases did not receive TB treatment at the time of discharge before the positive MTB growth 
in the blood sample was released.  
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Table 4.5 Characteristics of 16 patients with mycobacteraemia. 
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20-043 F 7 ND - + - - + - + + TBM + Withdrew + 
20-065 F 2 ND + + - - - - + + Miliary TB + Withdrew + 
20-097 F 144 ND - + - - - - + NA TBM - Survived + 
20-106 F 15 - + + - - - + + + Miliary TB + Withdrew + 
22-017 F 9 - + + + NA + - + + PTB - Withdrew + 
22-046 M 84 + + + + + + - + + PTB + Survived + 
22-066 M 2 - + + - + + - + + Miliary TB + Survived + 
22-084 F 5 - + + + - + NA NA + PTB + Survived + 
22-242 M 13 - + + + + + NA + + Miliary TB + Survived + 
22-327 F 102 ND + + - + + + + + Miliary TB - Survived + 
20-018 F 77 + + + - - - - - + Bacteraemia/HIV - Withdrew - 
20-029 M 1 + - - - - - - + NA Meningitis - Survived - 
22-053 M 4 ND + + - - + - + + PTB + Survived - 
22-072 M 82 - + + + + + - + + PTB - Survived - 
22-101 F 48 - + + + + + - + + Miliary TB + Survived - 
22-133 M 13 ND + + NA NA NA NA NA - Pneumonia - Survived - 
 
* Cases having negative routine culture  
ND: not done, NA: not available, M: male, F: female, PTB: pulmonary tuberculosis, TB: tuberculosis, (+/-): present/absent,  
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Table 4.6 Characteristics of 437 TB diagnosed patients (including confirmed TB and 
unconfirmed TB) 
 
* Unfavourable outcome includes deaths at the hospital and withdraw treatment. 
4.4 Discussion 
This is the first prospective study to evaluate the added value of mycobacterial blood culture 
in diagnosis of TB in children with suspicion of TB. The study population represents the 
diversity of TB manifestations in children from two large referral hospitals in an endemic TB 
setting, in which approximately half of children have a clinical presentation of 
extrapulmonary TB. The study compared the detection rate of MTB from blood samples 
Characteristics Total Patients with TB diagnosis (N, %) 
P-value 
* 
    
Mycobacteraemia 
present (n=15) 
Mycobacteraemia 
absent (n=422)   
Male 273 (62.5) 7 (46.7) 266 (63.0) 0.28 
Age (months) Median 
[IQR] 55.9 [10-92] 13.0 [4-82] 31.5 [10-93] 0.05 
BCG vaccination 
    Yes 400 (91.5) 12 (80.0) 388 (91.9) 0.21 
No 35 (8.0) 3 (20) 32 (7.6) 
 Unknown 2 (0.5) 0 2 (0.5) 
 TB contact 
    Any contact 126 (28.8) 7 (46.7) 119 (28.2) 0.31 
Family member 14 (3.2) 1 (6.7) 13 (3.1) 
 No contact 135 (30.9) 4 (26.7) 131 (31.) 
 Unknown contact 162 (37.1) 3 (20.0) 159 (37.7) 
 HIV infection  
(204 patients tested) 13 (6.4) 2 (22.2) 11 (5.6) 0.046 
Unfavourable outcome* 27 (6.2) 4 (26.7) 23 (5.5) 0.01 
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versus that from routine samples. Therefore, this study allows us to determine the true added 
yield of mycobacterial blood culture for TB diagnosis in children.  
 
The culture confirmation rate in children with a final TB diagnosis in this study (28.4%, 
98/345) was low, similar to that in most other studies performed in the paediatric setting (93, 
273). In a recent study by Giang et al. in a TB referral hospital in southern Vietnam, there 
were approximately 25% of cases with a positive MGIT culture (98).  
 
The findings in this study show that including blood culture to routine MTB diagnostics may 
marginally increase the overall yield of TB detection. Mycobacterial blood culture confirmed 
six TB cases for whom culture of other specimens was negative (5 cases) or unavailable (1 
case). However, the added diagnostic yield from blood culture was low as compared to the 
substantial additional cost with a number needed to test of approximately 70 per additional 
case detected with a unit cost for one bottle of Myco F/lytic of 7,50 USD, excluding the extra 
cost of identification reagents, consumables, maintenance and labour. Therefore, the costs for 
the Myco F/Lytic bottles alone are 525 USD per additional case detected. 
 
Blood specimens could be considered an attractive sample for diagnosis of TB in young 
children because of the higher frequency of haematogenous spread and disseminated disease. 
However, unlike our expectation of high frequency for mycobacteraemia in disseminated 
cases, only 21.4% cases were detected using blood culture as compared to 75% from 
respiratory samples using routine culture methods. An explanation for the low detection rate 
of MTB in blood may be that the mycobacteraemia is transient and occurs before presentation 
at the hospital and blood collection, or that the mycobacteraemia only occurs in a minority of 
children.  
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 In previous studies in adults (265, 274), blood culture positivity for mycobacteria was more 
frequently found in HIV infected patients and this difference was also observed in our study 
population (22.2% in HIV positive (2/15) vs. 5.6% in HIV negative (11/422), p = 0.046). 
However, not all children were tested for HIV infection and the number of the children with 
confirmed HIV infection in this study was small (n=13/223 tests), therefore, we can not 
comment on the true increased yield of mycobacterial blood culture for HIV infected 
children.  
 
The time to positivity of mycobacterial blood culture in children with suspected TB in this 
study was long (median TAT: 25 days), which is similar to TAT found in studies in adults 
(265, 275, 276). For example, in a study by Diep et al. among patients with prolonged fever 
in Vietnam, median TAT of mycobacterial blood culture was found as 24.5 (275). The slow 
turnaround time of mycobacterial blood culture seems to be unsuitable for early detection of 
TB in children and results would not significantly change the clinical decision to treat or not 
to treat at an early stage (33). Therefore, methods to shorten the time to detection of 
mycobacteria in blood are needed if blood culture is to have clinical utility. Recently it was 
found that detection of MTB in blood using GeneXpert MTB/RIF could produce results 
within a day (277). The sensitivity of GeneXpert  MTB/RIF was found to be similar to that of 
mycobacterial blood culture in a study of 104 HIV infected adults (33) but the high volume of 
blood used here (20 ml) would not be feasible in children. Another disadvantage of blood 
culture for MTB detection is the requirement of additional confirmation steps for MTB, 
which increases the laboratory workload and limits the utility of this test in most hospitals in 
countries with high burden of TB. GeneXpert  MTB/RIF testing does not require a second 
confirmation step as the amplification target is specific for MTBC.  
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This study has some limitations. The study used the standardised case definition of 
intrathoracic TB to define all TB forms, which may result in the misclassification of some 
cases. However, it is always difficult to encompass the entire spectrum of possible 
presentations of paediatric TB. A too broad standardised research case definition will include 
‘false positive’ TB cases, and underestimate the specificity of diagnostic tests, while a too 
narrow case definition will exclude true TB cases, and consequently overestimate test 
sensitivity. The case definition has recently been revised and it is likely it will continue to be 
refined as validation studies are conducted. Further case definitions for EPTB in children are 
needed to standardise research methods but will be very hard to establish. The standardised 
research case definition tool is not intended to be used as a diagnostic tool to guide research 
decisions, but rather to standardise clinical research on paediatric TB, including clinical trials 
and diagnostic evaluations. This will also facilitate comparison between sites and data 
synthesis into meta-analysis from multiple small studies. The decision to collect blood culture 
was dependent upon the attending clinician and therefore some cases would have been 
missed. Data were not available for eligible cases during the study period that were not 
enrolled. Despite these limitations, our study demonstrates the utility of mycobacterial blood 
culture to TB detection in children. 
  
In conclusion, mycobacterial blood culture contributes little to the overall routine diagnostic 
yield for diagnosis in children and cannot be recommended for use in resource-constrained 
settings.  
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Mycobacterium tuberculosis genotype and drug resistance in 
paediatric tuberculosis in northern Vietnam 
5.1 Introduction 
Tuberculosis (TB) in children reflects recent transmission and is a useful indicator of ongoing 
transmission in the community, including transmission of drug resistance (23, 278). Although 
surveillance data of childhood TB are of importance to measure the effectiveness of the local 
tuberculosis control programmes, it is rarely done in low and middle income countries 
(LMIC) with a high TB burden (185). The main reasons for this are the challenging nature of 
TB diagnostics in children (279) and the absence of systematic efforts to record data on 
paediatric TB. 
 
Vietnam ranks 12th among 22 countries with a high burden of TB in the world (43). Burden is 
defined based on the absolute number of TB cases, not (relative) incidence. Children are 
usually excluded in national tuberculosis surveys (183). In instances that children are included 
in the survey, the number of children contributes only a small proportion to the analyses 
(0.2%, 3/1312) (179). As TB culture is usually not done, there are limited data on drug 
susceptibility in children in LMICs, including Vietnam.  
 
It has been shown that certain genotypes of MTB are associated with drug resistance in some 
geographical locations, but data are often conflicting and the underlying mechanisms are not 
clearly understood. It is possible that discrepancies in drug resistance associations with 
lineages are due to differences in the circulating ‘background’ isolates compared, different 
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patterns of drug pressure in different populations, or simply that reported associations are due 
to chance. Global studies will help to elucidate the true nature of these associations. Some in 
vitro evidence appears to support a higher rate of drug resistance acquisition among the 
Beijing genotype isolates and a reduced fitness cost for this genotype of the resistance-
conferring mutations once acquired (150, 151, 163, 164, 187). These data lend support to the 
epidemiological observations of an association. For example, the worldwide prevalent Beijing 
genotype harbours higher frequencies of particular drug resistance-conferring mutations and 
was shown to be more frequently associated with drug resistance in some countries like 
Russia (280), China (281) and India (282). Epidemiological studies in Vietnamese adults 
showed that there is an association between drug resistance and the Beijing genotype in 
Vietnam (283-286). In a study among adults in three rural districts in the south of Vietnam, 
the researchers found that the Beijing genotype was associated with any drug resistance (OR 
3.7, P < 0.001) and multidrug resistance (OR 6.8, P < 0.001) among new patients (284). The 
Beijing genotype was also reported to be strongly linked to fluoroquinolone resistance (OR 
11.0, P = 0.001) in adult patients with pulmonary TB presenting at a referral TB hospital in 
Ho Chi Minh city, Vietnam (285). However, it is unknown whether there is an association 
between drug resistance and genotype of MTB among children. This would be an important 
observation because MTB isolates from children are representative of active transmission in 
the community, whereas adult TB cases are a mixture of recently acquired and reactivated 
TB. In this study, we aimed to characterise the drug susceptibility to first line anti TB drugs 
and the associations between drug resistance and genotypes of MTB from children admitted 
to the National Hospital of Paediatrics, Hanoi, and Vietnam during 2009-2013. The findings 
of this study will help to better understand characteristics of the current circulating MTB 
isolates in the community.  
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5.2 Methods 
Isolate collection 
MTB isolated by MODS from children presenting at NHP during 2009-2013 were used in this 
study. These isolates were collected from participants in the studies in Chapter 3 and 4. Once 
a specimen was found to be positive for MTB, laboratory details were recorded regarding the 
date of sampling, and specimen site. Clinical case notes and laboratory data were reviewed 
and demographic and clinical data extracted. The isolate was tested phenotypically by the 
indirect 1% proportion method for susceptibility to isoniazid, streptomycin, rifampicin and 
ethambutol (chapter 2, section 2.7.4). Multiplex allele specific PCR (MAS-PCR) to detect 
rifampicin (229) and isoniazid resistance (230) were performed on the phenotypically INH 
resistant isolates (Chapter 2, section 2.7.6). The 24-loci Mycobacterial interspersed repetitive 
units–variable number tandem repeats typing (MIRU-VNTR) typing procedure was 
subsequently performed, following the protocol described by Supply et al. (Chapter 2, section 
2.7.7) (206).  
Lineage identification 
Isolates were assigned to specific genotype lineages according to their MIRU patterns by 
comparing with the online reference database MIRUplus and the TB lineage website (chapter 
2, section 2.8). Some isolates, which could not be assigned to a specific family, were 
categorised as “unclassified”.  
Statistics 
The relative proportion of different genotype families is reported, comparing drug-susceptible 
to drug-resistant isolates. Statistical analysis was performed using SPSS program version 22 
(IBM Inc, Armonk, New York, USA). A P-value of < 0.05 was considered as statistically 
significant (two-sided). The Chi-square test or Fisher’s exact test was used to compare the 
proportions among groups of patients. To compare the age of patients infected with different 
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MTB lineages, the Mann-Whitney U test (pairwise comparisons) was used for continuous 
nonparametric data. Logistic regression was used to determine independent risk factors for 
infection with each lineage.  
5.3 Results 
5.3.1 Description of isolates 
MTB isolates were collected from 125 consecutive previously untreated children with 
positive MODS at NHP over a period of 5 years (from 2009 to 2013). The demographic 
characteristics of patients are shown in Table 5.1. The median age of the population was 20.4 
months (IQR: 7.6-91.3) with 65.6% (82/125) aged under 5 years. Approximately half of cases 
presented with extrapulmonary TB (61/125; 48.2%) of which tuberculous meningitis was the 
most common manifestation (49/61; 80.4%). HIV co-infection was documented in 19 patients 
(15.2%). The distribution of residential areas of the 125 patients included in this analysis is 
illustrated in Figure 5.1. Hanoi had the highest number of cases (39/125, 31.2%), reflecting 
the location of the hospitals, Nghe An was following (10/125, 8%), and the remaining cases 
were resident throughout northern Vietnam.  
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Table 5.1 Demographic and clinical characteristics of patients (n=125) 
Characteristics N % 
Male 68 54.4 
Age months (median, IQR) 20.4 [7.6-91.3] 
 Age (0-4 years) 82 65.6 
BCG vaccination *     
Yes 82 65.6 
No 7 5.6 
Unknown 36 28.8 
Contact to family member having TB 23 18.4 
TB manifestation     
PTB only 64 51.2 
TBM 49 39.2 
Disseminated TB 9 7.2 
other EPTB forms 3 2.4 
HIV infection    
Positive 20 16.0 
Negative 79 63.2 
Unknown 26 20.8 
Outcome     
Survival 97 77.6 
**Withdrawn treatment 22 17.6 
In-hospital mortality 6 4.8 
Residence in Hanoi city 39 31.2 
DST performed 121 96.8 
Genotyping completed 118 94.4 
IQR: Inter-quartile range; BCG: Bacillus Calmette–Guérin; PTB = pulmonary tuberculosis; 
TBM= tuberculous meningitis; DST = drug susceptibility testing; * BCG vaccination by 
interviewing patient’s parent; ** Withdrawn from treatment because of severe condition.  
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Figure 5.1 Province of residence of 125 patients from whom MTB was isolated.  
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5.3.2 Phenotypic drug susceptibility profiles of MTB isolates 
Phenotypic DST was performed for 121 isolates (97%). In 4 isolates (3%) no DST could be 
done due to bacterial contamination (2 cases) or loss of viability (2 cases). The drug 
susceptibility profiles of all isolates are shown in Table 5.2. Of all isolates tested, 81/121 
(66.9%) isolates were found to be fully susceptible to all four tested drugs. Resistance to INH 
was observed in 25/121 isolates (20.7%), which included 4/121 isolates (3.3%) with INH 
mono-resistance. Resistance to SM was detected in 34/121 isolates (28.1%), which included 
15/121 isolates (12.4%) with SM mono-resistance. Rifampicin resistance was found in 4/121 
isolates (3.3%). These 4 isolates were both also resistant to INH and therefore MDR. 
Resistance to EMB was rare, detected in only three isolates (2.5%, 3/121).  
 
Twenty-one isolates with an INH resistant phenotypic were subjected to MAS-PCR for 
mutation detection (Table 5.3). MAS-PCR failed in 3 isolates with no PCR product in two 
attempts. Among 18 successful MAS-PCRs for detecting INH resistance mutations, all 
isolates had the mutation at katG 315 while no mutation at inhA was detected. Among two 
isolates with phenotypic resistance to RIF, the MAS-PCR results revealed one had a mutation 
at codon 526 and one showed absence of mutation at all positions tested (531, 526 and 516). 
5.3.3 MIRU genotype distribution of MTB isolates 
24 loci MIRU-VNTR typing was done for 120 MTB isolates. Based on their MIRU-VNTR 
types, these isolates were assigned to four major lineages (Table 5.4). Among 120 MTB 
isolates genotyped, the East Asian/Beijing lineage was most frequently observed (63.3%, 
76/120), followed by the Euro-American lineage (16.7, 20/120). The proportion of the Beijing 
genotype was not significantly different among patients with PTB (38/62, 61.3%) or EPTB 
(37/56, 66.1%) (P=0.70) (see Table 5.5).  
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Table 5.2 Drug susceptibility profiles of 121 MTB isolates from children 
Drug susceptibility pattern No. (%) 
Fully susceptible 81 (66.9) 
Any resistance 40 (33.1) 
Mono-resistant 19 (15.7) 
SM  15 (12.4) 
INH  4 (3.3) 
Polyresistant but not MDR 17 (14.0) 
INH and SM  15 (12.4) 
INH, SM and ETB 2 (1.7) 
MDR 4 (3.3) 
INH and RIF resistant 2 (1.7) 
INH, RIF and SM resistant 
1 (0.8) 
INH, RIF, SM and EMB resistant 
1 (0.8) 
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Table 5.3 Resistance to INH and RIF of 21 isolates phenotypically resistant to INH by 
MAS-PCR 
No Study_ID INH Resistance RIF Resistance 
1 NHP004 R : katG S315T S 
2 NHP013 R : katG S315T S 
3 NHP015 NA S 
4 NHP018 R : katG S315T S 
5 NHP024 R : katG S315T S 
6 NHP027 R : katG S315T S 
7 NHP028 R : katG S315T S 
8 NHP029 R : katG S315T S 
9 NHP031 R : katG S315T S 
10 NHP032 R : katG S315T S 
11 NHP037 R : katG S315T S 
12 NHP041 R : katG S315T S 
13 NHP046 R : katG S315T S 
14 NHP050 R : katG S315T S 
15 NHP056 R : katG S315T S 
16 NHP057 R : katG S315T S 
17 NHP059 R : katG S315T S 
18 NHP061 R : katG S315T S 
19 NHP069 R : katG S315T S 
20 NHP080 NA S 
21 NHP090 R : katG S315T R 
 S: sensitive; R: resistant. 
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Table 5.4 Lineage classification of 120 MTB isolates from children. 
Lineage N % 
East-Asian (Beijing) 76 63.3 
Euro-American 20 16.7 
Indo-Oceanic 15 12.5 
Unclassified 9 7.4 
Total 120 100.0 
 
Table 5.5 MTB genotype and clinical characteristics in children 
 Characteristics All genotypes 
(N=118) 
Beijing 
genotype 
(N=75) 
Non Beijing 
genotypes 
(N=43) 
P-
value 
Age median (IQR)  16.1 [6.5-72.2] 16.2 [7.0-66.0] 16.0 [6.0-87.0] 0.68 
HIV co-infection  20 (16.0)  12 (27.9)  8 (10.7) 0.05 
Extrapulmonary TB 56 (47.5) 37 (49.3) 19 (44.2) 0.70 
Unfavourable 
outcome 
28 (23.7) 18 (24.0) 10 (23.3) 1.00 
Any drug resistance 38 (32.2) 29 (38.7) 9 (20.9) 0.06 
MDR 4 (3.4) 2 (2.7) 2 (47) 0.62 
5.3.4 Association of drug resistance with MTB genotypes  
Univariate logistic regression analysis of 118 isolates for which both DST and genotype data 
were available showed the Beijing genotype was significantly associated with INH (OR, 3.8; 
95% CI [1.2-11.9], P=0.02) and SM resistance (OR, 2.5; 95%CI [1.0-6.6], P=0.05) (Table 
5.6). The number of MDR cases was too small for further analysis. 
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Table 5.6 MTB genotype and drug resistance in children 
 
RIF=rifampicin; INH=isoniazid; SM=streptomycin; ETB=ethambutol; MDR=multidrug 
resistant; DR= drug resistant; OR=Odds ratio  
DR profile All genotypes 
N (%) 
Beijing 
genotype 
(N=75) 
n (%) 
Non Beijing 
genotypes 
(N=43) 
n(%) 
P-value OR (95% CI) 
Fully susceptibility 80 (67.8) 46 (61.3) 34 (79.1) 0.07 0.42 (0.2-1.0) 
INH mono resistant 4 (3.4) 4 (5.3) 0 0.30 NA 
SM monoresistant 13 (11.0) 8 (10.7) 5 (11.6) 1.00 0.9 (0.3-3.0) 
SM and INH resistant 19 (16.1) 17 (22.7) 2 (4.7) 0.01 6.0 (1.3-27.4) 
MDR 4 (3.4) 2 (2.7) 2 (4.7) 0.62 0.5 (0.8-4.1) 
DR to individual drugs           
RIF 4 (3.4) 2 (2.7) 2 (4.7) 0.62 0.5 (0.8-4.1) 
INH 25 (21.2) 21 (28.0) 4 (9.3) 0.02 3.8 (1.2-11.9) 
SM 32 (27.1) 25 (33.3) 7 (16.3) 0.05 2.5 (1.0-6.6) 
ETB 3 (2.5) 3 (4.0) 0 0.29 NA 
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5.4 Discussion 
As a consequence of the low rate of culture confirmation of TB among children, there are 
limited data on drug resistance and genotypes of MTB isolates from children although these 
data are thought to be useful for TB control programmes. To our knowledge, this study is one 
among few reports of drug susceptibility of MTB from children in Vietnam. In an earlier 
small retrospective study of 103 cases from northern Vietnam (287), only 14 cases had DST 
results available of which only one case was resistant to INH. The study reported here was 
performed prospectively on a total of 125 isolates collected over 5 years. This reflects the 
difficulty of conducting research on paediatric TB at two large referral centres in a high 
burden country: it took five years to collect 125 isolates from children. The findings of this 
study highlight the high resistance rate to isoniazid and streptomycin among children with TB 
in Vietnam. The MIRU-VNTR analysis also confirmed the dominance of the Beijing 
genotype in northern Vietnam.  
 
The resistance rate to any anti TB drug among children found in this study was similar to the 
rates reported in adults. It was slightly lower than those found among adults with new TB 
(33.0% vs. 39.1%) as reported by Hang et al. in a study investigating drug resistance to first 
line TB drugs in Hanoi (180). Our findings are also similar to the numbers reported by the 
Vietnamese national TB control programme in the fourth national drug resistance survey 
(33.1% versus 32.7%) (179). This reflects the high rates of drug resistance among adult TB 
cases in Vietnam, but also confirms that these resistant isolates are actively transmitting in the 
community, rather than being a ‘reservoir’ of latently infected cases from the era before 
DOTS control in Vietnam. 
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The findings that over 20% of children have INH-resistant TB and that the majority of these 
have the katG S315T mutation, which confers high-level INH resistance (163, 164) raises the 
question whether a change in treatment policy for paediatric TB is required. The majority of 
children are never tested for drug susceptibility, and due to the long turnaround time required 
of DST, routine DST would be unlikely to inform clinical treatment decisions. The 
GeneXpert  MTB/RIF test is only able to detect RIF resistance, and not INH resistance, at the 
present time, although a cartridge for INH resistance is under development. This study did not 
evaluate treatment outcome, and this should be reviewed before decisions are made to alter 
empiric treatment for children in Vietnam. WHO recommends the addition of ethambutol to 
the continuation phase for adults in areas with high isoniazid resistance (2HRZE/4HRE) (288) 
and this regimen is gradually being phased in in Vietnam. However, this regimen has been 
recommended based on expert opinion, without any supporting evidence from clinical trials. 
There is a high risk of ocular toxicity from ethambutol in young children due to the inability 
of children to report disturbances in eyesight, and the risk of increased adverse events in those 
unnecessarily treated with ethambutol is a greater concern than in adults, if this regimen is 
introduced as the standard regimen (289, 290). Therefore, it is unclear if a change in regimen 
is necessary or what the optimal regimen would be, but the data reported here clearly suggest 
that an evaluation of treatment outcomes is needed to determine whether the current regimen 
used for paediatric TB in Vietnam is effective in light of the high rates of INH resistance. 
Isoniazid preventative therapy (IPT) is used for exposed household contacts in Vietnam. The 
results found here suggest that IPT may not be the optimal prophylactic drug for use in 
Vietnam. The recently developed 12-dose INH-RIF regimen would also not be appropriate in 
this high INH-resistance setting, due to an increased risk of developing RIF resistance and 
therefore MDR in cases exposed to an INH resistant index case (291).  
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The MDR-TB proportion among children in this study is similar to that most recently 
reported in adults with new TB in the annual global TB report for Vietnam (43), but our 
numbers are small.  
 
The findings of genotype distribution in this population are consistent with most studies 
among adults with TB in Vietnam with the most prevalent genotype being the East 
Asian/Beijing lineage followed by the Euro-American and Indo-Oceanic lineages. The Indo-
Oceanic lineage is less prevalent in northern than southern Vietnam, reflecting the geographic 
proximity to China of the north, and to Indonesia / the Philipinnes in the south-east. This 
established presence of circulating Euro-American strains probably reflects the history of 
Vietnam, which was a French colony for approximately 100 years until the mid-twentieth 
century. The African lineages (lineages 4, 5 and 6) were not identified in this study and have 
not been reported in other molecular epidemiological studies from Vietnam (283, 285, 292-
297).  
 
The high proportion of the Beijing genotype among children (63.1%) is similar to the findings 
among adults in Hanoi between 2007 and 2009 (58.5% (272/465) but higher than the findings 
in the study by Anh et al., who reported 38.5% of 221 isolates from adults in northern 
Vietnam to belong to the Beijing genotype between 2003 and 2004 (294). The high 
percentage of the Beijing genotype among children suggests the widespread ongoing 
transmission of this genotype in the community, supporting the hypothesis that the Beijing 
genotype is established and endemic in the Vietnamese population (284, 295).  
 
An association between the Beijing genotype and resistance to isoniazid and streptomycin has 
been previously reported in adults in Vietnam (180, 298). This association was also found 
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among children in this study. Although the Beijing genotype was also reported to be strongly 
associated with MDR-TB in adults (284), we could not show the presence or absence of this 
association among children due to the limited number of MDR-TB cases in children (n=4). 
The underlying reasons for this association are not clear (165). Associations between DR and 
MDR-TB and the Beijing genotype have been reported from other locations and in vitro 
experiments have shown the more frequent acquisition of drug resistance mutations in Beijing 
genotype isolates (155). The availability of global WGS data for MTB is beginning to help in 
understanding the global distribution of MTB, the evolutionary changes this pathogen is 
undergoing and the evolution, distribution and epidemic spread of drug resistant MTB. 
However, much research remains necessary in order to fully understand under which 
circumstances and by what mechanism(s) the Beijing genotype is associated with drug 
resistance. 
 
Our study was limited by a hospital based study design; therefore, the samples may not be 
representative of all paediatric TB in the population. However, the isolates were collected 
from most areas in northern Vietnam, and provide a preliminary insight into the population 
structure of MTB circulating in children, especially in view of the total absence of DST and 
genotypic data from Vietnamese paediatric TB population. The genetic diversity may be 
biased by cultivability of different genotypes, particularly in paucibacillary disease. This may 
also affect the drug susceptibility patterns by selective analysis of only the culture positive 
subgroup of strains. However, it would be expected that, if there is any effect, the drug 
resistant strains would be less viable and therefore less likely to be isolated in culture. This 
would result in an under-estimation of the true resistance rate. The correspondence between 
drug resistance patterns seen in adults and those described here in children suggest that there 
is not a strong selective effect on the paediatric subpopulation with positive cultures. 
 132 
 
 
In summary, our observations in children strongly suggest a high proportion of resistance to 
isoniazid and streptomycin in the paediatric population and predominance of the Beijing 
genotype. The predominance in children suggests recent invasion and this could signal a more 
severe situation in Vietnam in the future in absence of more effective control. 
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Discussion and recommendations 
6.1 General conclusion and remarks 
Tuberculosis is a major public health problem which causes more deaths annually than any 
other infectious disease (43). Although significant progress has been made in global TB 
control since the change of the millennium, the global research efforts and intensification of 
control measures has focused largely on adults. There are approximately 1 million cases of 
TB in children each year, and many more become latently infected every year. (53). Accurate 
estimates of the burden of TB among children are difficult because diagnosing TB in children 
is more challenging than in adults. The major reasons are the paucibacillary nature of 
paediatric TB and the difficulty of collecting appropriate clinical samples for testing. 
Therefore, research to improve TB diagnostics in children, in particular the detection yield, is 
important.  
 
 In this thesis, my studies have focused on the evaluation of two diagnostic methods to detect 
MTB in children. In addition, to better understand the epidemiology of TB in children in 
northern Vietnam, the drug susceptibility of TB in children admitted to the National Hospital 
of Paediatrics was investigated. The work described in my thesis aimed to answer the 
following questions.  
1) What is the performance of MODS compared to conventional diagnostic methods in 
diagnosing TB in children? 
2) Does adding mycobacterial blood culture increase the overall yield of TB diagnosis in 
children? 
3) What is the prevalence of drug resistance in paediatric TB in Vietnam? 
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4) Is there an association between drug resistance and the lineage of MTB among 
children with TB in northern Vietnam? 
 
The findings of my thesis provide more evidence of the need to improve diagnostics of TB in 
children and contribute to understanding the epidemiology of TB in children.  
 
Performance of MODS assay in TB diagnosis in children 
Chapter 3 presents the findings of MODS performance on different types of specimens at the 
largest general paediatric hospital in Vietnam. I show that MODS was far more sensitive than 
conventional ZN smear (46.0% vs. 8.8%) and had a higher sensitivity than culture on solid 
media (46.0% vs. 38.9%). When analysed by sample type, the study showed that the 
improved yield from MODS as compared to solid media can be attributed to a higher yield 
from gastric aspirates (27.2% vs. 19.4%). The finding of the superior sensitivity of MODS 
against LJ culture in this study is consistent to results from a previous paediatric study in Peru 
with 91% of confirmed cases detected by MODS vs. 59% of confirmed cases detected by LJ 
(249). In a study at the referral TB hospital in southern Vietnam, MODS showed 39.7% of 
sensitivity (10, 250). Compared to solid culture, the median time to positivity of MODS was 
significantly shorter by approximately 4 weeks (median time: 7 vs. 35 days). In addition, 
MODS showed a low contamination rate in comparison to that found in commercial liquid 
culture (2.3% vs. 7%) (104, 299).  
 
With improved accuracy and faster time to diagnosis than solid culture, MODS is a useful 
liquid culture method to confirm TB cases in children in resource limited settings. It cannot 
be used to rule-out a diagnosis of TB. The findings in my thesis and recent studies provide 
strong evidence to support the implementation of MODS to improve case detection among 
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children in high-burden countries. During the time of these studies, considerable evidence for 
use of the GeneXpert MTB/RIF to diagnose paediatric was published and the test is now 
widely available in many urban centres in high burden countries following unprecedented 
scale-up of the assay. The assay has several advantages over MODS: shorter time to result (2 
hours vs. several days), less biohazard risk as culture is not required and the sample reagents 
rapidly inactivate MTB, the ability to simultaneously detect MDR-TB, minimal hands-on 
time whereas MODS requires repeated plate reading by microscope. However, the GeneXpert 
MTB/RIF has several disadvantages: high cost (10USD per cartridge), the need for machine 
maintenance and continuous uninterrupted power supply while cartridges are being processed. 
The relative costs and benefits of each assay must be weighed carefully in making a decision 
as to which assay is most appropriate to a context.  
 
During the recent years since the study was started, various modifications to the original 
MODS protocol have been evaluated to address the need for time consuming and tedious 
manual observation of MTB growth under microscopy and improve biosafety. Auto-MODS, 
which was recently proposed by Wang et al., uses the computer assisted digital camera to 
inspect the MODS culture and screw-capped tubes to enhance the biosafety (300, 301). 
Compared to commercial liquid culture (MGIT 960), Auto-MODS had a similar MTB 
detection yield (95.9% of sensitivity and 97.1% of specificity) but had slower time to 
detection (median time: 10 vs. 6 days). However, Auto-MODS is considerably cheaper with 
regards to both the initial set-up ($7,000 for MODS vs. $85,000 for MGIT system) and 
individual sample cost ($2.00 vs. $20.00). Similarly, another improvement of MODS by using 
a lens free imaging system replacing the human eye was reported by Solis et al. This novel 
system is able to digitalise a 24-mm2 surface with approximately 40X magnification in a 
single capture (302). The study findings showed that modified MODS notably reduced the 
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time of inspection. The interpretation of MODS results is simplified through a computer 
based algorithm that automatically recognises an MTB specific pattern from the digital image 
with a high sensitivity and specificity (99.1% and 99.7%)(303). However, it is not clear if 
MODS has any impact on the current paediatric TB diagnostic algorithm due to the relatively 
long time to result, by which time a clinical decision to treat or discharge has usually been 
made. The consideration about the operational feasibility of MODS comes from unfavourable 
findings in a retrospective review of clinical records at a primary health care centre in Peru 
before and after the introduction of MODS in 2008 (304), in which Mendoza-Ticona et al. 
found that universal access to MODS did not alter the final treatment outcome of new 
pulmonary TB in adults although it increased DST coverage and shortened the delayed time 
between the diagnosis of TB and receipt of DST results. Therefore, for large-scale 
introduction of this method into routine paediatric TB diagnostics in high burden countries, 
further research to evaluate effectiveness of introduction in clinical case management should 
be done and compared with the introduction of the GeneXpert MTB/RIF assay. 
 
Alternative specimens for TB diagnosis in children: additional value of mycobacterial 
blood culture. 
In chapter 4 I demonstrated that there is limited added diagnostic value of mycobacterial 
blood culture for TB diagnosis among children. The study was prospectively designed at both 
the general paediatric hospital and the referral TB hospital in Hanoi, an endemic TB setting, 
and recruited children with diverse TB manifestations. The findings of the study suggested 
that adding this test into the routine TB diagnostic algorithm may marginally increase the 
overall yield. However, the test performance was poor with low sensitivity and slow time to 
detection in comparison to routine culture. In addition, the added value of mycobacterial 
blood culture to the overall yield with one additional positive case compared to the high 
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incremental cost is too high for routine diagnosis of TB in resource limited settings. The test 
showed limited utility for diagnosis of TB in children in clinical context.  
 
Recently, a study of GeneXpert MTB/RIF on blood from adults with HIV found a sensitivity 
similar to blood mycobacterial culture using solid culture of sputum as reference but the high 
volume of blood required (20ml) is not feasible for children (33). Further research to simplify 
blood sample concentration and to improve the detection limit of GeneXpert MTB/RIF 
remains needed. In addition, evaluation of GeneXpert MTB/RIF on non-invasive samples, 
such as stool, should be considered. The French organization, “Agence National pour 
Research sur la SIDA” (National Agency for AIDS Research, ANRS), has conducted a multi-
country study systematically evaluating the yield of different specimens tested by GeneXpert 
MTB/RIF in HIV-positive children, but similar studies are needed in HIV-negative children 
(86). Since young children frequently swallow their sputum, MTB may be detected in the 
stool of children with PTB. Various studies have been performed on stool from children with 
PTB suspicion: the GeneXpert MTB/RIF assay detected MTB with a medium sensitivity (25–
69%) and a high specificity (91.7–100%) as compared to MGIT culture (87, 305). A recent 
study using a new processing protocol which enables to process a larger volume of stool (up 
to 1.2 gram vs. less than 0.2 g in previous studies) on GeneXpert MTB/RIF showed improved 
sensitivity (85% [95% CI 0.6–0.9]) for TB detection in children who were positive by 
GeneXpert MTB/RIF on gastric aspirate (88). However, the sensitivity remains low, for 
clinically diagnosed TB and stool testing cannot be used to exclude a diagnosis of TB. Given 
the high cost of GeneXpert MTB/RIF cartridges, testing of gastric aspirate remains a better 
approach, unless gastric lavage is contra-indicated. Further large clinical studies are needed to 
evaluate the optimal processing of samples other than sputum for GeneXpert MTB/RIF. 
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Drug resistance epidemiology of paediatric TB in northern Vietnam 
In chapter 5 in this thesis I present the drug susceptibility pattern to first line anti TB drugs 
among children with confirmed TB in northern Vietnam. Among culture positive patients 
presenting at NHP during 5 years (2009-2013), resistance to isoniazid and streptomycin is 
most prevalent, which accounts 1 among 4 cases. The high resistance rate to INH (20.7%, 
25/121) and SM (28.1%, 34/121) found in children is similar to that reported in adults with 
new TB in the population (180), strongly suggesting ongoing transmission of MTB resistant 
to these drugs in the community. Four cases with MDR-TB were recorded, but this number is 
too small to draw conclusions on the rate in population. Because the study was undertaken in 
a general paediatric hospital setting, the findings are not representative for all circulating 
MTB in the paediatric population in the region. However, this is the first comprehensive 
report attempting to understand the DR situation in children in northern Vietnam. To better 
understand the trends of DR, such studies should be performed periodically, such as every 5 
years, while waiting for establishment of national drug resistance surveillance. The data 
would provide indirect measurement of effectiveness of NTP for TB transmission control in 
the areas. 
 
I also describe the genetic characteristics of MTB from children in chapter 5. The Beijing 
genotype was most frequently found, followed by the Euro-American genotype. This pattern 
is similar to that found in new TB adults in Vietnam (294, 295). These findings provide 
important evidence to support the hypothesis of the epidemic spread of the Beijing genotype 
in the population (284, 306). The Beijing genotype has been shown to increase in prevalence 
in a number of geographical regions following its introduction. There are no data from 
Vietnam, but the Beijing genotype appears to have been endemic for a considerable time and 
data are only now emerging which will allow the temporal monitoring of its distribution. 
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WGS studies allow us to identify sub-lineages, which are most actively transmitted within a 
region and these data will help to determine if the Beijing genotype is more virulent in the 
Vietnamese population than other strains currently circulating. Studies attempting to show 
associations between the Beijing genotype and clinical presentation or outcome have reported 
conflicting results and no clear picture has emerged of any correlation between Beijing 
genotype and clinical presentation (165). The Beijing genotype has been reported to have 
increased virulence in animal models for TB (307). The Beijing genotype was demonstrated 
to be strongly associated with any drug resistance and MDR in epidemiological studies in 
Vietnam, in China (308), in Indonesia(309), and elsewhere  (283-286, 296, 298). In these 
studies, it was shown to be linked with drug resistance to isoniazid , which is among  the most 
important first line drugs, as found in this study and various studies in adults. Although the 
Beijing genotype was found to be strongly associated with MDR-TB in some adult studies in 
Vietnam  (284, 286) and  other countries such as China (310), countries in Soviet Union, there 
was no observation of association of this genotype with MDR among children in this study 
but this was due to small numbers. A study with large sample collection of MTB from 
children at national level would reveal whether this association exists in the population.  
 
6.2 Recommendations for future research  
Several calls to action on paediatric TB in the last decade have drawn attention to the 
neglected issue of paediatric TB and have led to some important advances. WHO now 
collects age-disaggregated data on paediatric TB and encourages national TB programmes to 
address paediatric TB as a strategic priority. Many countries, including Vietnam, have now 
revised National TB data collection to systematically collect data on paediatric TB.  
In 2015 new paediatric drug formulations of the first line TB drugs were made available for 
the first time to facilitate correct dosing in children but action is still needed to expand access. 
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Drugs previously had to be administered by splitting or crushing adult tablets, making precise 
dosing impossible. Further, the fixed dose combination tablets used by most national TB 
programmes are also of the wrong ratios to allow correct paediatric doing according to the 
latest guidelines. These new formulations are a major advance in improving treatment of 
paediatric TB.  
 
New approaches to TB diagnosis have been systematically evaluated in children, with some 
successes and failures. The GeneXpert  MTB/RIF test has been shown to be an effective test 
for diagnosing TB with high specificity in children, but sensitivity is low. This remains true 
for all microbiological and molecular tests for TB in children. The GeneXpert MTB/RIF test 
was endorsed by WHO for diagnosing TB in children following systematic review of the 
evidence in 2013(127). Despite these advances, there remain many urgent priorities for 
paediatric TB research.  
 
The findings of this thesis highlight some gaps in our current knowledge and reinforces the 
need for further study in order to improve the performance of current diagnostic tests for TB 
confirmation in children as well as to better understand TB drug resistance in children.  
 
TB diagnostic study in children 
MODS was endorsed by WHO and recommended for use in limited resource settings since 
2010. So far, direct evidence of utility of this test for TB detection in children including our 
research is limited, especially there is a lack of evidence as to whether MODS can be used for 
direct DST with paediatric specimens. The following research priorities should be addressed:  
 Investigate the performance of MODS for direct drug susceptibility testing in 
paediatric specimens, including second line drugs. 
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 Evaluate the cost effectiveness of MODS in case management, especially in general 
paediatric hospital and compare with GeneXpert MTB/RIF. 
Culture should be performed for all samples but takes at least one week, even for the most 
rapid liquid culture tests. In this study, MODS took a median of 7 days to return a positive 
result. Therefore, rapid molecular tests like GeneXpert MTB/RIF should be the initial test of 
choice, especially for severely ill children in whom prompt diagnosis and treatment is 
essential. A culture should still be performed alongside GeneXpert MTB/RIF as the yield is 
higher, and an isolate is necessary for full DST. Published MODS research evaluates mainly 
respiratory samples and only CSF for EPTB. Evidence of GeneXpert MTB/RIF on readily 
obtained samples like blood, urine or stool has shown disappointing sensitivity Several factors 
are likely to contribute to this, but the most important is the low bacillary load in such 
samples, which is likely to be addressed by increasing sample volumes and concentrating 
bacilli prior to inoculating the GeneXpert  MTB/RIF cartridge. Other factors include 
inhibitors to the PCR, which changes in sample processing may help to eliminate. Cepheid 
have announced the imminent release of a new GeneXpert MTB/RIF cartridge, called 
GeneXpert MTB/RIF Ultra which is claimed to be more sensitive than the previous version 
(311). This has been achieved by increasing the DNA targets and increasing the sample 
volume added to the reaction chamber, among other modifications. This new cartridge may 
substantially increase case yield in paediatric TB, and it is hoped sensitivity will approach that 
of culture. Multi-site, multi-country standardised evaluation of GeneXpert MTB/RIF Ultra in 
paediatric TB diagnosis is a priority. Further studies on GeneXpert MTB/RIF should be 
included as follows: 
 Develop and evaluate optimised specimen processing methods for stool, urine and 
other EPTB samples for GeneXpert MTB/RIF . 
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 Evaluate the accuracy of GeneXpert MTB/RIF Ultra vs. GeneXpert MTB/RIF for TB 
diagnosis in children 
Testing of multiple samples has repeatedly been shown to increase the overall yield of 
detection. The inclusion of blood samples in the study described in chapter 4 appeared to 
increase the overall yield, albeit only marginally. Other samples (such as urine, stool were not 
examined in this study due to resource limitations, but the optimal specimen collection 
protocol (sample type and volume) for paediatric TB should be systematically elucidated.  
 Evaluate other specimen collection protocols to determine the optimal combination of 
sample types and volume to maximise diagnostic yield of TB in children. 
Biomarkers in blood, urine and sputum have been systematically researched for three decades 
to try and devise an optimal diagnostic point of care test. Initial research focused on 
individual candidate biomarkers, but tests failed to demonstrate sufficient sensitivity, 
specificity, or often both. Recent approaches have used more sophisticated analytical 
techniques, such as MALDI-TOF and SELDI and attempted to identify combinations of 
biomarkers, or ‘signatures’, which identify TB cases (62). Jenum et al. showed the association 
of 12 immune biomarkers with the likelihood of TB disease among children. This attracts 
further research to exploit the potential of the immune markers for diagnosis TB in children 
but is unlikely to result in a point-of-care diagnostic in the next five years. 
 
Tuberculosis epidemiology in children 
To understand the epidemiology of TB in children, long-term research should be conducted to 
see the trends of incidence, which would reflect truly the transmission in the population. 
Because most studies on childhood tuberculosis resistance prevalence are based on isolates, 
which are rare in children, the findings may have selective bias and not reflect the true 
situation. As molecular detection becomes more sensitive, it should be possible to detect drug 
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resistance patterns by whole genome amplification from single bacilli in clinical samples. 
Several authors have reported successful whole genome sequencing of MTB from sputum 
samples, but not yet from children and it is likely that significant improvement in sensitivity 
will be required before this is possible. To better assess the drug resistance epidemiology and 
diagnosis in children, research to evaluate the optimal approach among existing methods 
should be a priority.  
 
Finally, treatment of TB in children has not been considered in this thesis, but the high rates 
of drug resistance in children in Vietnam shown in this study, highlight the urgent need for 
inclusion of children in trials of new drugs and drug combinations. Alongside these studies, 
PK studies must be conducted on children to ensure optimal dose and formulations are 
identified. 
 
The END TB strategy (253) has set an ambitious global target of TB elimination as a public 
health problem by 2035. This could potentially be achieved with sustained political and social 
commitment at all levels, but an essential component will be research leading to better drugs, 
diagnostics and an effective vaccine. Children must be included in this research at all levels to 
ensure this vulnerable population benefit from advances in TB diagnosis, prevention and 
management in tandem with the adult population. If these ambitious plans can be realised, 
children born today will see the consequences of TB removed from their children’s lives. If 
we fail to control drug resistant TB now, these children may see a world where TB is once 
again untreatable with chemotherapy and surgery and sanatoria are our only weapons. 
 
  
 144 
 
 
http://www.who.int/tb/childhood_TBinfographic.jpeg 
  
 145 
 
Bibliography 
1. WHO. Global Tuberculosis Report 2013. World Health Organization; 2014. 
2. Daniel TM. The history of tuberculosis. Respir Med. 2006;100(11):1862-70. 
3. Nerlich AG, Haas CJ, Zink A, Szeimies U, Hagedorn HG. Molecular evidence for 
tuberculosis in an ancient Egyptian mummy. Lancet. 1997;350(9088):1404. 
4. Cambau E, Drancourt M. Steps towards the discovery of Mycobacterium tuberculosis 
by Robert Koch, 1882. Clin Microbiol Infect. 2014;20(3):196-201. 
5. Mangtani P, Abubakar I, Ariti C, Beynon R, Pimpin L, Fine PE, et al. Protection by 
BCG vaccine against tuberculosis: a systematic review of randomized controlled trials. Clin 
Infect Dis. 2014;58(4):470-80. 
6. Trunz BB, Fine P, Dye C. Effect of BCG vaccination on childhood tuberculous 
meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-
effectiveness. Lancet. 2006;367(9517):1173-80. 
7. Pereira SM, Dantas OM, Ximenes R, Barreto ML. BCG vaccine against tuberculosis: 
its protective effect and vaccination policies. Rev Saude Publica. 2007;41 Suppl 1:59-66. 
8. Kelekci S, Karabel M, Karabel D, Hamidi C, Hosoglu S, Gurkan MF, et al. Bacillus 
Calmette-Guerin is a preventive factor in mortality of childhood tuberculous meningitis. Int J 
Infect Dis. 2014;21:1-4. 
9. Laifangbam S, Singh HL, Singh NB, Devi KM, Singh NT. A comparative study of 
fluorescent microscopy with Ziehl-Neelsen staining and culture for the diagnosis of 
pulmonary tuberculosis. Kathmandu Univ Med J (KUMJ). 2009;7(27):226-30. 
10. Ha DT, Lan NT, Wolbers M, Duong TN, Quang ND, Thi Van Thinh T, et al. 
Microscopic observation drug susceptibility assay (MODS) for early diagnosis of tuberculosis 
in children. PLoS One. 2009;4(12):e8341. 
11. Gabriel JM. The testing of Sanocrysin: science, profit, and innovation in clinical trial 
design, 1926-31. J Hist Med Allied Sci. 2014;69(4):604-32. 
12. Kayne GG. The Use of Sanocrysin in the Treatment of Pulmonary Tuberculosis: 
(Section of Medicine). Proc R Soc Med. 1935;28(11):1463-8. 
13. Diacon AH, von Groote-Bidlingmaier F, Donald PR. From magic mountain to table 
mountain. Swiss Med Wkly. 2012;142:w13665. 
14. Sougakoff W. Molecular epidemiology of multidrug-resistant strains of 
Mycobacterium tuberculosis. Clin Microbiol Infect. 2011;17(6):800-5. 
15. Falzon D, Hill G, Pal SN, Suwankesawong W, Jaramillo E. Pharmacovigilance and 
tuberculosis: applying the lessons of thioacetazone. Bull World Health Organ. 
2014;92(12):918-9. 
16. Jindani A, Nunn AJ, Enarson DA. Two 8-month regimens of chemotherapy for 
treatment of newly diagnosed pulmonary tuberculosis: international multicentre randomised 
trial. Lancet. 2004;364(9441):1244-51. 
17. Nunn AJ, Jindani A, Enarson DA, Study Ai. Results at 30 months of a randomised 
trial of two 8-month regimens for the treatment of tuberculosis. Int J Tuberc Lung Dis. 
2011;15(6):741-5. 
18. Emmerson AM, Jones AM. The quinolones: decades of development and use. J 
Antimicrob Chemother. 2003;51 Suppl 1:13-20. 
19. Basu S, Friedland GH, Medlock J, Andrews JR, Shah NS, Gandhi NR, et al. Averting 
epidemics of extensively drug-resistant tuberculosis. Proc Natl Acad Sci U S A. 
2009;106(18):7672-7. 
20. Mdluli K, Kaneko T, Upton A. The tuberculosis drug discovery and development 
pipeline and emerging drug targets. Cold Spring Harb Perspect Med. 2015;5(6). 
 146 
 
21. Steingart KR, Schiller I, DJ H, Pai M, Boehme CC, Dendukuri N. Xpert(R) MTB/RIF 
assay for pulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database Syst 
Rev. 2014;1:CD009593. 
22. Hesseling AC, Cotton MF, Jennings T, Whitelaw A, Johnson LF, Eley B, et al. High 
incidence of tuberculosis among HIV-infected infants: evidence from a South African 
population-based study highlights the need for improved tuberculosis control strategies. Clin 
Infect Dis. 2009;48(1):108-14. 
23. Seddon JA, Shingadia D. Epidemiology and disease burden of tuberculosis in 
children: a global perspective. Infect Drug Resist. 2014;7:153-65. 
24. Abdurrahman ST, Emenyonu N, Obasanya OJ, Lawson L, Dacombe R, Muhammad 
M, et al. The hidden costs of installing Xpert machines in a tuberculosis high-burden country: 
experiences from Nigeria. Pan Afr Med J. 2014;18:277. 
25. World Health Organisation. Child Growth Standards based on length/height, weight 
and age. Acta Paediatr Suppl. 2006;450:76-85. 
26. Gillespie SH, Crook AM, McHugh TD, Mendel CM, Meredith SK, Murray SR, et al. 
Four-Month Moxifloxacin-Based Regimens for Drug-Sensitive Tuberculosis. N Engl J Med. 
2014. 
27. Tameris MD, Hatherill M, Landry BS, Scriba TJ, Snowden MA, Lockhart S, et al. 
Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated 
with BCG: a randomised, placebo-controlled phase 2b trial. Lancet. 2013;381(9871):1021-8. 
28. Jindani A, Harrison TS, Nunn AJ, Phillips PP, Churchyard GJ, Charalambous S, et al. 
High-dose rifapentine with moxifloxacin for pulmonary tuberculosis. N Engl J Med. 
2014;371(17):1599-608. 
29. Marais BJ. Quantifying the tuberculosis disease burden in children. Lancet. 
2014;383(9928):1530-1. 
30. Seddon JA, Jenkins HE, Liu L, Cohen T, Black RE, Vos T, et al. Counting children 
with tuberculosis: why numbers matter. Int J Tuberc Lung Dis. 2015;19 Suppl 1:9-16. 
31. Cuevas LE, Browning R, Bossuyt P, Casenghi M, Cotton MF, Cruz AT, et al. 
Evaluation of tuberculosis diagnostics in children: 2. Methodological issues for conducting 
and reporting research evaluations of tuberculosis diagnostics for intrathoracic tuberculosis in 
children. Consensus from an expert panel. J Infect Dis. 2012;205 Suppl 2:S209-15. 
32. Graham SM, Ahmed T, Amanullah F, Browning R, Cardenas V, Casenghi M, et al. 
Evaluation of tuberculosis diagnostics in children: 1. Proposed clinical case definitions for 
classification of intrathoracic tuberculosis disease. Consensus from an expert panel. J Infect 
Dis. 2012;205 Suppl 2:S199-208. 
33. Feasey NA, Banada PP, Howson W, Sloan DJ, Mdolo A, Boehme C, et al. Evaluation 
of Xpert MTB/RIF for detection of tuberculosis from blood samples of HIV-infected adults 
confirms Mycobacterium tuberculosis bacteremia as an indicator of poor prognosis. J Clin 
Microbiol. 2013;51(7):2311-6. 
34. Yimer SA, Norheim G, Namouchi A, Zegeye ED, Kinander W, Tonjum T, et al. 
Mycobacterium tuberculosis lineage 7 strains are associated with prolonged patient delay in 
seeking treatment for pulmonary tuberculosis in Amhara Region, Ethiopia. J Clin Microbiol. 
2015;53(4):1301-9. 
35. World Health Organisation. The END TB strategy: Global strategy and targets for 
tuberculosis prevention, care and control after 2015. Geneva2014. 
36. Smith NH, Hewinson RG, Kremer K, Brosch R, Gordon SV. Myths and 
misconceptions: the origin and evolution of Mycobacterium tuberculosis. Nat Rev Microbiol. 
2009;7(7):537-44. 
37. Mostowy S, Behr MA. The origin and evolution of Mycobacterium tuberculosis. Clin 
Chest Med. 2005;26(2):207-16, v-vi. 
 147 
 
38. Brennan PJ. Structure, function, and biogenesis of the cell wall of Mycobacterium 
tuberculosis. Tuberculosis (Edinb). 2003;83(1-3):91-7. 
39. Brennan PJ, Nikaido H. The envelope of mycobacteria. Annu Rev Biochem. 
1995;64:29-63. 
40. Liu J, Barry CE, 3rd, Besra GS, Nikaido H. Mycolic acid structure determines the 
fluidity of the mycobacterial cell wall. J Biol Chem. 1996;271(47):29545-51. 
41. Marrakchi H, Laneelle MA, Daffe M. Mycolic acids: structures, biosynthesis, and 
beyond. Chem Biol. 2014;21(1):67-85. 
42. Doherty C, Nickerson D, Southern DA, Kieser T, Appoo J, Dawes J, et al. Trends in 
postcoronary artery bypass graft sternal wound dehiscence in a provincial population. Plast 
Surg (Oakv). 2014;22(3):196-200. 
43. WHO. Global Tuberculosis Report 2014. Geneva: 2015. 
44. Cegielski P, Nunn P, Kurbatova EV, Weyer K, Dalton TL, Wares DF, et al. 
Challenges and controversies in defining totally drug-resistant tuberculosis. Emerg Infect Dis. 
2012;18(11):e2. 
45. Heemskerk D, Caws M, Marais B, Farrar J. Tuberculosis in Adults and Children. 
London: Springer 
2015. 
46. O'Garra A, Redford PS, McNab FW, Bloom CI, Wilkinson RJ, Berry MP. The 
immune response in tuberculosis. Annu Rev Immunol. 2014;31:475-527. 
47. Murdaca G, Spano F, Contatore M, Guastalla A, Penza E, Magnani O, et al. Infection 
risk associated with anti-TNF-alpha agents: a review. Expert Opin Drug Saf. 2014:1-12. 
48. Davies P, D,O., Gordon S, B., Davies GR. Clinical tuberculosis: CRC Press; 2014. 
49. Dorhoi A, Reece ST, Kaufmann SH. For better or for worse: the immune response 
against Mycobacterium tuberculosis balances pathology and protection. Immunol Rev. 
2011;240(1):235-51. 
50. Davies PD, Yew WW, Ganguly D, Davidow AL, Reichman LB, Dheda K, et al. 
Smoking and tuberculosis: the epidemiological association and immunopathogenesis. Trans R 
Soc Trop Med Hyg. 2006;100(4):291-8. 
51. Lee CH, Lee MC, Shu CC, Lim CS, Wang JY, Lee LN, et al. Risk factors for 
pulmonary tuberculosis in patients with chronic obstructive airway disease in Taiwan: a 
nationwide cohort study. BMC Infect Dis. 2013;13:194. 
52. Dodd PJ, Gardiner E, Coghlan R, Seddon JA. Burden of childhood tuberculosis in 22 
high-burden countries: a mathematical modelling study. Lancet Glob Health. 2014;2(8):e453-
9. 
53. Marais BJ, Hesseling AC, Gie RP, Schaaf HS, Beyers N. The burden of childhood 
tuberculosis and the accuracy of community-based surveillance data. Int J Tuberc Lung Dis. 
2006;10(3):259-63. 
54. Oliwa JN, Karumbi JM, Marais BJ, Madhi SA, Graham SM. Tuberculosis as a cause 
or comorbidity of childhood pneumonia in tuberculosis-endemic areas: a systematic review. 
Lancet Respir Med. 2015;3(3):235-43. 
55. Drobac PC, Shin SS, Huamani P, Atwood S, Furin J, Franke MF, et al. Risk factors 
for in-hospital mortality among children with tuberculosis: the 25-year experience in Peru. 
Pediatrics. 2012;130(2):e373-9. 
56. Dangisso MH, Datiko DG, Lindtjorn B. Trends of tuberculosis case notification and 
treatment outcomes in the Sidama Zone, southern Ethiopia: ten-year retrospective trend 
analysis in urban-rural settings. PLoS One. 2014;9(12):e114225. 
57. Marais BJ, Gie RP, Schaaf HS, Beyers N, Donald PR, Starke JR. Childhood 
pulmonary tuberculosis: old wisdom and new challenges. Am J Respir Crit Care Med. 
2006;173(10):1078-90. 
 148 
 
58. Marais BJ, Graham SM. Childhood tuberculosis: A roadmap towards zero deaths. J 
Paediatr Child Health. 2014. 
59. Singh S, Kumar P, Sharma S, Mumbowa F, Martin A, Durier N. Rapid Identification 
and Drug Susceptibility Testing of Mycobacterium tuberculosis: Standard Operating 
Procedure for Non-Commercial Assays: Part 1: Microscopic Observation Drug Susceptibility 
Assay v2.4.12. J Lab Physicians. 2012;4(2):101-11. 
60. Cuevas LE. The urgent need for new diagnostics for symptomatic tuberculosis in 
children. Indian J Pediatr. 2011;78(4):449-55. 
61. Cuevas LE, Petrucci R, Swaminathan S. Tuberculosis diagnostics for children in 
high-burden countries: what is available and what is needed. Paediatr Int Child Health. 
2012;32 Suppl 2:S30-7. 
62. Nicol MP, Gnanashanmugam D, Browning R, Click ES, Cuevas LE, Detjen A, et al. 
A Blueprint to Address Research Gaps in the Development of Biomarkers for Pediatric 
Tuberculosis. Clin Infect Dis. 2015;61Suppl 3:S164-72. 
63. Sandgren A, Cuevas LE, Dara M, Gie RP, Grzemska M, Hawkridge A, et al. 
Childhood tuberculosis: progress requires an advocacy strategy now. Eur Respir J. 
2012;40(2):294-7. 
64. Donald PR, Marais BJ, Barry CE, 3rd. Age and the epidemiology and pathogenesis of 
tuberculosis. Lancet. 2010;375(9729):1852-4. 
65. Marais BJ, Gie RP, Schaaf HS, Hesseling AC, Obihara CC, Starke JJ, et al. The 
natural history of childhood intra-thoracic tuberculosis: a critical review of literature from the 
pre-chemotherapy era. Int J Tuberc Lung Dis. 2004;8(4):392-402. 
66. Marais BJ, Gie RP, Schaaf HS, Hesseling AC, Obihara CC, Nelson LJ, et al. The 
clinical epidemiology of childhood pulmonary tuberculosis: a critical review of literature 
from the pre-chemotherapy era. Int J Tuberc Lung Dis. 2004;8(3):278-85. 
67. Jaganath D, Mupere E. Childhood tuberculosis and malnutrition. J Infect Dis. 
2012;206(12):1809-15. 
68. Schaaf HS, Marais BJ, Hesseling AC, Gie RP, Beyers N, Donald PR. Childhood 
drug-resistant tuberculosis in the Western Cape Province of South Africa. Acta Paediatr. 
2006;95(5):523-8. 
69. Marais BJ, Gie RP, Schaaf HS, Hesseling AC, Enarson DA, Beyers N. The spectrum 
of disease in children treated for tuberculosis in a highly endemic area. Int J Tuberc Lung Dis. 
2006;10(7):732-8. 
70. Hesseling AC, Cotton MF, Fordham von Reyn C, Graham SM, Gie RP, Hussey GD. 
Consensus statement on the revised World Health Organization recommendations for BCG 
vaccination in HIV-infected infants. Int J Tuberc Lung Dis. 2008;12(12):1376-9. 
71. Marais BJ. Tuberculosis in children. J Paediatr Child Health. 2014;50(10):759-67. 
72. Marais BJ, Graham SM, Cotton MF, Beyers N. Diagnostic and management 
challenges for childhood tuberculosis in the era of HIV. J Infect Dis. 2007;196 Suppl 1:S76-
85. 
73. Jeena PM, Pillay P, Pillay T, Coovadia HM. Impact of HIV-1 co-infection on 
presentation and hospital-related mortality in children with culture proven pulmonary 
tuberculosis in Durban, South Africa. Int J Tuberc Lung Dis. 2002;6(8):672-8. 
74. Cuevas LE, Browning R, Bossuyt P, Casenghi M, Cotton MF, Cruz AT, et al. 
Evaluation of Tuberculosis Diagnostics in Children: 2. Methodological Issues for Conducting 
and Reporting Research Evaluations of Tuberculosis Diagnostics for Intrathoracic 
Tuberculosis in Children. Consensus From an Expert Panel. Journal of Infectious Diseases. 
2012;205(suppl 2):S209-S15. 
 149 
 
75. Graham SM, Cuevas LE, Jean-Philippe P, Browning R, Casenghi M, Detjen AK, et 
al. Clinical Case Definitions for Classification of Intrathoracic Tuberculosis in Children: An 
Update. Clin Infect Dis. 2015;61Suppl 3:S179-87. 
76. Marais S, Thwaites G, Schoeman JF, Torok ME, Misra UK, Prasad K, et al. 
Tuberculous meningitis: a uniform case definition for use in clinical research. Lancet Infect 
Dis. 2010;10(11):803-12. 
77. Grant LR, Hammitt LL, Murdoch DR, O'Brien KL, Scott JA. Procedures for 
collection of induced sputum specimens from children. Clin Infect Dis. 2012;54 Suppl 
2:S140-5. 
78. Zar HJ, Hanslo D, Apolles P, Swingler G, Hussey G. Induced sputum versus gastric 
lavage for microbiological confirmation of pulmonary tuberculosis in infants and young 
children: a prospective study. Lancet. 2005;365(9454):130-4. 
79. Planting NS, Visser GL, Nicol MP, Workman L, Isaacs W, Zar HJ. Safety and 
efficacy of induced sputum in young children hospitalised with suspected pulmonary 
tuberculosis. Int J Tuberc Lung Dis. 2014;18(1):8-12. 
80. Ruiz Jimenez M, Guillen Martin S, Prieto Tato LM, Cacho Calvo JB, Alvarez Garcia 
A, Soto Sanchez B, et al. "Induced sputum versus gastric lavage for the diagnosis of 
pulmonary tuberculosis in children". BMC Infect Dis. 2013;13:222. 
81. Mukherjee A, Singh S, Lodha R, Singh V, Hesseling AC, Grewal HM, et al. 
Ambulatory gastric lavages provide better yields of Mycobacterium tuberculosis than induced 
sputum in children with intrathoracic tuberculosis. Pediatr Infect Dis J. 2013;32(12):1313-7. 
82. Atwine D, Nansumba M, Orikiriza P, Riera M, Nackers F, Kamara N, et al. Intra-
gastric string test: an effective tool for diagnosing tuberculosis in adults unable to produce 
sputum. Int J Tuberc Lung Dis. 2015;19(5):558-64. 
83. Lora MH, Reimer-McAtee MJ, Gilman RH, Lozano D, Saravia R, Pajuelo M, et al. 
Evaluation of Microscopic Observation Drug Susceptibility (MODS) and the string test for 
rapid diagnosis of pulmonary tuberculosis in HIV/AIDS patients in Bolivia. BMC Infect Dis. 
2015;15:222. 
84. Nansumba M, Kumbakumba E, Orikiriza P, Muller Y, Nackers F, Debeaudrap P, et 
al. Detection Yield and Tolerability of String Test for Diagnosis of Childhood Intrathoracic 
Tuberculosis. Pediatr Infect Dis J. 2016;35(2):146-51. 
85. Chow F, Espiritu N, Gilman RH, Gutierrez R, Lopez S, Escombe AR, et al. La cuerda 
dulce--a tolerability and acceptability study of a novel approach to specimen collection for 
diagnosis of paediatric pulmonary tuberculosis. BMC Infect Dis. 2006;6:67. 
86. Marcy O, Ung V, Goyet S, Borand L, Msellati P, Tejiokem M, et al. Performance of 
Xpert MTB/RIF and Alternative Specimen Collection Methods for the Diagnosis of 
Tuberculosis in HIV-Infected Children. Clin Infect Dis. 2016. 
87. Nicol MP, Spiers K, Workman L, Isaacs W, Munro J, Black F, et al. Xpert MTB/RIF 
testing of stool samples for the diagnosis of pulmonary tuberculosis in children. Clin Infect 
Dis. 2013;57(3):e18-21. 
88. Banada PP, Naidoo U, Deshpande S, Karim F, Flynn JL, O'Malley M, et al. A Novel 
Sample Processing Method for Rapid Detection of Tuberculosis in the Stool of Pediatric 
Patients Using the Xpert MTB/RIF Assay. PLoS One. 2016;11(3):e0151980. 
89. Pohl C, Rutaihwa LK, Haraka F, Nsubuga M, Aloi F, Ntinginya NE, et al. Limited 
value of whole blood Xpert MTB/RIF for diagnosing tuberculosis in children. J Infect. 2016. 
90. David Alland MR, Laura Smith, Jamie Ryan, Mitchell Chancellor, Ann Marie 
Simmons, David Persing, Robert Kwiatkowski, Martin Jones, Soumitesh Chakravorty. Xpert 
MTB/RIF Ultra: A New Near-Patient TB Test With Sensitivity Equal to Culture.  CROI; 
Seattle, Washington2015. 
 150 
 
91. Zar HJ, Workman L, Isaacs W, Dheda K, Zemanay W, Nicol MP. Rapid diagnosis of 
pulmonary tuberculosis in African children in a primary care setting by use of Xpert 
MTB/RIF on respiratory specimens: a prospective study. Lancet Glob Health. 2013;1(2):e97-
104. 
92. Hatherill M, Hawkridge T, Zar HJ, Whitelaw A, Tameris M, Workman L, et al. 
Induced sputum or gastric lavage for community-based diagnosis of childhood pulmonary 
tuberculosis? Arch Dis Child. 2009;94(3):195-201. 
93. Thomas TA, Heysell SK, Moodley P, Montreuil R, Ha X, Friedland G, et al. 
Intensified specimen collection to improve tuberculosis diagnosis in children from Rural 
South Africa, an observational study. BMC Infect Dis. 2014;14:11. 
94. Pai M, Schito M. Tuberculosis diagnostics in 2015: landscape, priorities, needs, and 
prospects. J Infect Dis. 2015;211 Suppl 2:S21-8. 
95. Hobby GL, Holman AP, Iseman MD, Jones JM. Enumeration of tubercle bacilli in 
sputum of patients with pulmonary tuberculosis. Antimicrob Agents Chemother. 
1973;4(2):94-104. 
96. Singhal R, Myneedu VP. Microscopy as a diagnostic tool in pulmonary tuberculosis. 
Int J Mycobacteriol. 2015;4(1):1-6. 
97. Mase SR, Ramsay A, Ng V, Henry M, Hopewell PC, Cunningham J, et al. Yield of 
serial sputum specimen examinations in the diagnosis of pulmonary tuberculosis: a systematic 
review. Int J Tuberc Lung Dis. 2007;11(5):485-95. 
98. Giang do C, Duong TN, Ha DT, Nhan HT, Wolbers M, Nhu NT, et al. Prospective 
evaluation of GeneXpert for the diagnosis of HIV- negative pediatric TB cases. BMC Infect 
Dis. 2015;15:70. 
99. Singh S, Singh A, Prajapati S, Kabra SK, Lodha R, Mukherjee A, et al. Xpert 
MTB/RIF assay can be used on archived gastric aspirate and induced sputum samples for 
sensitive diagnosis of paediatric tuberculosis. BMC Microbiol. 2015;15:191. 
100. Bahr NC, Tugume L, Rajasingham R, Kiggundu R, Williams DA, Morawski B, et al. 
Improved diagnostic sensitivity for tuberculous meningitis with Xpert((R)) MTB/RIF of 
centrifuged CSF. Int J Tuberc Lung Dis. 2015;19(10):1209-15. 
101. Steingart KR, Henry M, Ng V, Hopewell PC, Ramsay A, Cunningham J, et al. 
Fluorescence versus conventional sputum smear microscopy for tuberculosis: a systematic 
review. Lancet Infect Dis. 2006;6(9):570-81. 
102. Javed H, Zafar A, Qayyum A, Rehman A, Ejaz H. Comparison of fluorescence 
microscopy and Ziehl-Neelsen technique in diagnosis of tuberculosis in paediatric patients. J 
Pak Med Assoc. 2015;65(8):879-81. 
103. Heemskerk D, Caws M, Marais B, Farrar J. Open Access Monographs and Book 
Chapters Funded by Wellcome Trust.  Tuberculosis in Adults and Children. London: Springer 
(c) The Author(s) 2015. The book is published with open access at SpringerLink.com.; 2015. 
104. Chihota VN, Grant AD, Fielding K, Ndibongo B, van Zyl A, Muirhead D, et al. 
Liquid vs. solid culture for tuberculosis: performance and cost in a resource-constrained 
setting. Int J Tuberc Lung Dis. 2010;14(8):1024-31. 
105. Rivera AB, Tupasi TE, Grimaldo ER, Cardano RC, Co VM. Rapid and improved 
recovery rate of Mycobacterium tuberculosis in Mycobacteria Growth Indicator Tube 
combined with solid Lowenstein Jensen medium. Int J Tuberc Lung Dis. 1997;1(5):454-9. 
106. Lu D, Heeren B, Dunne WM. Comparison of the Automated Mycobacteria Growth 
Indicator Tube System (BACTEC 960/MGIT) with Lowenstein-Jensen medium for recovery 
of mycobacteria from clinical specimens. Am J Clin Pathol. 2002;118(4):542-5. 
107. Palaci M, Ueki SY, Sato DN, Da Silva Telles MA, Curcio M, Silva EA. Evaluation of 
mycobacteria growth indicator tube for recovery and drug susceptibility testing of 
 151 
 
Mycobacterium tuberculosis isolates from respiratory specimens. J Clin Microbiol. 
1996;34(3):762-4. 
108. Cruciani M, Scarparo C, Malena M, Bosco O, Serpelloni G, Mengoli C. Meta-
analysis of BACTEC MGIT 960 and BACTEC 460 TB, with or without solid media, for 
detection of mycobacteria. J Clin Microbiol. 2004;42(5):2321-5. 
109. Nhu NT, Ha DT, Anh ND, Thu DD, Duong TN, Quang ND, et al. Evaluation of 
Xpert MTB/RIF and MODS assay for the diagnosis of pediatric tuberculosis. BMC Infect 
Dis. 2013;13:31. 
110. Moore DA, Mendoza D, Gilman RH, Evans CA, Hollm Delgado MG, Guerra J, et al. 
Microscopic observation drug susceptibility assay, a rapid, reliable diagnostic test for 
multidrug-resistant tuberculosis suitable for use in resource-poor settings. J Clin Microbiol. 
2004;42(10):4432-7. 
111. Agarwal A, Dhole TN, Sharma YK. Evaluation of p-nitro benzoic acid (pnb) 
inhibition test to differentiate Mycobacterium tuberculosis complex from non-tuberculous 
mycobacteria using microscopic observation of drug susceptibility (MODS) methodology. 
Indian J Tuberc. 2014;61(3):232-5. 
112. Limaye K, Kanade S, Nataraj G, Mehta P. Utility of Microscopic Observation of 
Drug Susceptibility (MODS) assay for Mycobacterium tuberculosis in resource constrained 
settings. Indian J Tuberc. 2010;57(4):207-12. 
113. Ha DT, Lan NT, Kiet VS, Wolbers M, Hang HT, Day J, et al. Diagnosis of 
pulmonary tuberculosis in HIV-positive patients by microscopic observation drug 
susceptibility assay. J Clin Microbiol. 2010;48(12):4573-9. 
114. Brady MF, Coronel J, Gilman RH, Moore DA. The MODS method for diagnosis of 
tuberculosis and multidrug resistant tuberculosis. J Vis Exp. 2008(17). 
115. Moore DA, Evans CA, Gilman RH, Caviedes L, Coronel J, Vivar A, et al. 
Microscopic-observation drug-susceptibility assay for the diagnosis of TB. N Engl J Med. 
2006;355(15):1539-50. 
116. Olaru-Peter S, Grigoriu C, Boiculese LV, Gradinaru AC, Macovei, II, Diculencu D, 
et al. Detection of Mycobacterium tuberculosis growth by direct microscopic observation has 
a lower cost, higher sensitivity and higher diagnostic value than liquid and solid media 
cultures. Indian J Med Microbiol. 2014;32(3):315-7. 
117. Caws M, Ha DTM, Torok E, Campbell J, Thu DDA, Chau TTH, et al. Evaluation of 
the MODS Culture Technique for the Diagnosis of Tuberculous Meningitis. PLoS One. 
2007;2(11):e1173. 
118. Alcaide F, Coll P. Advances in rapid diagnosis of tuberculosis disease and anti-
tuberculous drug resistance. Enferm Infecc Microbiol Clin. 2011;29 Suppl 1:34-40. 
119. Notomi T, Okayama H, Masubuchi H, Yonekawa T, Watanabe K, Amino N, et al. 
Loop-mediated isothermal amplification of DNA. Nucleic Acids Res. 2000;28(12):E63. 
120. Iwamoto T, Sonobe T, Hayashi K. Loop-mediated isothermal amplification for direct 
detection of Mycobacterium tuberculosis complex, M. avium, and M. intracellulare in sputum 
samples. J Clin Microbiol. 2003;41(6):2616-22. 
121. Ou X, Li Q, Xia H, Pang Y, Wang S, Zhao B, et al. Diagnostic accuracy of the 
PURE-LAMP test for pulmonary tuberculosis at the county-level laboratory in China. PLoS 
One. 2014;9(5):e94544. 
122. World Health Organization. The use of a commercial Loop-Mediated Isothermal 
Amplification Assay (Tb-Lamp) for the detection of tuberculosis. Expert Group Meeting 
Report. 2013. 
123. World Health Organization. Automated Real-Time Nucleic Acid Amplification 
Technology for Rapid and Simultaneous Detection of Tuberculosis and Rifampicin 
 152 
 
Resistance: Xpert MTB/RIF Assay for the Diagnosis of Pulmonary and Extrapulmonary TB 
in Adults and Children: Policy Update. Geneva2013. 
124. Raizada N, Sachdeva KS, Swaminathan S, Kulsange S, Khaparde SD, Nair SA, et al. 
Piloting Upfront Xpert MTB/RIF Testing on Various Specimens under Programmatic 
Conditions for Diagnosis of TB & DR-TB in Paediatric Population. PLoS One. 
2015;10(10):e0140375. 
125. Nicol MP, Workman L, Isaacs W, Munro J, Black F, Eley B, et al. Accuracy of the 
Xpert MTB/RIF test for the diagnosis of pulmonary tuberculosis in children admitted to 
hospital in Cape Town, South Africa: a descriptive study. Lancet Infect Dis. 2011;11(11):819-
24. 
126. Bates M, O'Grady J, Maeurer M, Tembo J, Chilukutu L, Chabala C, et al. Assessment 
of the Xpert MTB/RIF assay for diagnosis of tuberculosis with gastric lavage aspirates in 
children in sub-Saharan Africa: a prospective descriptive study. Lancet Infect Dis. 
2013;13(1):36-42. 
127. Detjen AK, DiNardo AR, Leyden J, Steingart KR, Menzies D, Schiller I, et al. Xpert 
MTB/RIF assay for the diagnosis of pulmonary tuberculosis in children: a systematic review 
and meta-analysis. Lancet Respir Med. 2015;3(6):451-61. 
128. Solomons RS, Visser DH, Friedrich SO, Diacon AH, Hoek KG, Marais BJ, et al. 
Improved diagnosis of childhood tuberculous meningitis using more than one nucleic acid 
amplification test. Int J Tuberc Lung Dis. 2015;19(1):74-80. 
129. Denkinger CM, Schumacher SG, Boehme CC, Dendukuri N, Pai M, Steingart KR. 
Xpert MTB/RIF assay for the diagnosis of extrapulmonary tuberculosis: a systematic review 
and meta-analysis. Eur Respir J. 2014;44(2):435-46. 
130. Albert H, Nathavitharana RR, Isaacs C, Pai M, Denkinger CM, Boehme CC. 
Development, roll-out and impact of Xpert MTB/RIF for tuberculosis: what lessons have we 
learnt and how can we do better? Eur Respir J. 2016. 
131. Forbes M, Kuck NA, Peets EA. Mode of action of ethambutol. J Bacteriol. 
1962;84:1099-103. 
132. Lawn SD. Point-of-care detection of lipoarabinomannan (LAM) in urine for diagnosis 
of HIV-associated tuberculosis: a state of the art review. BMC Infect Dis. 2012;12:103. 
133. Sarkar P, Biswas D, Sindhwani G, Rawat J, Kotwal A, Kakati B. Application of 
lipoarabinomannan antigen in tuberculosis diagnostics: current evidence. Postgrad Med J. 
2014;90(1061):155-63. 
134. Kroidl I, Clowes P, Reither K, Mtafya B, Rojas-Ponce G, Ntinginya EN, et al. 
Performance of urine lipoarabinomannan assays for paediatric tuberculosis in Tanzania. Eur 
Respir J. 2015;46(3):761-70. 
135. Marais BJ. Urine lipoarabinomannan testing in children with tuberculosis. Lancet 
Glob Health. 2014;2(5):e245-6. 
136. Nicol MP, Allen V, Workman L, Isaacs W, Munro J, Pienaar S, et al. Urine 
lipoarabinomannan testing for diagnosis of pulmonary tuberculosis in children: a prospective 
study. Lancet Glob Health. 2014;2(5):e278-84. 
137. Blok N, Visser DH, Solomons R, Van Elsland SL, den Hertog AL, van Furth AM. 
Lipoarabinomannan enzyme-linked immunosorbent assay for early diagnosis of childhood 
tuberculous meningitis. Int J Tuberc Lung Dis. 2014;18(2):205-10. 
138. Walzl G, Haks MC, Joosten SA, Kleynhans L, Ronacher K, Ottenhoff TH. Clinical 
immunology and multiplex biomarkers of human tuberculosis. Cold Spring Harb Perspect 
Med. 2015;5(4). 
139. Anderson ST, Kaforou M, Brent AJ, Wright VJ, Banwell CM, Chagaluka G, et al. 
Diagnosis of childhood tuberculosis and host RNA expression in Africa. N Engl J Med. 
2014;370(18):1712-23. 
 153 
 
140. Lalvani A, Pareek M. Interferon gamma release assays: principles and practice. 
Enferm Infecc Microbiol Clin. 2010;28(4):245-52. 
141. Hoa NB, Cobelens FG, Sy DN, Nhung NV, Borgdorff MW, Tiemersma EW. First 
national tuberculin survey in Viet Nam: characteristics and association with tuberculosis 
prevalence. Int J Tuberc Lung Dis. 2013;17(6):738-44. 
142. Machingaidze S, Wiysonge CS, Gonzalez-Angulo Y, Hatherill M, Moyo S, Hanekom 
W, et al. The utility of an interferon gamma release assay for diagnosis of latent tuberculosis 
infection and disease in children: a systematic review and meta-analysis. Pediatr Infect Dis J. 
2011;30(8):694-700. 
143. Graham SM. Treatment of paediatric TB: revised WHO guidelines. Paediatr Respir 
Rev. 2011;12(1):22-6. 
144. World Health Organization. Guidance for National Tuberculosis Programmes on the 
Management of Tuberculosis in Children. Geneva2014. 
145. WHO. Rapid advice: treatment of tuberculosis in children. Geneva: World Health 
Organization,; 2010. 
146. WHO. Treatment of tuberculosis: guidelines for national programmes. Geneva: 2003. 
147. World Health Organization. Guidance for national tuberculosis programmes on the 
management of tuberculosis in children. Geneva2006. 
148. Zhao P, Li XJ, Zhang SF, Wang XS, Liu CY. Social behaviour risk factors for drug 
resistant tuberculosis in mainland China: a meta-analysis. J Int Med Res. 2012;40(2):436-45. 
149. Seddon JA, Perez-Velez CM, Schaaf HS, Furin JJ, Marais BJ, Tebruegge M, et al. 
Consensus Statement on Research Definitions for Drug-Resistant Tuberculosis in Children. J 
Pediatric Infect Dis Soc. 2013;2(2):100-9. 
150. Borrell S, Gagneux S. Infectiousness, reproductive fitness and evolution of drug-
resistant Mycobacterium tuberculosis. Int J Tuberc Lung Dis. 2009;13(12):1456-66. 
151. Ford CB, Shah RR, Maeda MK, Gagneux S, Murray MB, Cohen T, et al. 
Mycobacterium tuberculosis mutation rate estimates from different lineages predict 
substantial differences in the emergence of drug-resistant tuberculosis. Nat Genet. 
2013;45(7):784-90. 
152. Luciani F, Sisson SA, Jiang H, Francis AR, Tanaka MM. The epidemiological fitness 
cost of drug resistance in Mycobacterium tuberculosis. Proc Natl Acad Sci U S A. 
2009;106(34):14711-5. 
153. Fonseca JD, Knight GM, McHugh TD. The complex evolution of antibiotic 
resistance in Mycobacterium tuberculosis. Int J Infect Dis. 2015;32:94-100. 
154. Gagneux S. Fitness cost of drug resistance in Mycobacterium tuberculosis. Clin 
Microbiol Infect. 2009;15 Suppl 1:66-8. 
155. Toungoussova OS, Caugant DA, Sandven P, Mariandyshev AO, Bjune G. Impact of 
drug resistance on fitness of Mycobacterium tuberculosis strains of the W-Beijing genotype. 
FEMS Immunol Med Microbiol. 2004;42(3):281-90. 
156. Campbell EA, Korzheva N, Mustaev A, Murakami K, Nair S, Goldfarb A, et al. 
Structural mechanism for rifampicin inhibition of bacterial rna polymerase. Cell. 
2001;104(6):901-12. 
157. Timmins GS, Deretic V. Mechanisms of action of isoniazid. Mol Microbiol. 
2006;62(5):1220-7. 
158. Zhang Y, Heym B, Allen B, Young D, Cole S. The catalase-peroxidase gene and 
isoniazid resistance of Mycobacterium tuberculosis. Nature. 1992;358(6387):591-3. 
159. Marrakchi H, Laneelle G, Quemard A. InhA, a target of the antituberculous drug 
isoniazid, is involved in a mycobacterial fatty acid elongation system, FAS-II. Microbiology. 
2000;146 ( Pt 2):289-96. 
 154 
 
160. Zhang Y, Mitchison D. The curious characteristics of pyrazinamide: a review. Int J 
Tuberc Lung Dis. 2003;7(1):6-21. 
161. Zhang Y, Scorpio A, Nikaido H, Sun Z. Role of acid pH and deficient efflux of 
pyrazinoic acid in unique susceptibility of Mycobacterium tuberculosis to pyrazinamide. J 
Bacteriol. 1999;181(7):2044-9. 
162. Hu Y, Coates AR, Mitchison DA. Sterilising action of pyrazinamide in models of 
dormant and rifampicin-tolerant Mycobacterium tuberculosis. Int J Tuberc Lung Dis. 
2006;10(3):317-22. 
163. Fenner L, Egger M, Bodmer T, Altpeter E, Zwahlen M, Jaton K, et al. Effect of 
mutation and genetic background on drug resistance in Mycobacterium tuberculosis. 
Antimicrob Agents Chemother. 2012;56(6):3047-53. 
164. Gagneux S, Burgos MV, DeRiemer K, Encisco A, Munoz S, Hopewell PC, et al. 
Impact of bacterial genetics on the transmission of isoniazid-resistant Mycobacterium 
tuberculosis. PLoS Pathog. 2006;2(6):e61. 
165. Parwati I, van Crevel R, van Soolingen D. Possible underlying mechanisms for 
successful emergence of the Mycobacterium tuberculosis Beijing genotype strains. Lancet 
Infect Dis. 2010;10(2):103-11. 
166. Jenkins HE, Zignol M, Cohen T. Quantifying the burden and trends of isoniazid 
resistant tuberculosis, 1994-2009. PLoS One. 2011;6(7):e22927. 
167. Seifert M, Catanzaro D, Catanzaro A, Rodwell TC. Genetic mutations associated with 
isoniazid resistance in Mycobacterium tuberculosis: a systematic review. PLoS One. 
2015;10(3):e0119628. 
168. Cicala C, Bucci M, F DA, Parente L, Cirino G. Sequential release of TNFalpha and 
phospholipase A(2) in a rat model of LPS-induced pleurisy. Mediators Inflamm. 
1997;6(3):211-5. 
169. Goldstein BP. Resistance to rifampicin: a review. J Antibiot (Tokyo). 
2014;67(9):625-30. 
170. Caws M, Duy PM, Tho DQ, Lan NT, Hoa DV, Farrar J. Mutations prevalent among 
rifampin- and isoniazid-resistant Mycobacterium tuberculosis isolates from a hospital in 
Vietnam. J Clin Microbiol. 2006;44(7):2333-7. 
171. Zhang Y, Shi W, Zhang W, Mitchison D. Mechanisms of Pyrazinamide Action and 
Resistance. Microbiol Spectr. 2014;2(4):Mgm2-0023-2013. 
172. Telenti A, Philipp WJ, Sreevatsan S, Bernasconi C, Stockbauer KE, Wieles B, et al. 
The emb operon, a gene cluster of Mycobacterium tuberculosis involved in resistance to 
ethambutol. Nat Med. 1997;3(5):567-70. 
173. Sreevatsan S, Stockbauer KE, Pan X, Kreiswirth BN, Moghazeh SL, Jacobs WR, Jr., 
et al. Ethambutol resistance in Mycobacterium tuberculosis: critical role of embB mutations. 
Antimicrob Agents Chemother. 1997;41(8):1677-81. 
174. Almeida Da Silva PE, Palomino JC. Molecular basis and mechanisms of drug 
resistance in Mycobacterium tuberculosis: classical and new drugs. J Antimicrob Chemother. 
2011;66(7):1417-30. 
175. Zignol M, Sismanidis C, Falzon D, Glaziou P, Dara M, Floyd K. Multidrug-resistant 
tuberculosis in children: evidence from global surveillance. Eur Respir J. 2013;42(3):701-7. 
176. Yuen CM, Tolman AW, Cohen T, Parr JB, Keshavjee S, Becerra MC. Isoniazid-
resistant tuberculosis in children: a systematic review. Pediatr Infect Dis J. 2013;32(5):e217-
26. 
177. Yuen CM, Jenkins HE, Rodriguez CA, Keshavjee S, Becerra MC. Global and 
Regional Burden of Isoniazid-Resistant Tuberculosis. Pediatrics. 2015;136(1):e50-9. 
 155 
 
178. Jenkins HE, Tolman AW, Yuen CM, Parr JB, Keshavjee S, Perez-Velez CM, et al. 
Incidence of multidrug-resistant tuberculosis disease in children: systematic review and 
global estimates. Lancet. 2014;383(9928):1572-9. 
179. Nhung NV, Hoa NB, Sy DN, Hennig CM, Dean AS. The fourth national anti-
tuberculosis drug resistance survey in Viet Nam. Int J Tuberc Lung Dis. 2015;19(6):670-5. 
180. Hang NT, Maeda S, Lien LT, Thuong PH, Hung NV, Thuy TB, et al. Primary drug-
resistant tuberculosis in Hanoi, Viet Nam: present status and risk factors. PLoS One. 
2013;8(8):e71867. 
181. Almeida D, Rodrigues C, Udwadia ZF, Lalvani A, Gothi GD, Mehta P, et al. 
Incidence of multidrug-resistant tuberculosis in urban and rural India and implications for 
prevention. Clin Infect Dis. 2003;36(12):e152-4. 
182. Factbook CW. Vietnam Age structure. 2014. 
183. Hoa NB, Sy DN, Nhung NV, Tiemersma EW, Borgdorff MW, Cobelens FG. 
National survey of tuberculosis prevalence in Viet Nam. Bull World Health Organ. 
2010;88(4):273-80. 
184. Fox GJ, Loan le P, Nhung NV, Loi NT, Sy DN, Britton WJ, et al. Barriers to 
adherence with tuberculosis contact investigation in six provinces of Vietnam: a nested case-
control study. BMC Infect Dis. 2015;15:103. 
185. Brent AJ. Childhood TB Surveillance: Bridging the Knowledge Gap to Inform 
Policy. J Trop Med. 2012;2012:865436. 
186. Thanh TH, Ngoc SD, Viet NN, Van HN, Horby P, Cobelens FG, et al. A household 
survey on screening practices of household contacts of smear positive tuberculosis patients in 
Vietnam. BMC Public Health. 2014;14:713. 
187. Coscolla M, Gagneux S. Does M. tuberculosis genomic diversity explain disease 
diversity? Drug Discov Today Dis Mech. 2010;7(1):e43-e59. 
188. Gagneux S, Small PM. Global phylogeography of Mycobacterium tuberculosis and 
implications for tuberculosis product development. Lancet Infect Dis. 2007;7(5):328-37. 
189. Desikan S, Narayanan S. Genetic markers, genotyping methods & next generation 
sequencing in Mycobacterium tuberculosis. Indian J Med Res. 2015;141(6):761-74. 
190. Gagneux S, DeRiemer K, Van T, Kato-Maeda M, de Jong BC, Narayanan S, et al. 
Variable host-pathogen compatibility in Mycobacterium tuberculosis. Proc Natl Acad Sci U S 
A. 2006;103(8):2869-73. 
191. Coll F, Preston M, Guerra-Assuncao JA, Hill-Cawthorn G, Harris D, Perdigao J, et al. 
PolyTB: a genomic variation map for Mycobacterium tuberculosis. Tuberculosis (Edinb). 
2013;94(3):346-54. 
192. Thierry D, Brisson-Noel A, Vincent-Levy-Frebault V, Nguyen S, Guesdon JL, 
Gicquel B. Characterization of a Mycobacterium tuberculosis insertion sequence, IS6110, and 
its application in diagnosis. J Clin Microbiol. 1990;28(12):2668-73. 
193. van Embden JD, Cave MD, Crawford JT, Dale JW, Eisenach KD, Gicquel B, et al. 
Strain identification of Mycobacterium tuberculosis by DNA fingerprinting: 
recommendations for a standardized methodology. J Clin Microbiol. 1993;31(2):406-9. 
194. Barlow RE, Gascoyne-Binzi DM, Gillespie SH, Dickens A, Qamer S, Hawkey PM. 
Comparison of variable number tandem repeat and IS6110-restriction fragment length 
polymorphism analyses for discrimination of high- and low-copy-number IS6110 
Mycobacterium tuberculosis isolates. J Clin Microbiol. 2001;39(7):2453-7. 
195. Groenen PM, Bunschoten AE, van Soolingen D, van Embden JD. Nature of DNA 
polymorphism in the direct repeat cluster of Mycobacterium tuberculosis; application for 
strain differentiation by a novel typing method. Mol Microbiol. 1993;10(5):1057-65. 
 156 
 
196. Kamerbeek J, Schouls L, Kolk A, van Agterveld M, van Soolingen D, Kuijper S, et 
al. Simultaneous detection and strain differentiation of Mycobacterium tuberculosis for 
diagnosis and epidemiology. J Clin Microbiol. 1997;35(4):907-14. 
197. Demay C, Liens B, Burguiere T, Hill V, Couvin D, Millet J, et al. SITVITWEB--a 
publicly available international multimarker database for studying Mycobacterium 
tuberculosis genetic diversity and molecular epidemiology. Infect Genet Evol. 
2012;12(4):755-66. 
198. Driscoll JR. Spoligotyping for molecular epidemiology of the Mycobacterium 
tuberculosis complex. Methods Mol Biol. 2009;551:117-28. 
199. Filliol I, Driscoll JR, Van Soolingen D, Kreiswirth BN, Kremer K, Valetudie G, et al. 
Global distribution of Mycobacterium tuberculosis spoligotypes. Emerg Infect Dis. 
2002;8(11):1347-9. 
200. Goguet de la Salmoniere YO, Li HM, Torrea G, Bunschoten A, van Embden J, 
Gicquel B. Evaluation of spoligotyping in a study of the transmission of Mycobacterium 
tuberculosis. J Clin Microbiol. 1997;35(9):2210-4. 
201. Supply P, Magdalena J, Himpens S, Locht C. Identification of novel intergenic 
repetitive units in a mycobacterial two-component system operon. Mol Microbiol. 
1997;26(5):991-1003. 
202. Supply P, Mazars E, Lesjean S, Vincent V, Gicquel B, Locht C. Variable human 
minisatellite-like regions in the Mycobacterium tuberculosis genome. Mol Microbiol. 
2000;36(3):762-71. 
203. Allix-Beguec C, Fauville-Dufaux M, Supply P. Three-year population-based 
evaluation of standardized mycobacterial interspersed repetitive-unit-variable-number 
tandem-repeat typing of Mycobacterium tuberculosis. J Clin Microbiol. 2008;46(4):1398-406. 
204. Allix-Beguec C, Harmsen D, Weniger T, Supply P, Niemann S. Evaluation and 
strategy for use of MIRU-VNTRplus, a multifunctional database for online analysis of 
genotyping data and phylogenetic identification of Mycobacterium tuberculosis complex 
isolates. J Clin Microbiol. 2008;46(8):2692-9. 
205. Oelemann MC, Diel R, Vatin V, Haas W, Rusch-Gerdes S, Locht C, et al. 
Assessment of an optimized mycobacterial interspersed repetitive- unit-variable-number 
tandem-repeat typing system combined with spoligotyping for population-based molecular 
epidemiology studies of tuberculosis. J Clin Microbiol. 2007;45(3):691-7. 
206. Supply P, Allix C, Lesjean S, Cardoso-Oelemann M, Rusch-Gerdes S, Willery E, et 
al. Proposal for standardization of optimized mycobacterial interspersed repetitive unit-
variable-number tandem repeat typing of Mycobacterium tuberculosis. J Clin Microbiol. 
2006;44(12):4498-510. 
207. van Deutekom H, Supply P, de Haas PE, Willery E, Hoijng SP, Locht C, et al. 
Molecular typing of Mycobacterium tuberculosis by mycobacterial interspersed repetitive 
unit-variable-number tandem repeat analysis, a more accurate method for identifying 
epidemiological links between patients with tuberculosis. J Clin Microbiol. 2005;43(9):4473-
9. 
208. Hill V, Zozio T, Sadikalay S, Viegas S, Streit E, Kallenius G, et al. MLVA based 
classification of Mycobacterium tuberculosis complex lineages for a robust phylogeographic 
snapshot of its worldwide molecular diversity. PLoS One. 2012;7(9):e41991. 
209. Bouklata N, Supply P, Jaouhari S, Charof R, Seghrouchni F, Sadki K, et al. 
Molecular Typing of Mycobacterium Tuberculosis Complex by 24-Locus Based MIRU-
VNTR Typing in Conjunction with Spoligotyping to Assess Genetic Diversity of Strains 
Circulating in Morocco. PLoS One. 2015;10(8):e0135695. 
210. Allix-Beguec C, Wahl C, Hanekom M, Nikolayevskyy V, Drobniewski F, Maeda S, 
et al. Proposal of a consensus set of hypervariable mycobacterial interspersed repetitive-unit-
 157 
 
variable-number tandem-repeat loci for subtyping of Mycobacterium tuberculosis Beijing 
isolates. J Clin Microbiol. 2014;52(1):164-72. 
211. Weniger T, Krawczyk J, Supply P, Niemann S, Harmsen D. MIRU-VNTRplus: a web 
tool for polyphasic genotyping of Mycobacterium tuberculosis complex bacteria. Nucleic 
Acids Res. 2010;38(Web Server issue):W326-31. 
212. Supply P, Lesjean S, Savine E, Kremer K, van Soolingen D, Locht C. Automated 
high-throughput genotyping for study of global epidemiology of Mycobacterium tuberculosis 
based on mycobacterial interspersed repetitive units. J Clin Microbiol. 2001;39(10):3563-71. 
213. Hasnain SE, O'Toole RF, Grover S, Ehtesham NZ. Whole genome sequencing: a new 
paradigm in the surveillance and control of human tuberculosis. Tuberculosis (Edinb). 
2015;95(2):91-4. 
214. Colijn C, Cohen T. Whole-genome sequencing of Mycobacterium tuberculosis for 
rapid diagnostics and beyond. Lancet Respir Med. 2016;4(1):6-8. 
215. Javid B, Torok ME. Whole-genome sequencing for the diagnosis of drug-resistant 
tuberculosis. Lancet Infect Dis. 2016;16(1):17. 
216. Ssengooba W, Meehan CJ, Lukoye D, Kasule GW, Musisi K, Joloba ML, et al. 
Whole genome sequencing to complement tuberculosis drug resistance surveys in Uganda. 
Infect Genet Evol. 2016;40:8-16. 
217. Torok ME, Reuter S, Bryant J, Koser CU, Stinchcombe SV, Nazareth B, et al. Rapid 
whole-genome sequencing for investigation of a suspected tuberculosis outbreak. J Clin 
Microbiol. 2013;51(2):611-4. 
218. Steiner A, Stucki D, Coscolla M, Borrell S, Gagneux S. KvarQ: targeted and direct 
variant calling from fastq reads of bacterial genomes. BMC Genomics.15:881. 
219. Lawn SD, Mwaba P, Bates M, Piatek A, Alexander H, Marais BJ, et al. Advances in 
tuberculosis diagnostics: the Xpert MTB/RIF assay and future prospects for a point-of-care 
test. Lancet Infect Dis. 2013;13(4):349-61. 
220. Urdea M, Penny LA, Olmsted SS, Giovanni MY, Kaspar P, Shepherd A, et al. 
Requirements for high impact diagnostics in the developing world. Nature. 2006;444 Suppl 
1:73-9. 
221. Leung E, Minion J, Benedetti A, Pai M, Menzies D. Microcolony culture techniques 
for tuberculosis diagnosis: a systematic review. Int J Tuberc Lung Dis. 2012;16(1):16-23, i-
iii. 
222. Parsons LM, Somoskovi A, Gutierrez C, Lee E, Paramasivan CN, Abimiku A, et al. 
Laboratory diagnosis of tuberculosis in resource-poor countries: challenges and opportunities. 
Clin Microbiol Rev. 2011;24(2):314-50. 
223. Organization WH. Guidance for national tuberculosis programmes on the 
management of tuberculosis in children. In: WHO, editor. 2006. 
224. Parashar D, Kabra SK, Lodha R, Singh V, Mukherjee A, Arya T, et al. Does 
neutralization of gastric aspirates from children with suspected intrathoracic tuberculosis 
affect mycobacterial yields on MGIT culture? J Clin Microbiol. 2013;51(6):1753-6. 
225. World Health Organization. Laboratory Service in Tuberculosis Control1998. 
226. Park WG, Bishai WR, Chaisson RE, Dorman SE. Performance of the Microscopic 
Observation Drug Susceptibility Assay in Drug Susceptibility Testing for Mycobacterium 
tuberculosis. J Clin Microbiol. 2002;40(12):4750-2. 
227. Initiative GL. Mycobacteriology laboratory manual. WHO Press, Geneva, 
Switzeland; 2014. 
228. World Health Organization. Guidelines for the programmatic management of drug-
resistant tuberculosis-2011 update. 2011. 
 158 
 
229. Tho DQ, Ha DT, Duy PM, Lan NT, Hoa DV, Chau NV, et al. Comparison of MAS-
PCR and GenoType MTBDR assay for the detection of rifampicin-resistant Mycobacterium 
tuberculosis. Int J Tuberc Lung Dis. 2008;12(11):1306-12. 
230. Tho DQ, Lan NT, Chau NV, Farrar J, Caws M. Multiplex allele-specific polymerase 
chain reaction for detection of isoniazid resistance in Mycobacterium tuberculosis. Int J 
Tuberc Lung Dis. 2011;15(6):799-803. 
231. de Beer JL, Kremer K, Kodmon C, Supply P, van Soolingen D, Global Network for 
the Molecular Surveillance of T. First worldwide proficiency study on variable-number 
tandem-repeat typing of Mycobacterium tuberculosis complex strains. J Clin Microbiol. 
2012;50(3):662-9. 
232. de Beer JL, Kodmon C, van Ingen J, Supply P, van Soolingen D, Global Network for 
Molecular Surveillance of T. Second worldwide proficiency study on variable number of 
tandem repeats typing of Mycobacterium tuberculosis complex. Int J Tuberc Lung Dis. 
2014;18(5):594-600. 
233. Shabbeer A, Cowan LS, Ozcaglar C, Rastogi N, Vandenberg SL, Yener B, et al. TB-
Lineage: an online tool for classification and analysis of strains of Mycobacterium 
tuberculosis complex. Infect Genet Evol. 2012;12(4):789-97. 
234. Swaminathan S, Rekha B. Pediatric Tuberculosis: Global Overview and Challenges. 
Clin Infect Dis. 2010;50(Supplement 3):S184-S94. 
235. Centers for Disease Control and Prevention (CDC). Epidemiology of Pediatric 
Tuberculosis in the United States 1993-2008 2008 [cited 2012]. Available from: 
http://www.cdc.gov/tb/publications/slidesets/pediatricTB/default.htm. 
236. Erkens CG, de Vries G, Keizer ST, Slump E, van den Hof S. The epidemiology of 
childhood tuberculosis in the Netherlands: still room for prevention. BMC Infect Dis. 
2014;14:295. 
237. van Rie A, Beyers N, Gie RP, Kunneke M, Zietsman L, Donald PR. Childhood 
tuberculosis in an urban population in South Africa: burden and risk factor. Arch Dis Child. 
1999;80(5):433-7. 
238. Ehiri J. Tuberculosis in Childhood and Pregnancy. In: Ehiri J, editor. Maternal and 
Child Health Global Challenges, Programs, and Policies. New York: Springer; 2009. p. 245-
69. 
239. López Ávalos GG, Prado Montes de Oca E. Classic and New Diagnostic Approaches 
to Childhood Tuberculosis. J Trop Med. 2012;2012. 
240. Zar HJ, Eley B, Nicol MP, Figaji A, Hawkridge A. Advances in childhood 
tuberculosis - contributions from the University of Cape Town. S Afr Med J. 
2012;102(6):518-21. 
241. Mukherjee A, Lodha R, Kabra S. Changing Trends in Childhood Tuberculosis. Indian 
J Pediatr. 2011;78(3):328-33. 
242. Nicol MP, Zar HJ. New specimens and laboratory diagnostics for childhood 
pulmonary TB: progress and prospects. Paediatr Respir Rev. 2011;12(1):16-21. 
243. Zar HJ, Hanslo D, Apolles P, Swingler G, Hussey G. Induced sputum versus gastric 
lavage for microbiological confirmation of pulmonary tuberculosis in infants and young 
children: a prospective study. The Lancet. 2005;365(9454):130-4. 
244. Gray JW. Childhood tuberculosis and its early diagnosis. Special Issue: Proceedings 
of the IX International Congress on Pediatric Laboratory Medicine. 2004;37(6):450-5. 
245. Small PM, Pai M. Tuberculosis Diagnosis — Time for a Game Change. N Engl J 
Med. 2010;363(11):1070-1. 
246. Newton SM, Brent AJ, Anderson S, Whittaker E, Kampmann B. Paediatric 
tuberculosis. The Lancet Infectious Diseases. 2008;8(8):498-510. 
 159 
 
247. Marais BJ, Pai M. Recent advances in the diagnosis of childhood tuberculosis. Arch 
Dis Child. 2007;92(5):446-52. 
248. Moore DA, Caviedes L, Gilman RH, Coronel J, Arenas F, LaChira D, et al. 
Infrequent MODS TB culture cross-contamination in a high-burden resource-poor setting. 
Diagn Microbiol Infect Dis. 2006;56(1):35-43. 
249. Oberhelman RA, Soto-Castellares G, Caviedes L, Castillo ME, Kissinger P, Moore 
DAJ, et al. Improved Recovery of Mycobacterium tuberculosis From Children Using the 
Microscopic Observation Drug Susceptibility Method. Pediatrics. 2006;118(1):e100-e6. 
250. Ha DTM, Lan NTN, Wolbers M, Duong TN, Quang ND, Thi VT, et al. Microscopic 
Observation Drug Susceptibility Assay (MODS) for Early Diagnosis of Tuberculosis in 
Children. PLoS One. 2009;4(12):e8341. 
251. Oberhelman RA, Soto-Castellares G, Gilman RH, Caviedes L, Castillo ME, Kolevic 
L, et al. Diagnostic approaches for paediatric tuberculosis by use of different specimen types, 
culture methods, and PCR: a prospective case-control study. The Lancet Infectious Diseases. 
2010;10(9):612-20. 
252. World Health Organization Global Tuberculosis Programme. Laboratory 
Service in Tuberculosis Control: Part II. Microscopy.  Contract No.: Report. 
253. Mark Stevenson with contributions from Telmo Nunes JSaaRT. epiR: 
Functions for analyzing epidemiological data. R package version 0.9-27 ed2010. 
254. Lumley TTaoS-RbT. survival: Survival analysis, including penalised 
likelihood. R package version 2.36-2 ed2010. 
255. Team RDC. R: A language and environment for statistical computing. Vienna, 
Austria: R Foundation for Statistical Computing; 2010. 
256. World Health Organization. WHO monitoring of Xpert MTB/RIF roll-out 
2012 [cited 2012]. Available from: http://who.int/tb/laboratory/mtbrifrollout/en/. 
257. Helb D, Jones M, Story E, Boehme C, Wallace E, Ho K, et al. Rapid Detection of 
Mycobacterium tuberculosis and Rifampin Resistance by Use of On-Demand, Near-Patient 
Technology. J Clin Microbiol. 2010;48(1):229-37. 
258. Menzies NA, Cohen T, Lin H-H, Murray M, Salomon JA. Population Health Impact 
and Cost-Effectiveness of Tuberculosis Diagnosis with Xpert MTB/RIF: A Dynamic 
Simulation and Economic Evaluation. PLoS Med. 2012;9(11):e1001347. 
259. World Health Organization. Automated Real-time Nucleic Acid Amplification 
Technology for Rapid and Simultaneous Dection of Tuberculosis and Rifampicin 
Resistance: Xpert MTB/RIF System Policy Statement. Geneva, Switzerland2011. 
260. Nicol MP, Workman L, Isaacs W, Munro J, Black F, Eley B, et al. Accuracy of the 
Xpert MTB/RIF test for the diagnosis of pulmonary tuberculosis in children admitted to 
hospital in Cape Town, South Africa: a descriptive study. The Lancet Infectious Diseases. 
2011;11(11):819-24. 
261. Evans CA. GeneXpert—A Game-Changer for Tuberculosis Control? PLoS Med. 
2011;8(7):e1001064. 
262. World Health Organisation. Guidance for National Tuberculosis Programmes on the 
management of tuberculosis in children. Chapter 1: introduction and diagnosis of tuberculosis 
in children. Int J Tuberc Lung Dis. 2006;10(10):1091-7. 
263. IUATD. Desk-guide for diagnosis and management of TB in children. 2010. 
264. Berti E, Galli L, Venturini E, de Martini M, Chiappini E. Tuberculosis in childhood: a 
systematic review of national and international guidelines. BMC Infect Dis. 2014;14 Suppl 
1:S3. 
265. Heysell SK, Thomas TA, Gandhi NR, Moll AP, Eksteen FJ, Coovadia Y, et al. Blood 
cultures for the diagnosis of multidrug-resistant and extensively drug-resistant tuberculosis 
 160 
 
among HIV-infected patients from rural South Africa: a cross-sectional study. BMC Infect 
Dis. 2010;10:344. 
266. Foroughi M, Montazeri SM, SeyedAlinaghi S, Badie BM, Heiydarpour P, Roosta N, 
et al. Incidence of isolation of Mycobacterium tuberculosis from blood samples in 
tuberculosis patients in Imam Khomeini Hospital, Tehran, Iran. Acta Med Iran. 
2011;49(8):556-9. 
267. Pavlinac PB, Naulikha JM, John-Stewart GC, Onchiri FM, Okumu AO, Sitati RR, et 
al. Mycobacterium tuberculosis Bacteremia Among Acutely Febrile Children in Western 
Kenya. Am J Trop Med Hyg. 2015;93(5):1087-91. 
268. David ST, Mukundan U, Brahmadathan KN, John TJ. Detecting mycobacteraemia for 
diagnosing tuberculosis. Indian J Med Res. 2004;119(6):259-66. 
269. Ssali FN, Kamya MR, Wabwire-Mangen F, Kasasa S, Joloba M, Williams D, et al. A 
prospective study of community-acquired bloodstream infections among febrile adults 
admitted to Mulago Hospital in Kampala, Uganda. J Acquir Immune Defic Syndr Hum 
Retrovirol. 1998;19(5):484-9. 
270. Archibald LK, den Dulk MO, Pallangyo KJ, Reller LB. Fatal Mycobacterium 
tuberculosis bloodstream infections in febrile hospitalized adults in Dar es Salaam, Tanzania. 
Clin Infect Dis. 1998;26(2):290-6. 
271. Jacob ST, Pavlinac PB, Nakiyingi L, Banura P, Baeten JM, Morgan K, et al. 
Mycobacterium tuberculosis Bacteremia in a Cohort of HIV-Infected Patients Hospitalized 
with Severe Sepsis in Uganda–High Frequency, Low Clinical Sand Derivation of a Clinical 
Prediction Score. PLoS One. 2013;8(8):e70305. 
272. Marais BJ. Childhood tuberculosis: epidemiology and natural history of disease. 
Indian J Pediatr. 2011;78(3):321-7. 
273. Sabi I, Kabyemera R, Mshana SE, Kidenya BR, Kasanga G, Gerwing-Adima LE, et 
al. Pulmonary TB bacteriologically confirmed by induced sputum among children at Bugando 
Medical Centre, Tanzania. Int J Tuberc Lung Dis. 2016;20(2):228-34. 
274. von Gottberg A, Sacks L, Machala S, Blumberg L. Utility of blood cultures and 
incidence of mycobacteremia in patients with suspected tuberculosis in a South African 
infectious disease referral hospital. Int J Tuberc Lung Dis. 2001;5(1):80-6. 
275. Nguyen DN, Nguyen TV, Dao TT, Nguyen LT, Horby P, Nguyen KV, et al. One year 
experience using mycobacterial blood cultures to diagnose tuberculosis in patients with 
prolonged fever in Vietnam. J Infect Dev Ctries. 2014;8(12):1620-4. 
276. Oplustil CP, Leite OH, Oliveira MS, Sinto SI, Uip DE, Boulos M, et al. Detection of 
mycobacteria in the bloodstream of patients with acquired immunodeficiency syndrome in a 
university hospital in Brazil. Braz J Infect Dis. 2001;5(5):252-9. 
277. Banada PP, Koshy R, Alland D. Detection of Mycobacterium tuberculosis in blood 
by use of the Xpert MTB/RIF assay. J Clin Microbiol. 2013;51(7):2317-22. 
278. Marais BJ, Obihara CC, Warren RM, Schaaf HS, Gie RP, Donald PR. The burden of 
childhood tuberculosis: a public health perspective. Int J Tuberc Lung Dis. 2005;9(12):1305-
13. 
279. Perez-Velez CM, Marais BJ. Tuberculosis in children. N Engl J Med. 
2012;367(4):348-61. 
280. Toungoussova OS, Sandven P, Mariandyshev AO, Nizovtseva NI, Bjune G, Caugant 
DA. Spread of drug-resistant Mycobacterium tuberculosis strains of the Beijing genotype in 
the Archangel Oblast, Russia. J Clin Microbiol. 2002;40(6):1930-7. 
281. Pang Y, Zhou Y, Zhao B, Liu G, Jiang G, Xia H, et al. Spoligotyping and drug 
resistance analysis of Mycobacterium tuberculosis strains from national survey in China. 
PLoS One. 2012;7(3):e32976. 
 161 
 
282. Almeida D, Rodrigues C, Ashavaid TF, Lalvani A, Udwadia ZF, Mehta A. High 
incidence of the Beijing genotype among multidrug-resistant isolates of Mycobacterium 
tuberculosis in a tertiary care center in Mumbai, India. Clin Infect Dis. 2005;40(6):881-6. 
283. Duong DA, Nguyen TH, Nguyen TN, Dai VH, Dang TM, Vo SK, et al. Beijing 
genotype of Mycobacterium tuberculosis is significantly associated with high-level 
fluoroquinolone resistance in Vietnam. Antimicrob Agents Chemother. 2009;53(11):4835-9. 
284. Buu TN, Huyen MN, Lan NT, Quy HT, Hen NV, Zignol M, et al. The Beijing 
genotype is associated with young age and multidrug-resistant tuberculosis in rural Vietnam. 
Int J Tuberc Lung Dis. 2009;13(7):900-6. 
285. An DD, Duyen NTH, Lan NTN, Ha DTM, Kiet VS, Chau NVV, et al. Beijing 
genotype of Mycobacterium tuberculosis is significantly associated with high-level 
fluoroquinolone resistance in Vietnam. Antimicrob Agents Chemother. 2009;53(11):4835-9. 
286. Caws M, Thwaites G, Stepniewska K, Nguyen TN, Nguyen TH, Nguyen TP, et al. 
Beijing genotype of Mycobacterium tuberculosis is significantly associated with human 
immunodeficiency virus infection and multidrug resistance in cases of tuberculous meningitis. 
J Clin Microbiol. 2006;44(11):3934-9. 
287. Blount RJ, Tran B, Jarlsberg LG, Phan H, Thanh Hoang V, Nguyen NV, et al. 
Childhood tuberculosis in northern Viet Nam: a review of 103 cases. PLoS One. 
2014;9(5):e97267. 
288. World Health Organization. Treatment of tuberculosis: guidelines: World Health 
Organization; 2010. 
289. Ezer N, Benedetti A, Darvish-Zargar M, Menzies D. Incidence of ethambutol-related 
visual impairment during treatment of active tuberculosis. Int J Tuberc Lung Dis. 
2013;17(4):447-55. 
290. Oxlade O, Schwartzman K, Pai M, Heymann J, Benedetti A, Royce S, et al. 
Predicting outcomes and drug resistance with standardised treatment of active tuberculosis. 
Eur Respir J. 2010;36(4):870-7. 
291. Sterling TR, Villarino ME, Borisov AS, Shang N, Gordin F, Bliven-Sizemore E, et al. 
Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med. 
2011;365(23):2155-66. 
292. Buu TN, Huyen MN, van Soolingen D, Lan NT, Quy HT, Tiemersma EW, et al. The 
Mycobacterium tuberculosis Beijing genotype does not affect tuberculosis treatment failure in 
Vietnam. Clin Infect Dis. 2010;51(8):879-86. 
293. Huyen MN, Buu TN, Tiemersma E, Lan NT, Dung NH, Kremer K, et al. 
Tuberculosis relapse in Vietnam is significantly associated with Mycobacterium tuberculosis 
Beijing genotype infections. J Infect Dis. 2013;207(10):1516-24. 
294. Maeda S, Hang NT, Lien LT, Thuong PH, Hung NV, Hoang NP, et al. 
Mycobacterium tuberculosis strains spreading in Hanoi, Vietnam: Beijing sublineages, 
genotypes, drug susceptibility patterns, and host factors. Tuberculosis (Edinb). 
2014;94(6):649-56. 
295. Nguyen VA, Choisy M, Nguyen DH, Tran TH, Pham KL, Thi Dinh PT, et al. High 
prevalence of Beijing and EAI4-VNM genotypes among M. tuberculosis isolates in northern 
Vietnam: sampling effect, rural and urban disparities. PLoS One. 2012;7(9):e45553. 
296. Thwaites GE, Chau TT, Caws M, Phu NH, Chuong LV, Sinh DX, et al. Isoniazid 
resistance, mycobacterial genotype and outcome in Vietnamese adults with tuberculous 
meningitis. Int J Tuberc Lung Dis. 2002;6(10):865-71. 
297. Caws M, Thwaites G, Dunstan S, Hawn TR, Lan NT, Thuong NT, et al. The 
influence of host and bacterial genotype on the development of disseminated disease with 
Mycobacterium tuberculosis. PLoS Pathog. 2008;4(3):e1000034. 
 162 
 
298. Buu TN, van Soolingen D, Huyen MN, Lan NT, Quy HT, Tiemersma EW, et al. 
Increased transmission of Mycobacterium tuberculosis Beijing genotype strains associated 
with resistance to streptomycin: a population-based study. PLoS One. 2012;7(8):e42323. 
299. Lawson L, Emenyonu N, Abdurrahman ST, Lawson JO, Uzoewulu GN, Sogaolu 
OM, et al. Comparison of Mycobacterium tuberculosis drug susceptibility using solid and 
liquid culture in Nigeria. BMC Res Notes. 2013;6:215. 
300. Kam KM. Microscopic observation drug susceptibility (MODS): where are we 
going? Int J Tuberc Lung Dis. 2014;18(2):127. 
301. Wang L, Mohammad SH, Chaiyasirinroje B, Li Q, Rienthong S, Rienthong D, et al. 
Evaluating the Auto-MODS assay, a novel tool for tuberculosis diagnosis for use in resource-
limited settings. J Clin Microbiol. 2015;53(1):172-8. 
302. Solis L, Coronel J, Rueda D, Gilman RH, Sheen P, Zimic M. Evaluation of a lens-
free imager to facilitate tuberculosis diagnostics in MODS. Tuberculosis (Edinb). 2016;97:26-
32. 
303. Alva A, Aquino F, Gilman RH, Olivares C, Requena D, Gutierrez AH, et al. 
Morphological characterization of Mycobacterium tuberculosis in a MODS culture for an 
automatic diagnostics through pattern recognition. PLoS One. 2013;8(12):e82809. 
304. Mendoza-Ticona A, Alarcon E, Alarcon V, Bissell K, Castillo E, Sabogal I, et al. 
Effect of universal MODS access on pulmonary tuberculosis treatment outcomes in new 
patients in Peru. Public Health Action. 2012;2(4):162-7. 
305. Kokuto H, Sasaki Y, Yoshimatsu S, Mizuno K, Yi L, Mitarai S. Detection of 
Mycobacterium tuberculosis (MTB) in Fecal Specimens From Adults Diagnosed With 
Pulmonary Tuberculosis Using the Xpert MTB/Rifampicin Test. Open Forum Infect Dis. 
2015;2(2):ofv074. 
306. Anh DD, Borgdorff MW, Van LN, Lan NT, van Gorkom T, Kremer K, et al. 
Mycobacterium tuberculosis Beijing genotype emerging in Vietnam. Emerg Infect Dis. 
2000;6(3):302-5. 
307. Aguilar D, Hanekom M, Mata D, Gey van Pittius NC, van Helden PD, Warren RM, 
et al. Mycobacterium tuberculosis strains with the Beijing genotype demonstrate variability in 
virulence associated with transmission. Tuberculosis (Edinb). 2010;90(5):319-25. 
308. Jiao W, Liu Z, Han R, Zhao X, Dong F, Dong H, et al. A country-wide study of 
spoligotype and drug resistance characteristics of Mycobacterium tuberculosis isolates from 
children in China. PLoS One. 2013;8(12):e84315. 
309. Lisdawati V, Puspandari N, Rif'ati L, Soekarno T, M M, K S, et al. Molecular 
epidemiology study of Mycobacterium tuberculosis and its susceptibility to anti-tuberculosis 
drugs in Indonesia. BMC Infect Dis. 2015;15:366. 
310. Zhang Z, Lu J, Liu M, Wang Y, Qu G, Li H, et al. Genotyping and molecular 
characteristics of multidrug-resistant Mycobacterium tuberculosis isolates from China. J 
Infect. 2015;70(4):335-45. 
311. alland D. Xpert MTB/RIF Ultra: A New Near-Patient TB Test With Sensitivity Equal 
to Culture, CROI abstract no. 91. February 23-26, 2015 | Seattle, Washington. 2015. 
 
  
 163 
 
Appendix A 
Evaluation of Microscopic Observation of Drug Suscepibility (MODS) technique for the 
diagnosis of Pediatric Tuberculosisat National Pediatric Hospital, Hanoi , Vietnam 
 
Introduction 
Pediatric pulmonary and extra-pulmonary tuberculosis (EPTB) requires rapid diagnosis and 
instigation of appropriate chemotherapy to improve outcome. The current options for rapid 
diagnosis of tuberculosis in developing countries are smear for acid fast bacilli (AFB) or 
PCR. Solid cultures techniques are more sensitive, but slow and hazardous. EPTB is often 
AFB smear and culture negative, and smear-negative and EPTB are more common in children 
compared to adults.(4) Furthermore, it is challenging to obtain adequate specimens for TB 
diagnostic tests from children, for instance many children are unable to produce sputum.(1) 
Thus, there remains a great need for new rapid diagnostic tests for pediatric TB.(5) 
The Microscopic Observation Drug Susceptibility (MODS) assay is a rapid culture system 
that allows early identification of TB and drug susceptibility testing.(6) The latter is a great 
advantage, as AFB smear and PCR do not allow for the microbiological isolation of M. 
tuberculosis and assessment of drug resistance.  
 
MODS 
MODS is a rapid liquid culture system that is performed in standard tissue culture plates and 
is read with an inverse light microscope. The technique allows the early identification of M. 
tuberculosis from clinical samples through recognition of the characteristic cord formation of 
M. tuberculosis. The rapid microbiological isolation of M. tuberculosis also allows for the 
subsequent drug susceptibility testing of the isolate and rapid identification of MDR TB. 
Without second line therapy, MDR TB is almost always fatal.(3) Also further transmission of 
MDR TB can be prevented.(3) 
 
A recent study in adults showed that the sensitivity of detection of positive sputum cultures 
was 97.8% for MODS culture, 89.0% for automated mycobacterial culture, and 84.0% for 
Löwenstein–Jensen (LJ) culture, with a median time to positivity of 7 days, 13 days, and 26 
days, respectively.(6) Also the median time to drug susceptibility results was faster for 
MODS as compared to automated and Löwenstein–Jensen culture: 7, 22, and 68 days, 
respectively. Furthermore, MODS is inexpensive, simple and applicable in resource-limited 
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settings, like Viet Nam (2). Another advantage is that the MODS assay is a closed system, 
which makes it a safer technique for laboratory workers than standard TB culture techniques.  
 
A good evaluation of MODS technique for the detection of pulmonary and EPTB in a 
pediatric setting in an endemic country is still lacking. One study on pulmonary TB has been 
performed in Peru, with similar results as the study in adults: better sensitivity and faster than 
standard culture techniques.(7) MODS has not been evaluated for extra-pulmonary TB in 
children. It has been evaluated for the isolation of M.tuberculosis from CSF in case of 
suspected tuberculous meningitis in adults at the Hospital of Tropical Diseases, Ho Chi Minh 
City, Vietnam (Maxine Caws et al. manuscript submitted) and is shown to be moderately 
sensitive (65%), specific (100%), with a median isolation time of 6 days. Both for pulmonary 
and EP TB, MODS is considered to be a potential valuable diagnostic test, that needs further 
evaluation. 
 
This study aims to evaluate the diagnostic value of MODS for both pulmonary and extra-
pulmonary TB in children admitted to the National Hospital of Pediatrics (NHP) in Viet Nam.  
 
Objectives: 
This project will aim to: 
1. Enhance the overall diagnostic capacity at NHP to diagnose childhood tuberculosis. 
Currently, the microbiology laboratory of NHP only performs PCR on diagnostic 
specimens. For culture, the specimens are transferred to the laboratory of the National 
Institute of Tuberculosis and Pulmonary Disease. 
2. Set up laboratory capacity to perform MODS technique for diagnosis of pulmonary 
and extra-pulmonary tuberculosis in children admitted to NHP. 
3. Compare MODS with conventional AFB smear, PCR and TB culture, through a lab 
enhancement program of children who attend NHP during a period of 2 years and are 
suspected of having any form of TB. 
4. Set up TB research projects, once MODS has been well established at NHP. 
5. Epidemiology of TB drug resistance in children admitted to NHP. 
 
Study design: 
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Pediatric patients admitted to NHP with suspected TB, both pulmonary and extra-pulmonary, 
are evaluated with MODS, AFB smear, PCR, and Lowenstein culture. The latter will be 
performed at the National Institute of Tuberculosis and Pulmonary Disease. 
 
Specimens that will be tested by MODS diagnostics 
Specimens from patients presenting at NHP with a clinical suspicion of any form of TB, will 
be eligible for enrollment.   
 
Doctors will be trained to sample adequate specimens from suspect TB cases. Suspect TB 
cases in this study are considered to have at least two of the following findings: 
-unexplained fever for more than 1 week 
-unexplained cough for more than 1 week 
-radiographic findings suggestive of tuberculosis. 
-failure to thrive/weight loss 
-enlarged non-tender lymph nodes or lymph node abscess, especially of the neck 
-signs of meningitis with history of at least one week 
-HIV positive 
-malnourished 
-TB contact history 
-treating doctor suspects TB based on findings not described above. 
 
As MODS can be considered as routine lab test, no informed consent will be requested from 
the patient or legal guardian(s). Patient data will be anonimized. 
 
Exclusion criteria for specimens to be tested by MODS 
The following specimens are excluded:  
-specimens from a patient that is on anti-tuberculous treatment 
 
Definitions 
Pulmonary tuberculosis 
Proven 
- microbiological detection of TB in respiratory or gastric specimen and pulmonary symptoms 
by AFB smear, PCR, or LJ culture. 
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Tuberculous meningitis: 
Proven:  
-microbiological detection of TB in CSF by either AFB stain, PCR,  or LJ culture 
-clinical meningitis, CT scan is consistent with TBM (basal meningeal enhancement, 
tuberculoma, oedema) and clinical response to antituberculous treatment. No other pathogens 
detected.  
 
Non - TBM:  
-CSF is positive for other pathogen 
-Sustained clinical improvement without anti-tuberculous treatment. 
 
For all other causes of pediatric tuberculosis: 
Only microbiological (AFB smear, PCR, LJ culture) confirmed TB is considered as ‘proven’. 
If otherwise, TB is not considered to be a cause of the patient’s clinical condition. 
 
Discrepancies 
In case of discrepant results, one test being positive and other is negative, it will be assessed 
whether the patient had symptoms that fit the diagnosis of tuberculosis. If so, the positive test 
will be considered to be ‘confirmed’ by the clinical presentation. 
 
Clinical Data Collection 
Basic demographic, presenting clinical features, TB contact history, BCG and vaccination 
history. HIV testing will be performed according to hospital practice. It is good clinical 
practice to test suspected TB patients for HIV. Patient data will be anonimized and entered 
into a database for further analysis. 
  
All patients Laboratory Diagnostics  
Sample collection 
Training will be given to clinicians on the indications and taking of appropriate samples for 
TB diagnosis: 
1. In case of suspected pulmonary tuberculosis, the following specimen types are encouraged 
to obtain: 
- morning sputum collected on two consecutive days (spot-morning-spot)  
 167 
 
- if an adequate sputum sample cannot be obtained, a gastric aspirate is performed on 
two successive mornings. 
- other samples (sputum/broncho alveolar lavage/pleural fluid/biopsy) will be taken 
as clinically indicated. 
2. In case of suspected TBM, cerebral spinal fluid will be obtained, according to hospital 
guidelines.  It will be encouraged to obtain large volume as possible in the children. 
3. Samples for extra-pulmonary tuberculosis will be obtained as clinically indicated. 
Sample size. 
On a yearly basis, around 350-400 specimens for TB diagnostics are received by the NHP 
microbiology laboratory. Therefore, it is expected that 750 specimens from approximately 
600 patients will be enrolled in this study. The estimated TB prevalence in our study 
population is estimated to be 20%, resulting in 120 positive cases in two years. At an 
estimated sensitivity of MODS to detect pulmonary TB of 90%, the confidence interval 
would be ± 6.4%.  
 
Residual specimens 
Residual specimen following laboratory investigations will be stored at -80˚C for further 
microbiological assessment in the event of contamination 
Forms and data handling. 
All data concerning the study will be recorded prospectively and will be transferred to a 
computerised database. Data will be anonymized. 
Ethical considerations. 
As this study will evaluate a routine diagnostic test, no Oxford University (OXTREC) 
approval will be obtained. The protocol will be submitted to the Review Board of NHP for 
local approval. All patient data will be anonymized for data entry. 
Publication 
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Publication will be in international peer-reviewed journals following relevant guidelines. No 
publication will be submitted in any language without prior approval of the involved 
investigators. 
Budget 
The Oxford University Clinical Research Unit (OUCRU) will meet the costs of procedures 
additional to routine care for study participants as agreed with the participating hospital. 
A room in NHP microbiology laboratory will be refurbished and equipped for MODS culture. 
Benching and equipment will be provided by OUCRU. 
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Appendix B 
Enhancing diagnostics for paediatric tuberculosis by blood culture 
Summary 
Detection of M. tuberculosis in clinical specimens of children has a low sensitivity because 
specimens are either difficult to collect or contain low levels of M. tuberculosis. Diagnostic 
criteria are non-specific and culture confirmation is challenging, as sputum samples are not 
often obtainable from small children and specimens typically have low yield. One is often 
forced to begin empiric treatment or treatment is delayed causing harm and risk to patient and 
contacts. The emergence of drug-resistant TB into the pediatric population demands greater 
attention to improved diagnostics and drug susceptibility testing (DST). Although children are 
typically thought to have paucibacillary disease, they are at greater risk for dissemination of 
TB. This may allow for detection of Mycobacterium tuberculosis from other bodily fluids 
than sputum or gastric aspirate, including blood and urine. Unfortunately, little is known 
about the overall yield from these various specimens. From pilot data collected among adults 
and children in Tugela Ferry, we know that it is feasible to collect and test various bodily 
fluid specimens for TB culture. Also among HIV-infected patients suspected to have 
extrapulmonary TB, approximately 33% have positive blood cultures for Mycobacterium 
tuberculosis when using the Bactec (automated liquid media) system. 
All children ≤ 15 years old suspected of active TB presenting to the National Hospital of 
Pediatrics (NHP) or National Lung Hospital (NLH), Hanoi, Vietnam, will be consecutively 
enrolled by trained staff and those eligible will have gastric aspirate, expectorate (if possible), 
blood and urine collected for mycobacterial culture to study the yield in this population. All 
specimens (sputum, gastric aspirate, blood and urine specimens) will be tested at the 
microbiology laboratory.  Sputum and gastric aspirate  will be digested and decontaminated 
by the N-acetyl-L-cysteine (NALC)-NaOH method. An aliquot will be used for microscopic 
sputum examination for AFB (Ziehl-Nielsen-stained) and the remainder will be cultured by 
routine mycobacterial culture technique. Urine will also be tested by a TB antigen test (LAM 
Test). Blood cultures (MycoF/Lytic) will be incubated for 42 days.. Drug susceptibility 
testing of all positive culture will be performed using molecular techniques (HAIN test). 
Culture results will be provided to the treating clinician immediately upon becoming 
available. 
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Hypothesis  
We hypothesize that blood cultures will detect Mycobacterium tuberculosis from children 
suspected of disseminated TB, and that a proportion of these non-sputum bodily fluids will 
detect both drug-susceptible and drug-resistant tuberculosis when sputum or gastric culture 
does not. 
 
Primary aims 
Among children (≤15years) suspected of active Mycobacterium tuberculosis presenting to 
NLH and NHP, Hanoi, Vietnam: 
 Assess the diagnostic yield of TB-blood culture as compared to direct smear and TB 
culture of expectorate and/or gastric aspirate and antigen test of urine. 
Secondary aim 
 Develop a diagnostic algorithm for suspected pediatric tuberculosis 
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Background 
Tuberculosis (TB) is a major cause of morbidity and mortality among children in developing 
nations [1]. The HIV epidemic has fueled a resurgence of TB globally [2]. Worldwide, 
approximately 10% of incident TB cases are thought to occur in children but in endemic 
areas, the proportion rises to an estimated 40% [3]. As concerning as the outbreak is in adults, 
further worry is that the diagnosis of TB is difficult in children [5]. Symptom-based 
diagnostic criteria are non-specific and culture confirmation is challenging, as sputum 
samples are often believed to be to too cumbersome to obtain from small children and 
specimens typically have low yield due to the paucibacillary nature of pediatric TB. Culture 
confirmation may be obtained in as few as 10% of cases of suspected pediatric TB. For these 
reasons, the true extent of the (drug-resistant) TB epidemic in children is unknown. Thus, 
either clinicians begin empiric treatment without diagnosis or no treatment is given at all. 
Current laboratory methods, if available at all in resource poor settings, employ smears from 
expectorated sputa or gastric aspirates which have low sensitivity in children [3]. While more 
rapid diagnostic techniques have been developed, there is still poor sensitivity in children. 
PCR based tests, for instance, perform well in smear positive samples, and can offer first-line 
drug susceptibility testing (DST). Similarly, a low-cost test, the Microscopic Observation 
Drug Susceptibility (MODS) assay was thought to be promising for diagnosis of pediatric 
tuberculosis [6,7] but work with the MODS assay among adults with suspected TB from the 
same community in Tugela Ferry have yielded differing results from published studies. 
Improving the diagnosis of pediatric TB must focus on better efforts, including more 
aggressive strategies to uncover disseminated disease. 
A single sputum induction has recently been demonstrated to have an equivalent culture yield 
to three gastric aspirates for the diagnosis of pediatric tuberculosis from a referral hospital in 
South Africa [8]. Despite the study’s findings, criticism has been targeted at the ability to 
perform adequate sputum induction at the rural or district level. Currently, gastric aspirate 
remains in the national practice guidelines as the preferred means of culture confirmation for 
children unable to expectorate.  
Culture confirmation of disseminated disease can be obtained from blood, urine, 
cerebrospinal fluid (CSF), peritoneal and pleural fluid, or purulent material from lymph node 
aspirates, abscesses or otorrhea. Unfortunately, little is known about the overall yield from 
these various specimens in children. Furthermore, among HIV-infected adults suspected to 
have extrapulmonary TB, approximately 33% have positive blood cultures for MTB when 
using an automated liquid culture system [9].  
 173 
 
Although WHO guidelines encourage body fluid collection in order to make a diagnosis of 
TB in children, at present,  blood and urine cultures are not obtained for mycobacterial 
culture. However, this study seeks to demonstrate that routine investigation of blood and urine 
will augment the yield of traditional sputum culture for children in whom disseminated 
disease is more likely. Improved culture confirmation will allow DST and a more accurate 
description of the drug-resistant TB epidemic for children in the region. 
Inclusion criteria  
 Aged 0-15, presenting at NLH and NHP  
 Any form of TB suspected based on at least two of the following findings: 
o unexplained fever for more than 2 weeks 
o unexplained cough for more than 2 weeks 
o radiographic findings suggestive of tuberculosis. 
o failure to thrive/weight loss or malnourished 
o enlarged non-tender lymph nodes or lymph node abscess, especially of 
the neck 
o signs of meningitis with prodromal stage of at least one week 
o HIV positive 
o TB contact history 
 Relevant material (sputum or gastric aspirate, blood, and urine) available for 
microbiological diagnosis. 
 Informed consent obtained from the patient’s legal guardian(s).  
Exclusion Criteria 
 Age >15 years 
 Diagnosed or treated for TB in the past year, received drugs effective against TB in 
last 3 months. 
 Clinical contra-indications to collect the required study specimens 
 
If patients are excluded, the patient will be thanked for their time and the form should be kept 
together with all other enrolled patient forms. This will be important at the end of the study to 
track how many patients were screened and reasons for exclusion. 
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Definitions 
Detection of M. tuberculosis from biological specimens 
Not TB 
Sputa, blood or relevant specimen negative by AFB smear, and culture for M. tuberculosis, 
with either a resolution of clinical symptoms and radiographic abnormalities following 
antibiotic therapy not involving drugs active against M. tuberculosis, or with an alternative 
diagnosis  
Clinical Data Collection 
Basic demographic, presenting clinical features, TB contact history, BCG and vaccination 
history. HIV testing will be performed according to hospital practice. Patient data will be 
anonymized and entered into a database for further analysis (see data management section). 
 
Sample size and analysis  
On a yearly basis, around 400 specimens for TB diagnostics are received by the NHP 
microbiology laboratory (specimens from NLH are added to reach the sample size since mid 
2012). Therefore, it is expected that 800 specimens from approximately 600 patients will be 
enrolled in this study . The estimated TB prevalence in our study population is estimated to be 
20%, resulting in 120 positive cases in two years. At an estimated sensitivity of blood or urine 
to detect disseminated TB of 25%, the confidence interval would be ± 6.4%. 
 
Patient enrollment 
Overview: All children age 0-15 years presenting to NHP or NLH thought to have TB 
infection according to inclusion criteria listed in this protocol are eligible for the study. In 
addition, any child with failure to thrive or if the clinician caring for the child has a strong 
clinical suspicion for TB, then the child will also be eligible for enrollment. 
General Procedures: Subjects will be enrolled Monday through Friday at NHP and NLH. On 
Monday through Friday mornings the study coordinator will contact the head of departments 
to discuss if any new admissions are TB suspects. The study coordinator can be contacted 
directly by any referring physician during business hours Mon-Fri. The study coordinator will 
also make periodic visits to the in- and outpatient departments to remind physicians about the 
study.  
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If the patient is eligible and all necessary consent/assent forms have been signed, then the 
sample collection procedure will start. It is estimated that 10 pediatric patients are TB 
suspects at NHP and NLH per week, and the goal will be to enroll all eligible pediatric 
suspects. 
 
General Patient Interview Form: All suspects will be screened for enrollment by trained 
hospital staff using the form titled, General Patient Interview Form. This is form needs to be 
completed on all screened patients. The first page contains patient identifiers (e.g., name, 
address, telephone number) and will be recorded on the cover sheet only, which will be 
separated and kept in a locked filing cabinet; only the study ID number should be used on 
each subsequent page General Patient Interview Form and placed in the upper right corner 
using a pre-printed label. 
 
Parent/Guardian Consent Form: This form is to be read and explained to the parent/guardian 
of the patient in Vietnamese. The form should be signed by the parent/guardian and the 
research assistant who has obtained the consent. The consent form will be stored together 
with the first page of the General Patient Interview Form and will be separate from the other 
patient data forms to maintain confidentiality. If the child is an orphan an appointed social 
worker can serve as temporary guardian for the child and sign the Parent/Guardian Consent 
Form. 
It is important for parent/guardians to understand all sections of the consent form, so as much 
time as is needed will be spent to clearly explain and answer questions. Key sections of the 
consent form to ensure the parent/guardian understands are: Procedures, Risks and Benefits, 
Alternatives, and Confidentiality. A copy of this form should be given to all parent/guardians. 
 
Patient procedures 
Patient fulfilling the inclusion criteria for suspected TB will be informed of the study. 
For those patients that assent and whose guardians provide consent samples will be 
collected as described below at the time of assessment and before a diagnosis is made 
or treatment commenced. Clinical assessment for TB will be performed by hospital 
staff according to normal procedures. All laboratory results will be returned to the 
patients doctors at the earliest possible time to assist in diagnosis. HIV testing will be 
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performed if informed parental consent is given. Participating patients will be 
assigned a study number. Patient names will not be included in the data base.  
 
Samples 
Samples for routine diagnosis 
 2 spontaneous sputum samples or 4ml gastric aspirate (spot, morning, spot) for 
concentrated smear, and liquid culture. .  
 2-6 ml of CSF if TBM suspected for concentrated smear and liquid culture. 
 3-5 mL blood sample will be taken in a MycoF-lytic blood culture bottle. 
 5 mL of morning urine for   antigen test Determine® TB-LAM (Alere, USA) 
Training will be given to clinicians on indications and appropriate collection of samples 
 
Patient Procedures 
Overview 
Once patients are determined to be eligible for the study, and all forms described in the 
Patient Enrollment section are completed, subjects must submit samples for blood and urine. 
In children 8 or older that are able to expectorate, they will have sputum collected. In children 
7 years of less or any child unable to expectorate, they will have sputum induction performed. 
Sputum induction will be preferentially invasive for children less than 5 years old. 
Additionally, in the subset of patients admitted to the ward and less than 5 years old, two 
morning gastric aspirates will be collected. All samples must then be clearly labeled and dated 
with the patient’s unique study number labels and stored for transport. A study specimen 
register will be completed each day by the study coordinator. Following collection of the last 
specimen, the patient’s participation in the study is complete. If a patient has another body 
fluid sent for mycobacterial culture aside from sputum, gastric aspirate, blood or urine by the 
treating physician during routine course of care, the result of the culture for that body fluid 
will be recorded, but no active collection of any other body fluid will take place for study 
purposes.  
 
Assigning a study number 
Once a patient is determined to be eligible for the study and all forms are completed, the 
patient must be assigned a study number. Study numbers and labels will be pre-printed and 
can be obtained from the study coordinator. A study number will be assigned in a sequential 
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manner by hospital , based on order of enrollment (the first patient enrolled at NHP will be 
MYC001, the second patient will be MYC002, etc. and for NLH the first patient will be 
NLHMYC001, and so on) 
Once a sheet of labels is obtained with the patient’s study number, enter the date of 
enrollment on the space indicated (date of each sample collection will also be entered for 
labels affixed to each sample container, and this date will differ from the date of enrollment 
for some samples. Study coordinator will need to assure that labels are affixed to the 
following: 
 Every page of the General Patient Interview Form and Specimen Test Request Form 
 Every sample collection bottle/tube with added date of collection and volume of 
collected sample 
 
Blood Collection 
For all subjects enrolled in the study, the nurse will collect between 3-5ml of blood under 
sterile conditions and inoculate the blood into a Bactec (MycoF-Lytic) mycobacterial culture 
bottle. The bottle will be labeled and transported  to the laboratory at NHP within a day  to be 
incubated in the Bactec 9050 automated system. 
 
Urine Collection  
Urine collection follows routine procedure to collect sterile urine. For subjects admitted to the 
hospital, first-morning, clean-catch urine samples will be obtained by the nurse for those who 
are able to void on command. For patients too young to void on command, an early morning 
urine specimen will be collected by securing a sterile plastic bag to the perineal area after 
sterilizing the skin (Optional). At least 5ml will be collected. Collection cups will be labeled 
with the study number and sent to laboratory for testing and storage. 
 
Gastric Aspirate 
For subjects admitted the hospital, the nurse will perform early morning gastric aspirates on at 
least two separate mornings. Gastric aspiration will be performed by NHP and NLH protocol, 
with attempt to withdraw at least 4ml of gastric fluid, accompanied by instillation of NaCl if 
necessary to produce adequate sample volume. Collection bottles will be labeled with the 
study number prior to transport to laboratory for testing and storage. 
 
Sputum Collection 
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All subjects enrolled in the study will have sputum collected. Those unable to produce 
adequate sputum samples will only have gastric aspirate performed. The sputum sample and 
Specimen Test Request Form will be sent to the laboratory for testing. 
 
Laboratory procedures 
Specimen arrival: Specimens will arrive daily Mon-Fri, before 1 pm.  
Specimen processing: Sputum and gastric aspirates will be decontaminated using the NALC-
NaOH method and processed for AFB microscopy (ZN) and culture . Urine will be also tested 
with Determine® TB-LAM (Alere, USA) to detect TB antigen. Blood cultures will be 
incubated and read daily up till 42 days. HAIN test will be performed at OUCRU lab on all 
positive cultures to confirm TB identification and resistance to isoniazid and rifampicin.  
Reporting Results 
All results of the specimens will be used for clinical care. Therefore it is essential that the 
laboratory manager will be responsible for assuring the timely and accurate reporting of AFB 
microscopy and culture results. Results of AFB microscopy and any positive culture result 
will be reported within 24 hours of the receipt of that result in the laboratory. Negative growth 
for  liquid culture  will be reported by week 4  after day received in laboratory and blood 
culture by week 7. If contamination exists or another reason for re-plating occurs, at week 7 a 
report will be sent that culture work is still in progress and results are pending.  
 
Storage of Isolate 
All isolates of positive TB cultures will be labeled and stored in secure freezers for possible 
future investigation. 
 
Data management 
Overview: The data manager will be responsible for coordinating all data received from NHP 
and NLH patient enrolment and lab results. These results will be coordinated in an electronic 
Peds TB Diagnosis Study Register (for purposes of patient care), paper printouts (also to be 
distributed for patient care to physicians, site of enrolment and treating physicians), and an 
anonymized Microsoft Access Database. 
Peds TB Diagnosis Study Register: The study number, specimen type (sputum, blood etc.), 
specimen date of collection, and patient demographic information will be entered in this 
register by the study coordinator. This information will be password protected. Once test 
results become available, the data capturer will include AFB microscopy, culture and DST 
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results into the study register. This register will be periodically printed and given to the 
participating departments for patient care purposes.  
Microsoft Access Database: The data capturer will enter all data from the study register and 
patient forms into the Access database on a weekly basis. The information contained within 
the Access database will be devoid of all patient name and contact information and will not be 
used for clinical care. 
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STUDY PERSONNEL 
Overview: The Pediatric TB Diagnosis Study will be conducted at NHP and NLP 
The study will be carried out by professionally trained study personnel who will be 
responsible for ensuring that all aspects of the project, from patient enrollment and specimen 
collection, to the reporting of results and data management, adhere to the protocol as 
approved by ethics committees at NHP, NLH, and Oxford University.  
The study will be overseen onsite by Dr. Heiman Wertheim. The laboratory aspects will be 
overseen by Dr. Hung (NLH), Dr. Hang (NHP), Ms Sinh (study coordinator of NHP), Dr Van 
(study coordinator of NLH), Ms Linh (study coordinator of OUCRU). 
Study coordinator: Responsibilities in this capacity include ensuring adequate weekly patient 
enrollment (target: 5-10 patients/week), proper labeling of all study samples and forms, 
ensuring that all forms are completed in full, coordinating transport of samples, and 
coordinating delivery of study results for data entry. The study coordinator will remain in 
direct communication with investigators from OUCRU via email and weekly telephone 
conference calls. 
Data management (Oxford staff): 1-2 data managers will be responsible for data entry. 
Responsibilities for the  project include updating and entering data from the enrollment forms 
into the Microsoft Access Database. The data capturer will also work with the study 
coordinator to ensure that all forms are complete, and that all information needed for each 
patient is available. 
Laboratory technicians: 2-3 laboratory technicians will be assigned to process the samples for 
sputum, gastric aspirate, blood and urine (and occasionally other specimens). 
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Appendix C 
Participant information sheet for participation in ‘improve TB diagnosis study’ for 
parents or legal guardians 
 
Patients admitted to the National Hospital of Pediatrics who are suspected of having 
tuberculosis are being asked to join a research study of improving the diagnosis of 
tuberculosis by testing blood. About 800 children will be asked to join the study.  
Participating in this study is your free choice. No one can force your decision. Please take 
your time to read this information before you decide. If you cannot read it, someone will read 
it for you. The person reviewing this form with you will answer any questions you have. If 
you are willing to have your child join this study you will be asked to sign or place your mark 
on the last page.    
 
Why is this study being done? 
Your child is suspected of having tuberculosis. Often it is very difficult to confirm this 
diagnosis by laboratory testing. In general, a sputum sample is tested by in the laboratory, but 
even if your child has tuberculosis, this test can be negative. Therefore it is important to find 
better tests for children who may have tuberculosis. It is known that children can have 
tuberculosis in body parts other than the lungs. Therefore we may be able to test for 
tuberculosis in the blood or urine. This study will collect blood and urine to test them against 
the regular tests to see if they can give a better test result.  
 
Who is doing this study?  
The research team has doctors from the National Hospital of Pediatrics and the Oxford 
University Clinical Research Unit in Hanoi.     
 
What will happen to your child in this study?   
Whether or not your child joins the study s/he will receive standard hospital care for her/his 
condition. This usually involves being examined everyday and laboratory testing decided by 
your treating doctor. For this research study you will have all of the routine tests decided by 
your doctor and you will also have samples taken of stomach fluid , sputum, blood and urine 
soon after the doctor suspects tuberculosis to be the cause of the symptoms.  
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The stomach fluid is taken by inserting a tube through your child’s nose and passing it down 
into the stomach. After the nurse has checked that the tube is in the right position, 10 mL of 
gastric fluid will be collected using a syringe connected to the tube. This procedure will be 
done twice on two separate mornings. This procedure is a part of regular care at the National 
Hospital for Pediatrics. Blood will be collected by inserting a needle into a vein. With a 
syringe the nurse will collect at least 3 mL and up to 5 mL. This blood is injected into a 
special bottle for testing. 5 mL of urine will be collected in a container at a time that your 
child has to urinate. On three different occasions, sputum will be collected by coughing lung 
fluid into a container. Sputum collection in the morning is the best time. It is possible that 
your child has signs of tuberculosis at other body sites, like the brain or abscess. In such 
cases, the doctor will collect samples as they normally would for regular care. All specimens 
(sputum, stomach fluid, blood, urine, or routine collected specimens for TB testing) will be 
tested at the laboratory of the National Hospital for Pediatrics.  
 
What will happen to the samples?   
These specimens will be tested for mycobacteria which can show if your child has 
tuberculosis. If you agree, samples collected as part of this study and also samples taken 
during your hospital stay to look for bacterial infection will be stored up to five years. 
 
Why are we asking to store samples? 
We want to store your child’s samples because some of the tests will not be done while you 
are in hospital. If other samples are taken which your doctor thinks are important for your 
treatment e.g. the fluid from your lung or more blood, we will also store the left over from 
these samples so they can be tested. 
 
One test we may want to do in the future is to see if certain people are more likely to develop 
infection compared to other people; this is called genetic testing. You can choose not to have 
this genetic testing done by marking at the end of this form 
 
What is the benefit of participating?   
You may benefit from the study because extra tests are being done which may tell your 
doctors about your illness and how to treat it earlier than usual.  
 
What are the risks of being in the study? 
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This study involves sample collection that is done routinely in this hospital. The risks for each 
sample are: 
 
-Stomach fluid collection. This test is already done regularily at NHP to test for tuberculosis. 
Minor problems can include nose bleed and discomfort. More significant problems include 
breaking the tissue in your throat or taking fluid from the lungs. These probems are rare when 
the samples are taken by experienced staff. In case such a problem may occur, your child will 
be treated for the problem. 
-Sputum collection. There are no risks related to this procedure. 
-Blood collection. Blood will be collected by inserting a needle into a vein. This can cause 
discomfort and anxiety with your child. Other complications can be bruising at the site where 
the needle was inserted.  
-Urine collection.. No risks are known for this procedure. 
 
What are the costs for being in the study?  
There will be no additional costs to you if you participate in this study. You will still be 
responsible for covering the costs of your regular care but the research team will cover all the 
costs of tests done as part of the study. 
 
What happens if I decide not to be in the study or change my mind later on?  
This is no problem. The doctors will respect your decision. No one can force you to join the 
study or to remain in the study, if you change your mind later on.  Your regular treatment will 
not be changed because of your decision.     
 
Can someone else decide to stop the study?  
The research team doctors can stop your child being in the study if they think his/her health 
may get worse because of the study or if your child does not follow the study procedures. The 
sponsor or the Ethics Committee that reviews this study can also decide to stop the study.   
 
Confidentiality 
All information about you and your child will be kept confidential. Your child’s medical 
records will be reviewed in strict confidence by the staff working on this study. Your name 
will not be used on any of the study documents or on the stored samples or in any reports or 
publications about this study.   
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Whom do I contact if I have questions or complaints? 
If you have any questions about the study you can contact Dr Le Thanh Hai at the National 
Hospital for Pediatrics.  His phone number is 098 906 3658.  If you have any questions about 
being in a research study you can contact the Clinical Research Office of the Hospital for 
Tropical Diseases at 083924 1983. 
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Consent from the parent, guardian or legal representative: 
 
I have read this consent form OR this consent form has been read to me.   
[Delete which does not apply] 
I have had the opportunity to ask questions about this study and these questions have been 
answered to my satisfaction. I freely give my permission to allow 
………………………………………… [write name] to join this study. I understand that I 
have the right to withdraw him/her from the study. I will be given a copy of this signed 
consent form to keep for my reference.  
I allow / do not allow* samples to be stored for future testing  * delete which does not apply. 
 
I allow / do not allow* genetic testing on the stored samples  * delete which does not apply. 
 
Name of person giving consent __________________________________ 
 
Signature or thumb print   __________________________________ 
 
Relationship to patient:   __________________ Date: ______ 
  
Person obtaining consent  __________________________________ 
 
Signature     __________________________________ 
 
Date:      __________________________________ 
 
Name witness     __________________________________ 
 
Signature     __________________________________ 
 
Date:      ____________________________ 
 
 
Assign Patient Study Number: TB ______________ 
